<body style="font: 10pt Times New Roman, Times, Serif"> <document>  <type>   10-K   <sequence>    1    <filename>     f10k2020_soligenix.htm     <description>      ANNUAL REPORT      <text>       <title>       </title>       <p style="margin: 0">       </p>       <!-- Field: Rule-Page -->       <div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%">        <div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">         <font style="font-family: Times New Roman, Times, Serif">         </font>        </div>       </div>       <!-- Field: /Rule-Page -->       <p style="margin: 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 6pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         <b>          UNITEDSTATES SECURITIES AND EXCHANGE COMMISSION         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         <b>          Washington,D.C. 20549         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 6pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         <b>          FORM10-K         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 6pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         (MarkOne)        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         ☒ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 6pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         Forthe Fiscal Year Ended         <b>          December 31, 2020         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 6pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 6pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         Forthe transition period from ____________ to ____________        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 6pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         CommissionFile No. 000-16929        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 6pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         <b>          SOLIGENIX,INC.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         (Exactname of registrant as specified in its charter)        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 6pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="border-bottom: black 1.5pt solid; width: 49%; text-align: center; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Delaware            </b>           </font>          </td>          <td style="width: 2%; text-align: center; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: black 1.5pt solid; width: 49%; text-align: center; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             41-1505029            </b>           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <font style="font-family: Times New Roman, Times, Serif">             (State        or other jurisdiction of            </font>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <font style="font-family: Times New Roman, Times, Serif">             incorporation        or organization)            </font>           </p>          </td>          <td style="text-align: center; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <font style="font-family: Times New Roman, Times, Serif">             (I.R.S.        Employer            </font>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <font style="font-family: Times New Roman, Times, Serif">             Identification        Number)            </font>           </p>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 6pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="border-bottom: black 1.5pt solid; width: 49%">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <font style="font-family: Times New Roman, Times, Serif">             <b>              29                                         EMMONS DRIVE, SUITE B-10             </b>            </font>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <font style="font-family: Times New Roman, Times, Serif">             <b>              PRINCETON,        NJ             </b>            </font>           </p>          </td>          <td style="width: 2%; text-align: center; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: black 1.5pt solid; width: 49%">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <font style="font-family: Times New Roman, Times, Serif">             <b>             </b>            </font>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <font style="font-family: Times New Roman, Times, Serif">             <b>              08540             </b>            </font>           </p>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: center; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (Address    of principal executive offices)           </font>          </td>          <td style="text-align: center; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (Zip    Code)           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; font-size: 6pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 33%; text-align: center; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: black 1.5pt solid; width: 34%; text-align: center; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             (609)    538-8200            </b>           </font>          </td>          <td style="width: 33%; text-align: center; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         (Registrant’stelephone number, including area code)        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 6pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         Securitiesregistered under Section 12 (b) of the Exchange Act:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 6pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr>          <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 32%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Title    of each class            </b>           </font>          </td>          <td style="vertical-align: top; width: 2%">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 32%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Trading    Symbol (s)            </b>           </font>          </td>          <td style="vertical-align: top; width: 2%">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: black 1.5pt solid; vertical-align: top; width: 32%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Name    of each exchange on which registered            </b>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Common Stock, par    value $0.01 per share           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            SNGX           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The Nasdaq Capital    Market           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Common Stock Purchase    Warrants           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            SNGXW           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The Nasdaq Capital    Market           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif; font-size: 6pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         Securitiesregistered under Section 12(g) of the Exchange Act:         <b>          None         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 6pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">        <font style="font-family: Times New Roman, Times, Serif">         Indicateby check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No☑        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 6pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">        <font style="font-family: Times New Roman, Times, Serif">         Indicateby check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐No ☑        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 6pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">        <font style="font-family: Times New Roman, Times, Serif">         Indicateby check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file suchreports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☑No ☐        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.2in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 6pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">        <font style="font-family: Times New Roman, Times, Serif">         Indicateby check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuantto Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period thatthe registrant was required to submit such files). Yes ☑ No ☐        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 6pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">        <font style="font-family: Times New Roman, Times, Serif">         Indicateby check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smallerreporting company. See the definition of “large accelerated filer”, “accelerated filer” and “smallerreporting company” in Rule 12b-2 of the Exchange Act. (Check one):        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.2in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 6pt">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top">          <td style="width: 25%; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Large    accelerated filer           </font>          </td>          <td style="width: 25%; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ☐           </font>          </td>          <td style="width: 25%; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Accelerated    filer           </font>          </td>          <td style="width: 25%; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ☐           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Non-accelerated    filer           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ☒           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Smaller reporting    company           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ☒           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td colspan="2" style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Emerging growth    company           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ☐           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 6pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">        <font style="font-family: Times New Roman, Times, Serif">         Ifan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.2in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 6pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">        Indicate by checkmark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness ofits internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registeredpublic accounting firm that prepared or issued its audit report.  ☐       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.2in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 6pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">        <font style="font-family: Times New Roman, Times, Serif">         Indicateby check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☑        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.2in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 6pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">        The aggregate market value of the common stock held by non-affiliatesof the registrant was $57,299,617 (assuming, for this purpose, that executive officers, directors and holders of 10% or more ofthe common stock are affiliates), based on the closing price of the registrant’s common stock as reported on The Nasdaq CapitalMarket on June 30, 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.2in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 6pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">        <font style="font-family: Times New Roman, Times, Serif">         OnMarch 23, 2021, there were 40,020,461 shares of the registrant’s common stock outstanding.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.2in">        <font style="font-family: Times New Roman, Times, Serif; font-size: 6pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         DOCUMENTSINCORPORATED BY REFERENCE: None.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 6pt">        </font>       </p>       <!-- Field: Rule-Page -->       <div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%">        <div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">         <font style="font-family: Times New Roman, Times, Serif">         </font>        </div>       </div>       <!-- Field: /Rule-Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="margin: 0pt">        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         <b>          SOLIGENIX,INC.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         <b>          ANNUALREPORT ON FORM 10-K         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         <b>          Forthe Year Ended December 31, 2020         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         <b>          Tableof Contents         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr>          <td style="border-bottom: black 1.5pt solid; width: 9%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Item            </b>           </font>          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: black 1.5pt solid; width: 80%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Description            </b>           </font>          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="vertical-align: bottom; border-bottom: black 1.5pt solid; width: 9%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Page            </b>           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td colspan="3">           <a href="#a_021">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Cautionary Note Regarding Forward-Looking    Statements            </font>           </a>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ii           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="vertical-align: top; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="#pa_001">             <b>              Part I             </b>            </a>           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1.           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: justify">           <a href="#a_001">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Business            </font>           </a>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1A.           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: justify">           <a href="#a_018">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Risk Factors            </font>           </a>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            27           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1B.           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: justify">           <a href="#a_002">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Unresolved Staff    Comments            </font>           </a>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            48           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2.           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: justify">           <a href="#a_003">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Properties            </font>           </a>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            48           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3.           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: justify">           <a href="#a_004">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Legal Proceedings            </font>           </a>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            48           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="#pa_002">             <b>              Part II             </b>            </a>           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            5.           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <a href="#a_005">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Market for Registrant’s    Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities            </font>           </a>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            49           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            6.           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: justify">           <a href="#a_006">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Selected Financial    Data            </font>           </a>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            50           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            7.           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: justify">           <a href="#a_007">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Management’s    Discussion and Analysis of Financial Condition and Results of Operations            </font>           </a>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            50           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            8.           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: justify">           <a href="#a_008">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Financial Statements    and Supplementary Data            </font>           </a>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            57           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            9.           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: justify">           <a href="#a_009">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Changes in and Disagreements    with Accountants on Accounting and Financial Disclosure            </font>           </a>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            58           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            9A.           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: justify">           <a href="#a_010">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Controls and Procedures            </font>           </a>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            58           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            9B.           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: justify">           <a href="#a_011">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Other Information            </font>           </a>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            58           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             <a href="#pa_003">              Part III             </a>            </b>           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10.           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: justify">           <a href="#a_012">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Directors, Executive    Officers and Corporate Governance            </font>           </a>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            59           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            11.           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: justify">           <a href="#a_013">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Executive Compensation            </font>           </a>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            64           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            12.           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: justify">           <a href="#a_014">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Security Ownership    of Certain Beneficial Owners and Management and Related Stockholder Matters            </font>           </a>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            69           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            13.           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: justify">           <a href="#a_015">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Certain Relationships    and Related Transactions and Director Independence            </font>           </a>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            70           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            14.           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: justify">           <a href="#a_016">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Principal Accountant    Fees and Services            </font>           </a>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            71           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             <a href="#pa_004">              Part IV             </a>            </b>           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            15.           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: justify">           <a href="#a_017">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Exhibits and Financial    Statement Schedules            </font>           </a>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            72           </font>          </td>         </tr>         <tr style="background-color: White">          <td colspan="3" style="vertical-align: top; text-align: justify">           <a href="#a_019">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Signatures            </font>           </a>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            75           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td colspan="3" style="vertical-align: top; text-align: justify">           <a href="#a_020">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Consolidated    Financial Statements            </font>           </a>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            F-1           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <!-- Field: Page; Sequence: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->         i         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">         <b>          <a name="a_021">          </a>          CautionaryNote Regarding Forward-Looking Statements         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <i>         </i>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         ThisAnnual Report on Form 10-K contains forward-looking statements, within the meaning of the Private Securities Litigation ReformAct of 1995, that reflect our current expectations about our future results, performance, prospects and opportunities. These forward-lookingstatements are not guarantees of future performance and are subject to significant risks, uncertainties, assumptions and otherfactors, which are difficult to predict and may cause actual results to differ materially from those expressed in, or impliedby, any forward-looking statements. The forward-looking statements within this report may be identified by words such as “believes,”“anticipates,” “expects,” “intends,” “may,” “would,” “will”and other similar expressions. However, these words are not the exclusive means of identifying these statements. Statements thatare not historical facts are based on our current expectations, beliefs, assumptions, estimates, forecasts and projections forour business and the industry and markets related to our business and are forward-looking statements.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Actualoutcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors whichmay affect these actual outcomes and results include, without limitation:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in; text-align: right">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            uncertainty as to    whether our product candidates will be sufficiently safe and effective to support regulatory approvals;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in; text-align: right">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            uncertainty inherent    in developing vaccines, and manufacturing and conducting preclinical and clinical trials of vaccines;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in; text-align: right">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our ability to obtain    future financing or funds when needed, either through the raising of capital, the incurrence of convertible or other indebtedness    or through strategic financing or commercialization partnerships;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in; text-align: right">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            that product development    and commercialization efforts will be reduced or discontinued due to difficulties or delays in clinical trials or a lack of    progress or positive results from research and development efforts;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in; text-align: right">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            maintenance and    progression of our business strategy;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in; text-align: right">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the possibility    that our products under development may not gain market acceptance;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in; text-align: right">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our expectations    about the potential market sizes and market participation potential for our product candidates may not be realized;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in; text-align: right">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our expected revenues    (including sales, milestone payments and royalty revenues) from our product candidates and any related commercial agreements    of ours may not be realized;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in; text-align: right">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the ability of our    manufacturing partners to supply us or our commercial partners with clinical or commercial supplies of our products in a safe,    timely and regulatory compliant manner and the ability of such partners to timely address any regulatory issues that have    arisen or may in the future arise; and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in; text-align: right">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            competition existing    today or that may arise in the future, including the possibility that others may develop technologies or products superior    to our products;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in; text-align: right">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the effect that    global pathogens could have on financial markets, materials sourcing, patients, governments and population (e.g. Coronavirus    Disease 2019 (“COVID-19”)); and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in; text-align: right">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            other factors, including    those “Risk Factors” set forth under Part I, Item 1A. “Risk Factors” in this Annual Report.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Exceptas expressly required by the federal securities laws, we undertake no obligation to publicly update or revise any forward-lookingstatements to reflect events or circumstances occurring subsequent to the filing of this Form 10-K with the U.S. Securities andExchange Commission (“the SEC”) or for any other reason. You should carefully review and consider the various disclosureswe make in this report and our other reports filed with the SEC that attempt to advise interested parties of the risks, uncertaintiesand other factors that may affect our business.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 3; Options: NewSection; Value: 2 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->         ii         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <a name="pa_001">          </a>          PARTI         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <a name="a_001">          </a>          Item1. Business         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <i>         </i>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <i>          ThisAnnual Report on Form 10-K contains statements of a forward-looking nature relating to future events or our future financial performance.These statements are only predictions and actual events or results may differ materially. In evaluating such statements, you shouldcarefully consider the various factors identified in this report that could cause actual results to differ materially from thoseindicated in any forward-looking statements, including those set forth in “Risk Factors” in this Annual Report onForm 10-K. See “Cautionary Note Regarding Forward Looking Statements.”         </i>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <u>           OurBusiness Overview          </u>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Weare a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where thereis an unmet medical need. We maintain two active business segments: Specialized BioTherapeutics and Public Health Solutions.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         OurSpecialized BioTherapeutics business segment is developing and moving toward potential commercialization of SGX301 (synthetichypericin) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (“CTCL”).With a successful Phase 3 study completed, regulatory approval is being sought and commercialization activities for this productcandidate are being advanced initially in the United States (“U.S.”) Development programs in this business segmentalso include our first-in-class innate defense regulator (“IDR”) technology, dusquetide (SGX942) for the treatmentof inflammatory diseases, including oral mucositis in head and neck cancer, and proprietary formulations of oral beclomethasone17,21-dipropionate (“BDP”) for the prevention/treatment of gastrointestinal (“GI”) disorders characterizedby severe inflammation including pediatric Crohn's disease (SGX203) and acute radiation enteritis (SGX201).        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         OurPublic Health Solutions business segment includes active development programs for RiVax         <sup>          ®         </sup>         , our ricin toxin vaccinecandidate and SGX943, our therapeutic candidate for antibiotic resistant and emerging infectious disease and our vaccine programstargeting filoviruses (such as Marburg and Ebola) and CiVax         <sup>          TM         </sup>         , our vaccine candidate for the prevention of COVID-19(caused by SARS-CoV-2). The development of our vaccine programs incorporates the use of our proprietary heat stabilization platformtechnology, known as ThermoVax         <sup>          ®         </sup>         . To date, this business segment has been supported with government grant and contractfunding from the National Institute of Allergy and Infectious Diseases (“NIAID”), the Biomedical Advanced Researchand Development Authority (“BARDA”) and the Defense Threat Reduction Agency (“DTRA”).        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        An outline of our business strategy follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Following positive primary endpoint results for the Phase 3 clinical trial of SGX301, as well as further statistically significant improvement in response rates with longer treatment (18 weeks compared to 12 and 6 weeks of treatment), pursue New Drug Application (“NDA”) filing and commercialization in the U.S. while continuing to explore ex-U.S. partnership.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td>           Continue to analyze the full dataset from the Phase 3 clinicaltrial of SGX942 to better understand why the study did not achieve the statistically significant benefit expected, despite demonstratingclinically meaningful reductions in oral mucositis consistent with the previous Phase 2 study. Any clarity gained from furtheranalysis, especially with respect to specific subsets of patients that may benefit from SGX942 therapy, will be communicated toand discussed with the United States (“U.S.”) Food and Drug Administration (“FDA”) and the European MedicinesAgency (“EMA”).          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Continue development of RiVax            <sup>             ®            </sup>            (ricin toxin vaccine) and CiVax            <sup>             TM            </sup>            (COVID-19 vaccine) in combination with our ThermoVax            <sup>             ®            </sup>            technology to develop new heat stable vaccines in biodefense with NIAID funding support.           </font>          </td>         </tr>        </tbody>       </table>       <p style="margin: 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="margin: 0">       </p>       <!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         1         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="margin: 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="margin: 0">       </p>       <p style="margin: 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px">           <font style="font: 10pt Times New Roman, Times, Serif">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font: 10pt Times New Roman, Times, Serif">            Continue development of our therapeutic SGX943 and our vaccine programs targeting filoviruses (such as Marburg and Ebola) with DTRA and NIAID funding support.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">          </td>          <td>          </td>          <td style="text-align: justify">          </td>         </tr>        </tbody>       </table>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px">           <font style="font: 10pt Times New Roman, Times, Serif">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font: 10pt Times New Roman, Times, Serif">            Continue to apply for and secure additional government funding for each of our Specialized BioTherapeutics and Public Health Solutions programs through grants, contracts and/or procurements.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px">           <font style="font: 10pt Times New Roman, Times, Serif">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font: 10pt Times New Roman, Times, Serif">            Pursue business development opportunities for our pipeline programs, as well as explore all strategic alternatives, including but not limited to merger/acquisition strategies.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px">           <font style="font: 10pt Times New Roman, Times, Serif">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font: 10pt Times New Roman, Times, Serif">            Acquire or in-license new clinical-stage compounds for development.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in">       </p>       <p style="margin: 0">        <u>         Corporate Information        </u>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Wewere incorporated in Delaware in 1987 under the name Biological Therapeutics, Inc. In 1987, we merged with Biological Therapeutics,Inc., a North Dakota corporation, pursuant to which we changed our name to “Immunotherapeutics, Inc.” We changed ourname to “Endorex Corp.” in 1996, to “Endorex Corporation” in 1998, to “DOR BioPharma, Inc.”in 2001, and finally to “Soligenix, Inc.” in 2009. Our principal executive offices are located at 29 Emmons Drive,Suite B-10, Princeton, New Jersey 08540 and our telephone number is (609) 538-8200.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <u>           OurProduct Candidates in Development          </u>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Thefollowing tables summarize our product candidates under development:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <u>           SpecializedBioTherapeutics Product Candidates*          </u>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: bottom">          <td style="border-bottom: black 1.5pt solid; width: 25%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Soligenix    Product Candidate            </b>           </font>          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: black 1.5pt solid; width: 25%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Therapeutic    Indication            </b>           </font>          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: black 1.5pt solid; width: 48%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Stage    of Development            </b>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            SGX301           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Cutaneous T-Cell    Lymphoma           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Phase 2 trial completed;    demonstrated significantly higher response rate compared to placebo; Phase 3 trial completed; demonstrated statistical significance    in primary endpoint in March 2020 (Cycle 1) and demonstrated continued improvement in treatment response with extended treatment    in April 2020 (Cycle 2) and October 2020 (Cycle 3)           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            SGX942           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Oral Mucositis in    Head and Neck Cancer           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Phase 2 trial completed;    demonstrated significant response compared to placebo with positive long-term (12 month) safety also reported; Phase 3 clinical    trial results announced December 2020: the primary endpoint of median duration of severe oral mucositis (“SOM”)    did not achieve the pre-specified criterion for statistical significance (p≤0.05); although biological activity was observed    with a 56% reduction in the median duration of SOM from 18 days in the placebo group to 8 days in the SGX942 treatment group           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            SGX203            <b>             †            </b>           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Pediatric Crohn’s    disease           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Phase 1/2 clinical    trial completed; efficacy data, pharmacokinetic (PK)/pharmacodynamic (PD) profile and safety profile demonstrated; Phase 3    clinical trial initiation contingent upon additional funding, such as through partnership           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            SGX201            <b>             †            </b>           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Acute Radiation Enteritis           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Phase 1/2 clinical    trial completed; safety profile and preliminary efficacy demonstrated; further clinical development contingent upon additional    funding, such as through partnership           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 5; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         2         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <u>           PublicHealth Solutions*†          </u>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="width: 25%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ThermoVax            <sup>             ®            </sup>           </font>          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 25%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Thermostability    of vaccines for Ricin toxin, Ebola, Marburg and SARS-CoV-2 (COVID-19) viruses           </font>          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 48%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Pre-clinical           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            RiVax            <sup>             ®            </sup>           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <font style="font-family: Times New Roman, Times, Serif">             Vaccine        against            </font>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <font style="font-family: Times New Roman, Times, Serif">             Ricin        Toxin Poisoning            </font>           </p>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Phase 1a and 1b    trials completed, safety and neutralizing antibodies for protection demonstrated; Phase 1c trial initiated December 2019,    closed January 2020           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            SGX943           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Therapeutic against    Emerging Infectious Diseases           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Pre-clinical           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            CiVax™           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Vaccine against COVID-19           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Pre-clinical           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Rule-Page -->       <div style="margin-top: 0; margin-bottom: 0; width: 25%">        <div style="font-size: 1pt; border-top: Black 1.5pt solid">        </div>       </div>       <!-- Field: /Rule-Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 15pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            <i>             *            </i>           </font>          </td>          <td style="width: 5pt">          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">            <i>             Timelines                                         subject to potential disruption due to COVID-19 outbreak.            </i>           </font>          </td>         </tr>        </tbody>       </table>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 6pt; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 15pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            <b>             †            </b>           </font>          </td>          <td style="width: 5pt">          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">            <i>             Contingent                                         upon continued government contract/grant funding or other funding source.            </i>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <u>           SpecializedBioTherapeutics Overview          </u>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           SGX301– for Treating Cutaneous T-Cell Lymphoma          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         SGX301is a novel, first-in-class, photodynamic therapy that utilizes safe visible light for activation. The active ingredient in SGX301is synthetic hypericin, a photosensitizer which is topically applied to skin lesions and then activated by visible fluorescentlight 18 to 24 hours later. Hypericin is also found in several species of         <i>          Hypericum         </i>         plants, although the drug used in SGX301is chemically synthesized by a proprietary manufacturing process and not extracted from plants. Importantly, hypericin is optimallyactivated with visible light thereby avoiding the negative consequences of ultraviolet light, and enabling deeper penetrationof the light energy and activation of hypericin. Other light therapies using UVA or UVB light can result in serious adverse effectsincluding secondary skin cancers.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Combinedwith photoactivation, in clinical trials synthetic hypericin has demonstrated significant anti-proliferative effects on activatednormal human lymphoid cells and inhibited growth of malignant T-cells isolated from CTCL patients. In both settings, it appearsthat the mode of action is an induction of cell death in a concentration as well as a light dose-dependent fashion. These effectsappear to result, in part, from the generation of singlet oxygen during photoactivation of hypericin.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Hypericinis one of the most efficient known generators of singlet oxygen, the key component for phototherapy. The generation of singletoxygen induces necrosis and apoptosis in adjacent cells. The use of topical synthetic hypericin coupled with directed visiblelight results in generation of singlet oxygen only at the treated site. We believe that the use of visible light (as opposed tocancer-causing ultraviolet light) is a major advance in photodynamic therapy. In a published Phase 2 clinical study in CTCL, aftersix weeks of twice weekly therapy, a majority of patients experienced a statistically significant (p         <u>          &lt;         </u>         0.04) improvementwith SGX301 whereas the placebo was ineffective: 58.3% compared to 8.3%, respectively.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 6; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         3         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        SGX301 has received Orphan Drugdesignation as well as Fast Track designation from the FDA. The Orphan Drug Act is intended to assist and encouragecompanies to develop safe and effective therapies for the treatment of rare diseases and disorders. In addition to providinga seven-year term of market exclusivity for SGX301 upon final FDA approval, Orphan Drug designation also positions us to beable to leverage a wide range of financial and regulatory benefits, including government grants for conducting clinicaltrials, waiver of FDA user fees for the potential submission of a NDA for SGX301, and certain tax credits. In addition, FastTrack is a designation that the FDA reserves for a drug intended to treat a serious or life-threatening condition and onethat demonstrates the potential to address an unmet medical need for the condition. Fast Track designation is designed tofacilitate the development and expedite the review of new drugs. For instance, should events warrant, we will be eligible tosubmit a NDA for SGX301 on a rolling basis, permitting the FDA to review sections of the NDA prior to receiving the completesubmission. Additionally, NDAs for Fast Track development programs ordinarily will be eligible for priority review. SGX301for the treatment of CTCL also was granted Orphan Drug designation from the EMA Committee for Orphan Medical Products andPromising Innovative Medicine (“PIM”) designation from the Medicines and Healthcare Products Regulatory Agency(“MHRA”) in the United Kingdom (“UK”).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         InAugust 2018, the U.S. Patent Office granted us a patent titled “Systems and Methods for Producing Synthetic Hypericin”for the unique proprietary process manufacturing the highly purified form of synthetic hypericin, the active pharmaceutical ingredientin SGX301.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         InOctober 2019, the U.S. Patent Office allowed the divisional patent application titled “Systems and Methods for ProducingSynthetic Hypericin”. The allowed claims are directed to unique, proprietary methods to produce a novel, highly purifiedform of synthetic hypericin. This new divisional claim set expands on the previous issued claims in the parent U.S. patent.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         InApril 2020, the European patent office granted the divisional patent application titled “Formulations and Methods of Treatmentof Skin Conditions” (No. 2932973). The granted claims are directed to the therapeutic use of synthetic hypericin in thetreatment of CTCL. This new patent expands on our comprehensive patent estate, which includes protection on the composition ofthe purified synthetic hypericin, methods of synthesis and therapeutic methods of use in both CTCL and psoriasis, and is beingpursued worldwide.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Basedon the positive and previously published Phase 2 results, we initiated our pivotal Phase 3 clinical study of SGX301 for the treatmentof CTCL during December 2015 and completed the trial in 2020. This trial, referred to as the “FLASH” study (         <u>          F         </u>         luorescent         <u>          L         </u>         ight         <u>          A         </u>         ctivated         <u>          S         </u>         ynthetic         <u>          H         </u>         ypericin), aims to evaluate the response to SGX301 as a skin directed therapyto treat early stage CTCL. We have completed the study with approximately 35 CTCL centers across the U.S. participating in thispivotal trial. The Phase 3 protocol was a highly powered, double-blind, randomized, placebo-controlled, multicenter trial thatenrolled 169 subjects (166 evaluable). The trial consisted of three treatment cycles, each of eight weeks duration. Treatmentswere administered twice weekly for the first six weeks and treatment response was determined at the end of the eighth week. Inthe first treatment cycle, approximately 66% of subjects received SGX301 and 33% received placebo treatment of their index lesions.In the second cycle, all subjects received SGX301 treatment of their index lesions, and in the third cycle, all subjects receivedSGX301 treatment of all of their lesions. The majority of subjects enrolled to date have elected to continue into the third optional,open-label cycle of the study. Subjects were followed for an additional six months after their last evaluation visit. The primaryefficacy endpoint was assessed on the percentage of patients in each of the two treatment groups (i.e., SGX301 and placebo) achievinga partial or complete response of the treated lesions, defined as a ≥ 50% reduction in the total Composite Assessment of IndexLesion Disease Severity (“CAILS”) score for three index lesions at the Cycle 1 evaluation visit (Week 8) comparedto the total CAILS score at baseline. Other secondary measures assessed treatment response including duration, degree of improvement,time to relapse and safety. We continue to work closely with the Cutaneous Lymphoma Foundation, as well as the National Organizationfor Rare Disorders.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         DuringSeptember 2017, the National Cancer Institute (“NCI”), part of the National Institutes of Health (“NIH”)awarded us a Small Business Innovation Research (“SBIR”) grant of approximately $1.5 million over two years to supportthe conduct of our pivotal, Phase 3, randomized, double-blind, placebo-controlled study evaluating SGX301 (synthetic hypericin)as a treatment for CTCL. This grant was exhausted as of December 2019.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         DuringOctober 2018, an Independent Data Monitoring Committee (“DMC”) completed an unblinded interim analysis with data fromapproximately 100 subjects, including an assessment of the Phase 3 FLASH study’s primary efficacy endpoint. The DMC provideda positive recommendation to randomize approximately 40 additional subjects into the trial to maintain the rigorous assumptionof 90% statistical power for the primary efficacy endpoint. No safety concerns were reported by the DMC based on the interim analysis.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 7; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         4         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Positiveprimary endpoint analysis for the Phase 3 study for SGX301 was completed in March 2020. The study enrolled 169 patients (166 evaluable)randomized 2:1 to receive either SGX301 (116 patients) or placebo (50 patients) and demonstrated a statistically significant treatmentresponse (p=0.04) in the CAILS primary endpoint assessment at 8 weeks for Cycle 1. A total of 16% of the patients receiving SGX301achieved at least a 50% reduction in their index lesions compared to only 4% of patients in the placebo group at 8 weeks. SGX301treatment in the first cycle was safe and well tolerated.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         DuringApril 2020, analysis of the second open-label treatment cycle (“Cycle 2”) was completed, showing that continued treatmentwith SGX301 twice weekly for an additional 6 weeks (12 weeks total) increased the positive response rate to 40% (p&lt;0.0001 comparedto placebo and p&lt;0.0001 compared to 6-weeks treatment). After the subsequent additional 6-week treatment, the response ratein patients receiving a total of 12 weeks treatment increased two and a half-fold. Treatment responses were assessed at Week 8(after 6 weeks of treatment) and at Week 16 (after 12 weeks of treatment). A positive response was defined as an improvement ofat least 50% in the CAILS score for the three index lesions evaluated in both Cycles 1 and 2. The data continued to indicate thatSGX301 is safe and well tolerated.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         DuringOctober 2020, analysis of the optional third open-label treatment cycle (“Cycle 3”) was completed. Cycle 3 was focusedon safety and all patients could elect to receive SGX301 treatment of all their lesions for an additional 6 weeks or up to 18weeks in total. Of note, 66% of patients elected to continue with this optional safety cycle of the study. Of the subset of patientsthat received SGX301 throughout all three cycles of treatment (18 weeks), 49% of them demonstrated a treatment response (p=0.046vs. patients completing 12 weeks of SGX301 treatment in Cycle 2; p&lt;0.0001 vs. patients receiving placebo in Cycle 1). Moreover,in a subset of patients evaluated in this cycle, it was demonstrated that SGX301 is not systemically available, consistent withthe general safety of this topical product observed to date. At the end of Cycle 3, SGX301 continued to be well tolerated despiteextended and increased use of the product to treat multiple lesions.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Inaddition, continued analysis of results from the protocol mandated efficacy cycles (Cycles 1 and 2) of the study revealed that12 weeks of treatment (Cycle 2) with SGX301 was equally effective on both patch (response 37%, p=0.0009) and plaque (response42%, p&lt;0.0001) lesions when compared to Cycle 1 placebo lesion responses, further demonstrating the unique benefits of themore deeply penetrating visible light activation of hypericin.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         DuringJanuary 2021, we announced that we signed an exclusive Supply, Distribution and Services Agreement with The Daavlin DistributingCo. (“Daavlin”), securing long-term supply and distribution of a commercially ready light device, which is anintegral component of the regulatory and commercial strategy for SGX301 for the treatment of CTCL.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Pursuantto the Agreement, Daavlin will exclusively manufacture the proprietary light device for use with SGX301 for the treatment of CTCL.Upon approval of SGX301 by the FDA, we will promote SGX301 and the companion light device, and facilitate the direct purchaseof the device from Daavlin. Daavlin will exclusively distribute and sell the SGX301 light device to us, physicians and patients.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         InFebruary 2021, we announced that the Hong Kong Registrar of Patents granted a patent for the application titled "Formulationsand Methods of Treatment of Skin Conditions" (No. 16102842.8), published on January 29, 2021 under PublicationNo. 1214771 B. The granted claims are directed to the therapeutic use of synthetic hypericin in the treatment of CTCL, similarto those granted in Europe in 2020. This new patent is the first granted in Hong Kong and expands on our comprehensivepatent estate, which includes protection on the composition of the purified synthetic hypericin, methods of synthesis and therapeuticmethods of use in both CTCL and psoriasis.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Weestimate the potential worldwide market for SGX301 is in excess of $250 million for all applications, including the treatmentof CTCL. This potential market information is a forward-looking statement, and investors are urged not to place undue relianceon this statement. While we have determined this potential market size based on assumptions that we believe are reasonable, thereare a number of factors that could cause our expectations to change or not be realized.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 8; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         5         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          CutaneousT-Cell Lymphoma         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         CTCLis a class of non-Hodgkin’s lymphoma (“NHL”), a type of cancer of the white blood cells that are an integralpart of the immune system. Unlike most NHLs, which generally involve B-cell lymphocytes (involved in producing antibodies), CTCLis caused by an expansion of malignant T-cell lymphocytes (involved in cell-mediated immunity) normally programmed to migrateto the skin. These skin-trafficking malignant T-cells migrate to the skin, causing various lesions to appear that may change shapeas the disease progresses, typically beginning as a rash and eventually forming plaques and tumors. Mycosis fungoides (“MF”)is the most common form of CTCL. It generally presents with skin involvement only, manifested as scaly, erythematous patches.Advanced disease with diffuse lymph node and visceral organ involvement is usually associated with a poorer response rate to standardtherapies. A relatively uncommon sub-group of CTCL patients present with extensive skin involvement and circulating malignantcerebriform T-cells, referred to as Sézary syndrome. These patients have substantially graver prognoses (expected five-yearsurvival rate of 24%), than those with MF (expected five-year survival rate of 88%).        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         CTCLmortality is related to stage of disease, with median survival generally ranging from about 12 years in the early stages to only2.5 years when the disease has advanced. There is currently no FDA-approved drug for front-line treatment of early stage CTCL.Treatment of early-stage disease generally involves skin-directed therapies. One of the most common unapproved therapies usedfor early-stage disease is oral 5 or 8-methoxypsoralen (“Psoralen”) given with ultraviolet A (“UVA”) light,referred to as PUVA, which is approved for dermatological conditions such as disabling psoriasis not adequately responsive toother forms of therapy, idiopathic vitiligo and skin manifestations of CTCL in persons who have not been responsive to other formsof treatment. Psoralen is a mutagenic chemical that interferes with DNA causing mutations and other malignancies. Moreover, UVAis a carcinogenic light source that when combined with the Psoralen, results in serious adverse effects including secondary skincancers; therefore, the FDA requires a Black Box warning for PUVA.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         CTCLconstitutes a rare group of NHLs, occurring in about 4% of the approximate 500,000 individuals living with NHL. We estimate, basedupon review of historic published studies and reports and an interpolation of data on the incidence of CTCL, that it affects over20,000 individuals in the U.S., with approximately 2,800 new cases seen annually.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          Dusquetide         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Dusquetide(research name: SGX94) is an IDR that regulates the innate immune system to simultaneously reduce inflammation, eliminate infectionand enhance tissue healing.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Dusquetideis based on a new class of short, synthetic peptides known as IDRs. It has a novel mechanism of action in that it modulates thebody’s reaction to both injury and infection and is both simultaneously anti-inflammatory and anti-infective. IDRs haveno direct antibiotic activity but modulate host responses, increasing survival after infections with a broad range of bacterialGram-negative and Gram-positive pathogens including both antibiotic sensitive and resistant strains, as well as accelerating resolutionof tissue damage following exposure to a variety of agents including bacterial pathogens, trauma and chemo- or radiation-therapy.IDRs represent a novel approach to the control of infection and tissue damage via highly selective binding to an intracellularadaptor protein, sequestosome-1, also known as p62, which has a pivotal function in signal transduction during activation andcontrol of the innate defense system. Preclinical data indicate that IDRs may be active in models of a wide range of therapeuticindications including life-threatening bacterial infections as well as the severe side-effects of chemo- and radiation-therapy.Additionally, due to selective binding to p62, dusquetide may have potential anti-tumor action.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Dusquetidehas demonstrated efficacy in numerous animal disease models including mucositis, colitis, skin infection and other bacterial infectionsand has been evaluated in a double-blind, placebo-controlled Phase 1 clinical trial in 84 healthy volunteers with both singleascending dose and multiple ascending dose components. Dusquetide was shown to have a good safety profile and be well-toleratedin all dose groups when administered by IV over 7 days and was consistent with safety results seen in pre-clinical studies. Webelieve that market opportunities for dusquetide include, but are not limited to, oral and GI mucositis, acute Gram-positive bacterialinfections (e.g., methicillin resistant         <i>          Staphylococcus aureus         </i>         (MRSA)), acute Gram-negative infections (e.g., acinetobacter,melioidosis), and acute radiation syndrome.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 9; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         6         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           SGX942– for Treating Oral Mucositis in Head and Neck Cancer          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         SGX942is our product candidate containing our IDR technology, dusquetide, targeting the treatment of oral mucositis in head and neckcancer patients. Oral mucositis in this patient population is an area of unmet medical need where there are currently no approveddrug therapies. Accordingly, we received Fast Track designation for the treatment of oral mucositis as a result of radiation and/orchemotherapy treatment in head and neck cancer patients from the FDA. In addition, dusquetide has been granted PIM designationin the UK by the MHRA for the treatment of severe oral mucositis in head and neck cancer patients receiving chemoradiation therapy.The U.S. Patent and Trademark Office and the European Patent Office granted us the patent titled “Novel Peptides and Analogsfor Use in the Treatment of Oral Mucositis” on August 16, 2016 and January 23, 2019, respectively. The newly issued patentclaims therapeutic use of dusquetide and related IDR analogs, and adds to composition of matter claims for dusquetide and relatedanalogs that have been granted in the U.S. and worldwide.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Weinitiated a Phase 2 clinical study of SGX942 for the treatment of oral mucositis in head and neck cancer patients in Decemberof 2013. We completed enrollment in this trial in the second half of 2015, and in December 2015 released positive preliminaryresults. In this Phase 2 proof-of-concept clinical study that enrolled 111 patients, SGX942, at a dose of 1.5 mg/kg, successfullyreduced the median duration of severe oral mucositis by 50%, from 18 days to 9 days (p=0.099) in all patients and by 67%, from30 days to 10 days (p=0.040) in patients receiving the most aggressive chemoradiation therapy for treatment of their head andneck cancer. The p-values met the prospectively defined statistical threshold of p&lt;0.1 in the study protocol. A less severeoccurrence of oral mucositis, ulcerative oral mucositis (defined as oral mucositis with a WHO score ≥2 corresponding to theoccurrence of overt ulceration in the mouth), was also monitored during the study. In the patients receiving the most aggressivechemoradiation therapy, the median duration of oral mucositis was found to decrease from 65 days in the placebo treated patientsto 51 days in the patients treated with SGX942 1.5 mg/kg (p=0.099).        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Inaddition to identifying the best dose of 1.5 mg/kg, this study achieved all objectives, including increased incidence of “completeresponse” of tumor at the one month follow-up visit (47% in placebo vs. 63% in SGX942 at 1.5 mg/kg). Decreases in mortalityand decreases in infection rate were also observed with SGX942 treatment, consistent with the preclinical results observed inanimal models.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         SGX942was found to be generally safe and well tolerated, consistent with the safety profile observed in the prior Phase 1 study conductedin 84 healthy volunteers. The long-term (12 month) follow-up data was consistent with the preliminary positive safety and efficacyfindings. While the placebo population experienced the expected 12-month survival rate of approximately 80%, as defined in theSurveillance, Epidemiology, and End Results statistics 1975-2012 from the National Cancer Institute, the SGX942 1.5 mg/kg treatmentgroup reported a 12-month survival rate of 93% (7% mortality in the SGX942 1.5 mg/kg group compared to 19% in the placebo group).Similarly, tumor resolution (complete response) at 12 months was better in the SGX942 1.5 mg/kg treatment group relative to theplacebo population (80% in the 1.5 mg/kg group compared to 74% in the placebo group). Moreover, in the patients receiving chemotherapyevery third week, the SGX942 1.5 mg/kg treatment group had a tumor resolution rate (complete response) of 82% throughout the 12months following chemoradiation therapy, while the placebo group experienced a 64% complete response rate. The long-term follow-upresults from the Phase 2 study are reviewed in “Dusquetide: Reduction in Oral Mucositis associated with Enduring AncillaryBenefits in Tumor Resolution and Decreased Mortality in Head and Neck Cancer Patients” published online in BiotechnologyReports and available at the following link: https://doi.org/10.1016/j.btre.2017.05.002. In addition to safety, evaluations ofother secondary efficacy endpoints, such as the utilization of opioid pain medication, indicated that the SGX942 1.5 mg/kg treatmentgroup had a 40% decrease in the use of opioids at the later stage of the treatment phase of the trial, when oral mucositis isusually most severe and expected to increase pain medication use. This was in contrast to the placebo group, which demonstrateda 10% increase in use of opioids over this same period. Data from this Phase 2 trial was published online in the Journal of Biotechnology.The publication also delineates the supportive nonclinical data in this indication, demonstrating consistency in the qualitativeand quantitative biological response, including dose response, across the nonclinical and clinical data sets. The results areavailable at the following link: http://authors.elservier.com/sd/article/S01681656116315668.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         OnSeptember 9, 2016, we and SciClone Pharmaceuticals, Inc. (“SciClone”) entered into an exclusive license agreement,pursuant to which we granted rights to SciClone to develop, promote, market, distribute and sell SGX942 in defined territories.Under the terms of the license agreement, SciClone will be responsible for all aspects of development, product registration andcommercialization in the territories, having access to data generated by us. In exchange for exclusive rights, SciClone will payus royalties on net sales, and we will supply commercial drug product to SciClone on a cost-plus basis, while maintaining worldwidemanufacturing rights.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 10; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         7         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         DuringJuly 2017, we initiated our pivotal Phase 3 clinical trial referred to as the “DOM–INNATE” study (         <u>          D         </u>         usquetidetreatment in         <u>          O         </u>         ral         <u>          M         </u>         ucositis – by modulating         <u>          INNATE         </u>         immunity) with a controlled roll-out of U.S. studysites, followed by the addition of European centers in 2018. Approximately 50 U.S. and European oncology centers are participatingin this pivotal Phase 3 study. Based on the positive and previously published Phase 2 results (Study IDR-OM-01), the pivotal Phase3 clinical trial (Study IDR-OM-02) was a highly powered, double-blind, randomized, placebo-controlled, multinational trial thatsought to enroll approximately 260 subjects with squamous cell carcinoma of the oral cavity and oropharynx who were scheduledto receive a minimum total cumulative radiation dose of 55 Gy fractionated as 2.0-2.2 Gy per day with concomitant cisplatin chemotherapygiven as a dose of 80-100 mg/m         <sup>          2         </sup>         every third week. Subjects were randomized to receive either 1.5 mg/kg SGX942 or placebogiven twice a week during and for two weeks following completion of chemoradiation therapy (“CRT”). The primary endpointfor the study was the median duration of SOM, which was assessed by oral examination at each treatment visit and then throughsix weeks following completion of CRT. Oral mucositis is evaluated using the WHO Grading system. SOM is defined as a WHO Gradeof ≥3. Subjects are followed for an additional 12 months after the completion of treatment.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        During September 2017, the National Institute of Dental andCraniofacial Research (“NIDCR”), part of the NIH, awarded us a SBIR grant of approximately $1.5 million over two yearsto support the conduct of our Phase 3, multinational, randomized, double-blind, placebo-controlled study evaluating SGX942 (dusquetide)as a treatment for severe oral mucositis in patients with head and neck cancer receiving CRT. This grant was completed in August2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         OnApril 9, 2019, the U.S. Patent Office issued a new patent No. 10,253,068 titled “Novel Peptides for Treating and PreventingImmune-Related Disorders, Including Treating and Preventing Infection by Modulating Innate Immunity” for our dusquetiderelated analogs.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         InApril 2019, the Paediatric Committee of the EMA approved our Paediatric Investigation Plan (“PIP”) for SGX942, a prerequisitefor filing a Marketing Authorization Application (“MAA”) for any new medicinal product in Europe. The EMA also agreedthat we may defer conducting the PIP until successful completion of our ongoing pivotal Phase 3 clinical trial of SGX942, whichallows us to file the adult indication MAA prior to completion of the PIP.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         InAugust 2019, the NIDCR awarded us a Phase I SBIR grant of approximately $150,000 to support the evaluation of SGX942 (dusquetide)in pediatric indications. This award will facilitate the assessment of SGX942 safety in juvenile animals, supporting future studiesin pediatric populations, including oral mucositis indications in pediatric patients undergoing stem cell transplants and treatmentsfor head and neck cancer.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         DuringAugust 2019, an independent DMC completed an unblinded interim analysis with data from approximately 90 subjects, including anassessment of the Phase 3 DOM-INNATE study’s primary efficacy endpoint. The DMC provided a positive recommendation to randomizeapproximately 70 additional subjects into the trial to maintain the rigorous assumption of 90% statistical power for the primaryefficacy endpoint. No safety concerns were reported by the DMC based on the interim analysis.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         InFebruary 2020, the Japanese Patent Office granted the patent titled “Novel Peptides and Analogs for Use in the Treatmentof Oral Mucositis.” This allowance builds on similar intellectual property in the U.S., New Zealand, Australia and Singaporeand patent applications pending in other jurisdictions worldwide. The new claims cover therapeutic use of dusquetide (active ingredientin SGX942) and related IDR analogs, and add to composition of matter claims for dusquetide and related analogs that have beengranted in the U.S. and worldwide.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 11; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         8         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         InJune 2020, the pivotal Phase 3 DOM–INNATE study (Study IDR-OM-02) completed enrollment of 268 subjects. In December 2020,we announced the results of our Phase 3 clinical trial for SGX942 noting that the primary endpoint of median duration of SOM didnot achieve the pre-specified criterion for statistical significance (p≤0.05); although biological activity was observed witha 56% reduction in the median duration of SOM from 18 days in the placebo group to 8 days in the SGX942 treatment group. Despitethis clinically meaningful improvement, the variability in the distribution of the data yielded a p-value that was not statisticallysignificant. Other secondary endpoints supported the biological activity of dusquetide, including a statistically significant50% reduction in the median duration of SOM in the per-protocol population, which decreased from 18 days in the placebo groupto 9 days in the SGX942 treatment group (p=0.049), consistent with the findings in the Phase 2 trial (Study IDR-OM-01). Similarly,incidence of SOM also followed this biological trend as seen in the Phase 2 study, decreasing by 16% in the SGX942 treatment grouprelative to the placebo group in the per-protocol population. The per-protocol population was defined as the population receivinga minimum of 55 Gy radiation and at least 10 doses of study drug (placebo or SGX942) throughout the intended treatment period,with no major protocol deviations (e.g. breaks in study drug administration longer than 8 days between successive doses). We areanalyzing the data to better determine why the study did not meet expectations. If there is any clarity gained from further analysisof the dataset, especially with respect to specific subsets of patients that may benefit from SGX942 therapy, we will communicateour findings and explore follow-up discussions with the FDA and the EMA.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          OralMucositis         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Mucositisis the clinical term for damage done to the mucosa by anticancer therapies. It can occur in any mucosal region, but is most commonlyassociated with the mouth, followed by the small intestine. We estimate, based upon our review of historic studies and reports,and an interpolation of data on the incidence of mucositis, that mucositis affects approximately 500,000 people in the U.S. peryear and occurs in 40% of patients receiving chemotherapy. Mucositis can be severely debilitating and can lead to infection, sepsis,the need for parenteral nutrition and narcotic analgesia. The GI damage causes severe diarrhea. These symptoms can limit the dosesand duration of cancer treatment, leading to sub-optimal treatment outcomes.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Themechanisms of mucositis have been extensively studied and have been linked to the interaction of chemotherapy and/or radiationtherapy with the innate defense system. Bacterial infection of the ulcerative lesions is regarded as a secondary consequence ofdysregulated local inflammation triggered by therapy-induced cell death, rather than as the primary cause of the lesions.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Weestimate, based upon our review of historic studies and reports, and an interpolation of data on the incidence of oral mucositis,that oral mucositis is a subpopulation of approximately 90,000 patients in the U.S., with a comparable number in Europe. Oralmucositis almost always occurs in patients with head and neck cancer treated with radiation therapy (greater than 80% incidenceof severe mucositis) and is common in patients undergoing high dose chemotherapy and hematopoietic cell transplantation, wherethe incidence and severity of oral mucositis depends greatly on the nature of the conditioning regimen used for myeloablation.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          OralBDP         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         OralBDP (beclomethasone 17,21-dipropionate) represents a first         <b>          -         </b>         of         <b>          -         </b>         its         <b>          -         </b>         kind oral, locally acting therapy tailoredto treat GI inflammation. BDP has been marketed in the U.S. and worldwide since the early 1970s as the active pharmaceutical ingredientin a nasal spray and in a metered-dose inhaler for the treatment of patients with allergic rhinitis and asthma. Oral BDP is specificallyformulated for oral administration as a single product consisting of two tablets. One tablet is intended to release BDP in theupper sections of the GI tract and the other tablet is intended to release BDP in the lower sections of the GI tract.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Basedon its pharmacological characteristics, oral BDP may have utility in treating other conditions of the GI tract having an inflammatorycomponent. We are planning to pursue development programs for the treatment of pediatric Crohn’s disease, acute radiationenteritis and GI acute radiation syndrome pending further grant funding. We are also exploring the possibility of testing oralBDP for local inflammation associated with ulcerative colitis, among other indications.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         InJuly 2019, the European Patent Office issued two patents, both titled “Topically Active Steroids for use in Radiation andChemotherapeutic Injury”, following the expiration of the objection period. The new patents (#2,373,160 and #2,902,031)claim use of oral beclomethasone 17,21-dipropionate (BDP) for treatment of damage to the GI tract as a result of acute radiationinjury, including total body irradiation in the accidental or biodefense context.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Weestimate the potential worldwide market for oral BDP is in excess of $500 million for all applications, including the treatmentof pediatric Crohn’s disease. This potential market information is a forward-looking statement, and investors are urgednot to place undue reliance on this statement. While we have determined this potential market size based on assumptions that webelieve are reasonable, there are a number of factors that could cause our expectations to change or not be realized.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 12; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         9         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           SGX203– for Treating Pediatric Crohn’s Disease          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         SGX203is a two tablet delivery system of BDP specifically designed for oral use that allows for administration of immediate and delayedrelease BDP throughout the small bowel and the colon. The FDA has given SGX203 Orphan Drug designation as well as Fast Track designationfor the treatment of pediatric Crohn’s disease. We will pursue a pivotal Phase 3 clinical trial of SGX203 for the treatmentof pediatric Crohn’s disease contingent upon additional funding, such as through partnership funding support.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          PediatricCrohn’s Disease         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Crohn’sdisease causes inflammation of the GI tract. Crohn’s disease can affect any area of the GI tract, from the mouth to theanus, but it most commonly affects the lower part of the small intestine, called the ileum. The swelling caused by the diseaseextends deep into the lining of the affected organ. The swelling can induce pain and can make the intestines empty frequently,resulting in diarrhea. Because the symptoms of Crohn’s disease are similar to other intestinal disorders, such as irritablebowel syndrome and ulcerative colitis, it can be difficult to diagnose. People of Ashkenazi Jewish heritage have an increasedrisk of developing Crohn’s disease.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         Crohn’sdisease can appear at any age, but it is most often diagnosed in adults in their 20s and 30s. However, approximately 30% of peoplewith Crohn’s disease develop symptoms before 20 years of age. We estimate, based upon our review of historic published studiesand reports, and an interpolation of data on the incidence of pediatric Crohn’s disease, that pediatric Crohn’s diseaseis a subpopulation of approximately 80,000 patients in the U.S. with a comparable number in Europe. Crohn’s disease tendsto be both severe and extensive in the pediatric population and a relatively high proportion (approximately 40%) of pediatricCrohn’s patients have involvement of their upper GI tract.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Crohn’sdisease presents special challenges for children and teens. In addition to bothersome and often painful symptoms, the diseasecan stunt growth, delay puberty, and weaken bones. Crohn’s disease symptoms may sometimes prevent a child from participatingin enjoyable activities. The emotional and psychological issues of living with a chronic disease can be especially difficult foryoung people.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           SGX201– for Preventing Acute Radiation Enteritis          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         SGX201is a delayed-release formulation of BDP specifically designed for oral use. In 2012, we completed a Phase 1/2 clinical trial testingSGX201 in prevention of acute radiation enteritis. Patients with rectal cancer scheduled to undergo concurrent radiation and chemotherapyprior to surgery were randomized to one of four dose groups. The objectives of the study were to evaluate the safety and maximaltolerated dose of escalating doses of SGX201, as well as the preliminary efficacy of SGX201 for prevention of signs and symptomsof acute radiation enteritis. The study demonstrated that oral administration of SGX201 was safe and well tolerated across allfour dose groups. There was also evidence of a potential dose response with respect to diarrhea, nausea and vomiting and the assessmentof enteritis according to National Cancer Institute Common Terminology Criteria for Adverse Events for selected GI events. Inaddition, the incidence of diarrhea was lower than that seen in published historical control data in this patient population.This program was supported in part by a $500,000 two-year SBIR grant awarded by the NIH. We continue to work with our RadiationEnteritis medical advisors to identify additional funding opportunities to support the clinical development program.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Wehave received Fast Track designation from the FDA for SGX201 for acute radiation enteritis.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 13; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         10         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          AcuteRadiation Enteritis         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Externalradiation therapy is used to treat most types of cancer, including cancer of the bladder, uterine, cervix, rectum, prostate, andvagina. During delivery of treatment, some level of radiation will also be delivered to healthy tissue, including the bowel, leadingto acute and chronic toxicities. The large and small bowels are very sensitive to radiation and the larger the dose of radiationthe greater the damage to normal bowel tissue. Radiation enteritis is a condition in which the lining of the bowel becomes swollenand inflamed during or after radiation therapy to the abdomen, pelvis, or rectum. Most tumors in the abdomen and pelvis need largedoses, and almost all patients receiving radiation to the abdomen, pelvis, or rectum will show signs of acute enteritis.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Patientswith acute enteritis may have nausea, vomiting, abdominal pain and bleeding, among other symptoms. Some patients may develop dehydrationand require hospitalization. With diarrhea, the GI tract does not function normally, and nutrients such as fat, lactose, bilesalts, and vitamin B12 are not well absorbed.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Symptomswill usually resolve within two to six weeks after therapy has ceased. Radiation enteritis is often not a self-limited illness,as over 80% of patients who receive abdominal radiation therapy complain of a persistent change in bowel habits. Moreover, acuteradiation injury increases the risk of development of chronic radiation enteropathy, and overall 5% to 15% of the patients whoreceive abdominal or pelvic irradiation will develop chronic radiation enteritis.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Weestimate, based upon our review of historic published studies and reports, and an interpolation of data on the treatment coursesand incidence of cancers occurring in the abdominal and pelvic regions, there to be over 100,000 patients annually in the U.S.,with a comparable number in Europe, who receive abdominal or pelvic external beam radiation treatment for cancer, and these patientsare at risk of developing acute and chronic radiation enteritis.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         <b>          PublicHealth Solutions Overview         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           ThermoVax           <sup>            ®           </sup>           – Thermostability Technology          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         ThermoVax         <sup>          ®         </sup>         is a novel method for thermostabilizing vaccines with a variety of adjuvants, resulting in a single vial which can be reconstitutedwith water for injection immediately prior to use.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Oneof the adjuvants utilized in ThermoVax         <sup>          ®         </sup>         is aluminum salts (known colloquially as Alum). Alum is the most widelyemployed adjuvant technology in the vaccine industry.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Thevalue of ThermoVax         <sup>          ®         </sup>         lies in its potential ability to eliminate the need for cold chain production, transportation,and storage for Alum-adjuvanted vaccines. This would relieve the high costs of producing and maintaining vaccines under refrigeratedconditions. Based on historical reports from the World Health Organization and other scientific reports, we believe that a meaningfulproportion of vaccine doses globally are wasted due to excursions from required cold chain temperature ranges. This is due tothe fact that many vaccines need to be maintained either between 2 and 8 degrees Celsius (“C”), frozen below -20 degreesC, or frozen below -60 degrees C, and even brief excursions from these temperature ranges usually necessitate the destructionof the product or the initiation of costly stability programs specific for the vaccine lots in question. ThermoVax         <sup>          ®         </sup>         hasthe potential to facilitate easier storage and distribution of strategic national stockpile vaccines for ricin exposure in emergencysettings.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         ThermoVax         <sup>          ®         </sup>         development, specifically in the context of an Alum adjuvant, was supported pursuant to our $9.4 million NIAID grant enablingdevelopment of thermo-stable ricin (RiVax         <sup>          ®         </sup>         ) and anthrax vaccines. Proof-of-concept preclinical studies with ThermoVax         <sup>          ®         </sup>         indicate that it is able to produce stable vaccine formulations using adjuvants, protein immunogens, and other componentsthat ordinarily would not withstand long temperature variations exceeding customary refrigerated storage conditions. These studieswere conducted with our Alum-adjuvanted ricin toxin vaccine, RiVax         <sup>          ®         </sup>         and our Alum-adjuvanted anthrax vaccine. Eachvaccine was manufactured under precise lyophilization conditions using excipients that aid in maintaining native protein structureof the key antigen. When RiVax         <sup>          ®         </sup>         was kept at 40 degrees C (104 degrees Fahrenheit) for up to one year, all of theanimals vaccinated with the lyophilized RiVax         <sup>          ®         </sup>         vaccine developed potent and high titer neutralizing antibodies.In contrast, animals that were vaccinated with the liquid RiVax         <sup>          ®         </sup>         vaccine kept at 40 degrees C did not develop neutralizingantibodies and were not protected against ricin exposure. The ricin A chain is extremely sensitive to temperature and rapidlyloses the ability to induce neutralizing antibodies when exposed to temperatures higher than 8 degrees C. When the anthrax vaccinewas kept for up to 16 weeks at 70 degrees C, it was able to develop a potent antibody response, unlike the liquid formulationkept at the same temperature. Moreover, we also have demonstrated the compatibility of our thermostabilization technology withother secondary adjuvants such as TLR-4 agonists.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 14; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         11         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Wealso entered into a collaboration agreement with Axel Lehrer, PhD of the Department of Tropical Medicine, Medical Microbiologyand Pharmacology, John A. Burns School of Medicine, University of Hawai         <font style="text-transform: uppercase">          ʻ         </font>         iat Manoa (“UH Manoa”) and Hawaii Biotech, Inc. (“HBI”) to develop a heat stable subunit Ebola vaccine.Dr. Lehrer, a co-inventor of the Ebola vaccine with HBI, has shown proof of concept efficacy with subunit Ebola vaccines in non-humanprimates. The most advanced Ebola vaccines involve the use of vesicular stomatitis virus and adenovirus vectors – live,viral vectors which complicate the manufacturing, stability and storage requirements. Dr. Lehrer’s vaccine candidate isbased on highly purified recombinant protein antigens, circumventing many of these manufacturing difficulties. Dr. Lehrer andHBI have developed a robust manufacturing process for the required proteins. Application of ThermoVax         <sup>          ®         </sup>         may allowfor a product that can avoid the need for cold chain distribution and storage, yielding a vaccine ideal for use in both the developedand developing world. This agreement has expired in accordance with its terms.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         OnDecember 21, 2010, we executed a worldwide exclusive license agreement with the University of Colorado (“UC”) forcertain patents relating to ThermoVax         <sup>          ®         </sup>         in all fields of use. In April 2018, the UC delivered a notice of terminationof our license agreement based upon our failure to achieve one of the development milestones: initiation of the Phase 1 clinicaltrial of the heat stabilization technology by March 31, 2018. After negotiating with the UC, we and the UC agreed to extend thetermination date to October 31, 2018 in order to allow us time to agree upon a potential agreement that would allow us to keepthe rights to, and to continue to develop, the heat stabilization technology or a product candidate containing the heat stabilizationtechnology in our field of use.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         DuringSeptember 2017, we announced we will be participating in a NIAID Research Project (R01) grant awarded to UH Manoa for the developmentof a trivalent thermostabilized filovirus vaccine (including protection against         <i>          Zaire ebolavirus         </i>         ,         <i>          Sudan ebolavirus         </i>         and         <i>          Marburg Marburgvirus         </i>         ), with our awarded funding of approximately $700,000 over five years. Previous collaborationsdemonstrated the feasibility of developing a heat stable subunit Ebola vaccine. Under the terms of the subaward, we will continueto support vaccine formulation development with our proprietary vaccine thermostabilization technology, ThermoVax         <sup>          ®         </sup>         .Ultimately, the objective is to produce a thermostable trivalent filovirus vaccine for protection against Ebola and related diseases,allowing worldwide distribution without the need for cold storage. Based on current U.S. government needs, efforts have recentlybeen expanded to focus on a monovalent or bivalent vaccine to specifically address         <i>          Marburg marburgvirus         </i>         .        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         OnOctober 31, 2018, in a series of related transactions, (a) we and the UC agreed to terminate the original license agreement, (b)the UC and VitriVax, Inc. (“VitriVax”) executed a worldwide exclusive license agreement for the heat stabilizationtechnology for all fields of use, and (c) we and VitriVax executed a worldwide exclusive sublicense agreement, which was amendedand restated in October 2020, for the heat stabilization technology for use in the fields of ricin and Ebola vaccines. We paida $100,000 sublicense fee on the effective date of the sublicense agreement. Under the amended sublicense agreement to maintainthe sublicense we are obliged to pay a minimum annual royalty of $20,000 until first commercial sale of a sublicensed product,upon which point, we shall pay an earned royalty of 2% of net sales subject to a minimum royalty of $50,000 each year. We arealso required to pay royalty on any sub-sublicense income based on a declining percentage of all sub-sublicense income calculatedwithin the contractual period until reaching a minimum of 15% after two years. In addition, we are required to pay VitriVax milestonefees of: (a) $25,000 upon initiation of a Phase 2 clinical trial of the sublicensed product, (b) $100,000 upon initiation of aPhase 3 clinical trial of the sublicensed product, (c) $100,000 upon regulatory approval of a sublicensed product, and (d) $1million upon achieving $10 million in aggregate net sales of a sublicensed product in the U.S. or equivalent. To date none ofthese milestones have been met.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         OnFebruary 7, 2019, European Journal of Pharmaceutics and Biopharmaceutics published a scientific article demonstrating the successfulthermostabilization of an Alum-adjuvanted Ebola subunit vaccine candidate.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         OnJuly 31, 2019, we and our collaborators presented two posters on the trivalent vaccine program. The first poster outlined thestability of the lyophilized formulations of the Ebola virus glycoprotein upon lyophilization and storage at temperatures as highas 40 degrees C (104 degrees F) and identified potential stability assays. The second poster further demonstrated the abilityto co-lyophilize multiple antigens in the presence of an emulsion forming adjuvant, facilitating the development of a thermostabletrivalent vaccine.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 15; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         12         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On March 11, 2020, we entered into a research collaborationwith the Axel Lehrer, PhD of the Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns School ofMedicine, UH Manoa to further expand the filovirus collaboration to investigation of potential coronavirus vaccines, includingfor SARS-CoV-2 (causing COVID-19). This research collaboration will utilize the technology platform developed in the search forfilovirus vaccines and will use well-defined surface glycoprotein(s) from one or more coronaviruses, which are expected to be protectivefor COVID-19.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         OnApril 16, 2020, we obtained an exclusive worldwide license for CiVax         <sup>          TM         </sup>         , a novel vaccine adjuvant, from BTG SpecialtyPharmaceuticals (“BTG”), a division of Boston Scientific Corporation, for the fields of coronavirus infection (includingSARS-CoV-2, the cause of COVID-19), and pandemic flu. CiVax         <sup>          TM         </sup>         is a novel adjuvant, which has been shown to enhanceboth cell-mediated and antibody-mediated immunity. We and our collaborators, including UH Manoa and Dr. Axel Lehrer, have successfullydemonstrated the utility of CiVax         <sup>          TM         </sup>         in the development of our heat stable filovirus vaccine program, with vaccine candidatesagainst Ebola and Marburg virus disease. Given this previous success, CiVax         <sup>          TM         </sup>         will potentially be an important componentof our vaccine technology platform currently being assessed for use against coronaviruses including SARS-CoV-2, the cause of COVID-19.The license agreement was executed between us and Protherics Medicines Development, one of the companies that make up the BTGspecialty pharmaceuticals business, which owns the CiVax         <sup>          TM         </sup>         intellectual property.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On July 28, 2020, we announced the availabilityof a pre-print manuscript (available at https://doi.org/10.1101/2020.07.24.220715), followed by the peer-reviewed publication onOctober 30, 2020 (https://www.frontiersin.org/articles/10.3389/fimmu.2020.599587/full)), describing CiVax        <sup>         TM        </sup>        , a prototypeCOVID-19 vaccine, using the novel CoVaccine HT™ adjuvant and demonstrating significant immunogenicity, including strong totaland neutralizing antibody responses, with a balanced Th1 response, as well as enhancement of cell mediated immunity. These areall considered to be critical attributes of a potential COVID-19 vaccine.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On September 15, 2020, we announced thepublication of a paper detailing the thermostabilization of the filovirus GP proteins and key assays describing their stability(available at: https://www.jpharmsci.org/article/S0022-3549(20)30509-8/fulltext).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On December 28, 2020, we announced NIAIDawarded us a Direct to Phase II SBIR grant of approximately $1.5 million to support manufacture, formulation (includingthermostabilization) and characterization of COVID-19 and Ebola Virus Disease (“EVD”) vaccine candidates in conjunctionwith the CoVaccine HT™ adjuvant. This award also will support immune characterization of this novel, emulsified adjuvantthat has unique potency and compatibility with lyophilization strategies to enable thermostabilization of subunit vaccines.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On March 4, 2021, we announced the publicationof pre-clinical immunogenicity studies for CiVax        <sup>         TM        </sup>        , demonstrating rapid-onset, broad-spectrum, neutralizing antibodyand cell-mediated immunity is confirmed using full-length Spike protein antigens. The article, titled "Recombinant proteinsubunit SARS-CoV-2 vaccines formulated with CoVaccine HT™ adjuvant induce broad, Th1 biased, humoral and cellular immuneresponses in mice," has been posted as an accelerated preprint on bioRxiv (available at: https://www.biorxiv.org/content/10.1101/2021.03.02.433614v1)        <i>         .        </i>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <i>         </i>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           RiVax           <sup>            ®           </sup>           –Ricin Toxin Vaccine          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        RiVax        <sup>         ®        </sup>        is our proprietaryvaccine candidate being developed to protect against exposure to ricin toxin and if approved, would be the first ricin vaccine.The immunogen in RiVax        <sup>         ®        </sup>        induces a protective immune response in animal models of ricin exposure and functionallyactive antibodies in humans. The immunogen consists of a genetically inactivated ricin A chain subunit that is enzymatically inactiveand lacks residual toxicity of the holotoxin. RiVax        <sup>         ®        </sup>        has demonstrated statistically significant (p &lt; 0.0001)preclinical survival results, providing 100% protection against acute lethality in an aerosol exposure non-human primate model(Roy et al, 2015, Thermostable ricin vaccine protects rhesus macaques against aerosolized ricin: Epitope-specific neutralizingantibodies correlate with protection, PNAS USA 112:3782-3787), and has also been shown to be well tolerated and immunogenic intwo Phase 1 clinical trials in healthy volunteers. Results of the first Phase 1 human trial of RiVax        <sup>         ®        </sup>        establishedthat the immunogen was safe and induced antibodies that we believe may protect humans from ricin exposure. The antibodies generatedfrom vaccination, concentrated and purified, were capable of conferring immunity passively to recipient animals, indicating thatthe vaccine was capable of inducing functionally active antibodies in humans. The outcome of this study was published in the Proceedingsof the National Academy of Sciences (Vitetta et al., 2006, A Pilot Clinical Trial of a Recombinant Ricin Vaccine in Normal Humans,PNAS, 103:2268-2273). The second trial that was completed in September 2012 and was sponsored by University of Texas SouthwesternMedical Center (“UTSW”) evaluated a more potent formulation of RiVax        <sup>         ®        </sup>        that contained an Alum-adjuvant.The results of the Phase 1b study indicated that Alum-adjuvanted RiVax        <sup>         ®        </sup>        was safe and well tolerated, and inducedgreater ricin neutralizing antibody levels in humans than adjuvant-free RiVax        <sup>         ®        </sup>        . The outcomes of this second studywere published in the Clinical and Vaccine Immunology (Vitetta et al., 2012, Recombinant Ricin Vaccine Phase 1b Clinical Trial,Clin. Vaccine Immunol. 10:1697-1699).       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 16; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         13         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Wehave adapted the original manufacturing process for the immunogen contained in RiVax         <sup>          ®         </sup>         for thermostability and largescale manufacturing and recent studies have confirmed that the thermostabilized RiVax         <sup>          ®         </sup>         formulation enhances thestability of the RiVax         <sup>          ®         </sup>         antigen, enabling storage for at least 1 year at temperatures up to 40 °C (104 °F).The program will pursue approval via the FDA “Animal Rule” since it is not possible to test the efficacy of the vaccinein a clinical study which would expose humans to ricin. Uniform, easily measured and species-neutral immune correlates of protectionthat can be measured in humans and animals, and are indicative of animal survival to subsequent ricin challenge, are central tothe application of the “Animal Rule”. Recent work has identified such potential correlates of immune protection inanimals and work to qualify and validate these approaches is continuing, with the goal of utilizing these assays in a plannedPhase 1/2 clinical trial with the thermostable RiVax         <sup>          ®         </sup>         formulation. During September 2018, we published an extendedstability study of RiVax         <sup>          ®         </sup>         , showing up to 100% protection in mice after 12 months storage at 40 °C (104 °F)as well as identification of a potential in vitro stability indicating assay, critical to adequately confirming the long-termshelf life of the vaccine. We have entered into a collaboration with IDT Biologika GmbH to scale-up the formulation/filling processand continue development and validation of analytical methods established at IDT to advance the program. We also initiated a developmentagreement with Emergent BioSolutions, Inc. to implement a commercially viable, scalable production technology for the RiVax         <sup>          ®         </sup>         drug substance protein antigen.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The development of RiVax        <sup>         ®        </sup>        has been sponsored through a series of overlapping challenge grants, UC1, and cooperative grants, U01, from the NIH, granted tous and to UTSW where the vaccine originated. The second clinical trial was supported by a grant from the FDA’s Office ofOrphan Products to UTSW. To date, we and UTSW have collectively received approximately $25 million in grant funding from the NIHfor the development of RiVax        <sup>         ®        </sup>        . In September 2014, we entered into a contract with the NIH for the development ofRiVax        <sup>         ®        </sup>        pursuant to which we have been awarded an additional $21.2 million of funding in the aggregate. The developmentagreements with Emergent BioSolutions and IDT were specifically funded under this NIH contract.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         In2017, NIAID exercised options to fund additional animal efficacy studies and good manufacturing practices compliant RiVax         <sup>          ®         </sup>         bulk drug substance and finished drug product manufacturing, which is required for the conduct of future preclinical andclinical safety and efficacy studies. The exercised options provide us with approximately $4.5 million in additional non-dilutivefunding, bringing the total amount awarded to date under this contract to $21.2 million, which expired in February 2021. Thetotal award of up to $21.2 million supported the preclinical, manufacturing and clinical development activities necessary to advanceheat stable RiVax         <sup>          ®         </sup>         with the FDA. In addition to this funding for the development of RiVax         <sup>          ®         </sup>         , biomarkersfor RiVax         <sup>          ®         </sup>         testing have been successfully identified, facilitating potential approval under the FDA Animal Rule.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         DuringDecember 2019, we initiated a third Phase 1 double-blind, placebo-controlled, randomized study in eight healthy adult volunteersubjects designed to evaluate the safety and immunogenicity of RiVax         <sup>          ®         </sup>         utilizing ThermoVax         <sup>          ®         </sup>         . DuringJanuary 2020, we suspended the study after Emergent Manufacturing Operations Baltimore LLC (“EMOB”), the manufacturerof the drug substance, notified us that, after releasing the final drug product to us, EMOB identified that the active drug substancetested outside the established specification parameters. Two subjects had received doses as part of the study before the manufacturerprovided this notice. Those two subjects will continue to be monitored and data captured in accordance with the study protocol;however, they will not receive further doses of study drug. A clinical safety report will be generated at study completion.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         DuringApril 2020, we received notification from NIAID that they would not be exercising the final contract option to support the conductof a Phase 1/2 clinical study in healthy volunteers. As a result, the total contract award will not exceed $21.2 million. Thiscontract subsequently expired in February 2021.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 17; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         14         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Inconnection with failures relating to the manufacture of RiVax® bulk drug substance, on July 1, 2020, we filed a demand forarbitration against Emergent Biosolutions, Inc. (“EBS”), Emergent Product Development Gaithersburg, Inc. (“EPDG”);and EMOB (together with EBS and EPDG, “Emergent”) with the American Arbitration Association in Mercer County, NewJersey. We have alleged that (a) EPDG breached contracts, an express warranty, a warranty of merchantability, and a warranty offitness for a particular purpose, (b) EMOB breached a contract; (c) EPDG was unjustly enriched; (d) EPDG and EMOB were negligentin the performance of their work; and (e) EBS fraudulently induced us into entering into the contracts with EPDG and EMOB. Weare seeking to recover damages in excess of $19 million from Emergent. Emergent has answered the demand for arbitration denyingthe allegations and asserting affirmative defenses. While we intend to vigorously pursue this arbitration, we cannot offer anyassurances as to any result from the arbitration or that we will recover any damages from Emergent. For more details regardingthe arbitration against Emergent, see Part I – Item 3. “Legal Proceedings” in this Annual Report.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         RiVax         <sup>          ®         </sup>         has been granted Orphan Drug designation as well as Fast Track designation by the FDA for the prevention of ricin intoxication.In addition, RiVax         <sup>          ®         </sup>         has also been granted Orphan Drug designation in the European Union (“EU”) fromthe EMA Committee for Orphan Medical Products.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Assumingdevelopment efforts are successful for RiVax         <sup>          ®         </sup>         , we believe potential government procurement contract(s) couldreach as much as $200 million. This potential procurement contract information is a forward-looking statement, and investors areurged not to place undue reliance on this statement. While we have determined this potential procurement contract value basedon assumptions that we believe are reasonable, there are a number of factors that could cause our expectations to change or notbe realized.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Asa new chemical entity, an FDA approved RiVax         <sup>          ®         </sup>         vaccine has the potential to qualify for a biodefense Priority ReviewVoucher (“PRV”). Approved under the 21st Century Cures Act in late 2016, the biodefense PRV is awarded upon approvalas a medical countermeasure when the active ingredient(s) have not been otherwise approved for use in any context. PRVs are transferableand can be sold, with sales in recent years of approximately $100 million. When redeemed, PRVs entitle the user to an acceleratedreview period of nine months, saving a median of seven months review time as calculated in 2009. However, FDA must be advised90 days in advance of the use of the PRV and the use of a PRV is associated with an additional user fee ($2.2 million for fiscalyear 2020).        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         <b>          RicinToxin         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Ricintoxin can be cheaply and easily produced, is stable over long periods of time, is toxic by several routes of exposure and thushas the potential to be used as a biological weapon against military and/or civilian targets. As a bioterrorism agent, ricin couldbe disseminated as an aerosol, by injection, or as a food supply contaminant. The potential use of ricin toxin as a biologicalweapon of mass destruction has been highlighted in a Federal Bureau of Investigation Bioterror report released in November 2007titled Terrorism 2002-2005, which states that “Ricin and the bacterial agent anthrax are emerging as the most prevalentagents involved in WMD investigations” (http://www.fbi.gov/stats-services/publications/terrorism-2002-2005/terror02_05.pdf).In recent years, Al Qaeda in the Arabian Peninsula has threatened the use of ricin toxin to poison food and water supplies andin connection with explosive devices. Domestically, the threat from ricin remains a concern for security agencies. In April 2013,letters addressed to the U.S. President, a Senator and a judge tested positive for ricin. As recently as September 2020, ricin-lacedletters addressed to the White House and others addressed to Texas law enforcement agencies were intercepted before delivery raisingfresh concerns about the deadly toxin.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         TheCenters for Disease Control and Prevention has classified ricin toxin as a Category B biological agent. Ricin works by first bindingto glycoproteins found on the exterior of a cell, and then entering the cell and inhibiting protein synthesis leading to celldeath. Once exposed to ricin toxin, there is no effective therapy available to reverse the course of the toxin. The recent ricinthreat to government officials has heightened the awareness of this toxic threat. Currently, there is no FDA approved vaccineto protect against the possibility of ricin toxin being used in a terrorist attack, or its use as a weapon on the battlefieldnor is there a known antidote for ricin toxin exposure.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 18; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         15         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           SGX943– for Treating Emerging and/or Antibiotic-Resistant Infectious Diseases          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         SGX943is an IDR, containing the same active ingredient as SGX942. Dusquetide is a fully synthetic, 5-amino acid peptide with high aqueoussolubility and stability. Extensive         <i>          in vivo         </i>         preclinical studies have demonstrated enhanced clearance of bacterial infectionwith SGX943 administration. SGX943 has shown efficacy against both Gram-negative and Gram-positive bacterial infections in preclinicalmodels, independent of whether the bacteria is antibiotic-resistant or antibiotic-sensitive.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Theinnate immune system is responsible for rapid and non-specific responses to combat bacterial infection. Augmenting these responsesrepresents an alternative approach to treating bacterial infections. In animal models, IDRs are efficacious against both antibiotic-sensitiveand antibiotic-resistant infections, both Gram-positive and Gram-negative bacteria, and are active irrespective of whether thebacteria occupies a primarily extracellular or intracellular niche. IDRs are also effective as stand-alone agents or in conjunctionwith antibiotics. An IDR for the treatment of serious bacterial infections encompasses a number of clinical advantages including:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Treatment when antibiotics    are contraindicated, such as:           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 72px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            o           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            before the infectious    organism and/or its antibiotic susceptibility is known; or           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 72px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            o           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            in at-risk populations    prior to infection.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            An ability to be    used as an additive, complementary treatment with antibiotics, thereby:           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 72px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            o           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            enhancing efficacy    of sub-optimal antibiotic regimens (e.g., partially antibiotic-resistant infections);           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 72px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            o           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            enhancing clearance    of infection, thereby minimizing the generation of antibiotic resistance (e.g., in treating melioidosis); and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 72px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            o           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            reducing the required    antibiotic dose, again potentially minimizing the generation of antibiotic resistance.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            An ability to modulate the deleterious consequences of inflammation in response to the infection, including the inflammation caused by antibiotic-driven bacterial lysis.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Being unlikely to    generate bacterial resistance since the IDR acts on the host, and not the pathogen.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Importantly,systemic inflammation and multi-organ failure is the ultimate common outcome of not only emerging and/or antibiotic-resistantinfectious diseases, but also of most biothreat agents (e.g.,         <i>          Burkholderia pseudomallei         </i>         ), indicating that dusquetide wouldbe applicable not only to antibiotic-resistant infection, but also to biothreat agents, especially where the pathogen is not knownand/or has been engineered for enhanced antibiotic resistance.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         InMay 2019, we were awarded a DTRA subcontract of approximately $600,000 over three years to participate in a biodefense contractfor the development of medical countermeasures against bacterial threat agents. As of December 31, 2020, there was negligiblerevenue earned or expense incurred related to the DTRA subcontract.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          TheDrug Approval Process         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         TheFDA and comparable regulatory agencies in state, local and foreign jurisdictions impose substantial requirements on the clinicaldevelopment, manufacture and marketing of new drug and biologic products. The FDA, through regulations that implement the FederalFood, Drug, and Cosmetic Act, as amended (“FDCA”), and other laws and comparable regulations for other agencies, regulateresearch and development activities and the testing, manufacture, labeling, storage, shipping, approval, recordkeeping, advertising,promotion, sale, export, import and distribution of such products. The regulatory approval process is generally lengthy, expensiveand uncertain. Failure to comply with applicable FDA and other regulatory requirements can result in sanctions being imposed onus or the manufacturers of our products, including holds on clinical research, civil or criminal fines or other penalties, productrecalls, or seizures, or total or partial suspension of production or injunctions, refusals to permit products to be importedinto or exported out of the U.S., refusals of the FDA to grant approval of drugs or to allow us to enter into government supplycontracts, withdrawals of previously approved marketing applications and criminal prosecutions.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 19; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         16         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Beforehuman clinical testing in the U.S. of a new drug compound or biological product can commence, an Investigational New Drug (“IND”),application is required to be submitted to the FDA. The IND application includes results of pre-clinical animal studies evaluatingthe safety and efficacy of the drug and a detailed description of the clinical investigations to be undertaken.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Clinicaltrials are normally done in three phases, although the phases may overlap. Phase 1 trials are smaller trials concerned primarilywith metabolism and pharmacologic actions of the drug and with the safety of the product. Phase 2 trials are designed primarilyto demonstrate effectiveness and safety in treating the disease or condition for which the product is indicated. These trialstypically explore various doses and regimens. Phase 3 trials are expanded clinical trials intended to gather additional informationon safety and effectiveness needed to clarify the product’s benefit-risk relationship and generate information for properlabeling of the drug, among other things. The FDA receives reports on the progress of each phase of clinical testing and may requirethe modification, suspension or termination of clinical trials if an unwarranted risk is presented to patients. When data is requiredfrom long-term use of a drug following its approval and initial marketing, the FDA can require Phase 4, or post-marketing, studiesto be conducted.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Withcertain exceptions, once successful clinical testing is completed, the sponsor can submit a NDA, for approval of a drug, or aBiologic License Application (“BLA”), for biologics such as vaccines, which will be reviewed, and if successful, approvedby the FDA, allowing the product to be marketed. The process of completing clinical trials for a new drug is likely to take anumber of years and require the expenditure of substantial resources. Furthermore, the FDA or any foreign health authority maynot grant an approval on a timely basis, if at all. The FDA may deny the approval of an NDA or BLA, in its sole discretion, ifit determines that its regulatory criteria have not been satisfied or may require additional testing or information. Among theconditions for marketing approval is the requirement that the prospective manufacturer’s quality control and manufacturingprocedures conform to good manufacturing practice regulations. In complying with standards contained in these regulations, manufacturersmust continue to expend time, money and effort in the area of production, quality control and quality assurance to ensure fulltechnical compliance. Manufacturing facilities, both foreign and domestic, also are subject to inspections by, or under the authorityof, the FDA and by other federal, state, local or foreign agencies.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Evenafter initial FDA or foreign health authority approval has been obtained, further studies, including Phase 4 post-marketing studies,may be required to provide additional data on safety and will be required to gain approval for the marketing of a product as atreatment for clinical indications other than those for which the product was initially tested. For certain drugs intended totreat serious, life-threatening conditions that show great promise in earlier testing, the FDA can also grant conditional approval.However, drug developers are required to study the drug further and verify clinical benefit as part of the conditional approvalprovision, and the FDA can revoke approval if later testing does not reproduce previous findings. The FDA may also condition approvalof a product on the sponsor agreeing to certain mitigation strategies that can limit the unfettered marketing of a drug. Also,the FDA or foreign regulatory authority will require post-marketing reporting to monitor the side effects of the drug. Resultsof post-marketing programs may limit or expand the further marketing of the product. Further, if there are any modifications tothe drug, including any change in indication, manufacturing process, labeling or manufacturing facility, an application seekingapproval of such changes will likely be required to be submitted to the FDA or foreign regulatory authority.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Inthe U.S., the FDCA, the Public Health Service Act, the Federal Trade Commission Act, and other federal and state statutes andregulations govern, or influence the research, testing, manufacture, safety, labeling, storage, record keeping, approval, advertisingand promotion of drug, biological, medical device and food products. Noncompliance with applicable requirements can result in,among other things, fines, recall or seizure of products, refusal to permit products to be imported into the U.S., refusal ofthe government to approve product approval applications or to allow us to enter into government supply contracts, withdrawal ofpreviously approved applications and criminal prosecution. The FDA may also assess civil penalties for violations of the FDCAinvolving medical devices.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 20; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         17         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Forbiodefense development, such as with RiVax         <sup>          ®         </sup>         , the FDA has instituted policies that are expected to result in shorterpathways to market. This potentially includes approval for commercial use utilizing the results of animal efficacy trials, ratherthan efficacy trials in humans. However, we will still have to establish that the vaccine and countermeasures it is developingare safe in humans at doses that are correlated with the beneficial effect in animals. Such clinical trials will also have tobe completed in distinct populations that are subject to the countermeasures; for instance, the very young and the very old, andin pregnant women, if the countermeasure is to be licensed for civilian use. Other agencies will have an influence over the benefit-riskscenarios for deploying the countermeasures and in establishing the number of doses utilized in the Strategic National Stockpile.We may not be able to sufficiently demonstrate the animal correlation to the satisfaction of the FDA, as these correlates aredifficult to establish and are often unclear. Invocation of the animal rule may raise issues of confidence in the model systemseven if the models have been validated. For many of the biological threats, the animal models are not available and we may haveto develop the animal models, a time-consuming research effort. There are few historical precedents, or recent precedents, forthe development of new countermeasure for bioterrorism agents. Despite the animal rule, the FDA may require large clinical trialsto establish safety and immunogenicity before licensure and it may require safety and immunogenicity trials in additional populations.Approval of biodefense products may be subject to post-marketing studies, and could be restricted in use in only certain populations.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Vaccinesare approved under the BLA process that exists under the Public Health Service Act. In addition to the greater technical challengesassociated with developing biologics, the potential for generic competition is lower for a BLA product than a small molecule productsubject to an NDA under the Federal Food, Drug and Cosmetic Act. Under the Patient Protection and Affordable Care Act enactedin 2010, a “generic” version of a biologic is known as a biosimilar and the barriers to entry – whether legal,scientific, or logistical – for a biosimilar version of a biologic approved under a BLA are higher.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           OrphanDrug Designation          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Underthe Orphan Drug Act, the FDA may grant orphan drug designation to drugs or biologics intended to treat a rare disease or condition– generally a disease or condition that affects fewer than 200,000 individuals in the U.S. Orphan drug designation mustbe requested before submitting an NDA or BLA. After the FDA grants orphan drug designation, the generic identity of the drug orbiologic and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantagein, or shorten the duration of, the regulatory review and approval process. The first NDA or BLA applicant to receive FDA approvalfor a particular active ingredient to treat a particular disease with FDA orphan drug designation is entitled to a seven-yearexclusive marketing period in the U.S. for that product, for that indication. During the seven-year exclusivity period, the FDAmay not approve any other applications to market the same drug or biologic for the same disease, except in limited circumstances,such as a showing of clinical superiority to the product with orphan drug exclusivity. Orphan drug exclusivity does not preventthe FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a differentdisease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver ofthe NDA or BLA application user fee.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           FastTrack Designation and Accelerated Approval          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         TheFDA is required to facilitate the development, and expedite the review, of drugs or biologics that are intended for the treatmentof a serious or life-threatening disease or condition for which there is no effective treatment and which demonstrate the potentialto address unmet medical needs for the condition. Under the fast track program, the sponsor of a new drug or biologic candidatemay request that the FDA designate the candidate for a specific indication as a fast track drug or biologic concurrent with, orafter, the filing of the IND for the candidate. The FDA must determine if the drug or biologic candidate qualifies for fast trackdesignation within 60 days of receipt of the sponsor’s request. Unique to a fast track product, the FDA may initiate reviewof sections of a fast track product’s NDA or BLA before the application is complete. This rolling review is available ifthe applicant provides, and the FDA approves, a schedule for the submission of the remaining information and the applicant paysapplicable user fees. However, the FDA’s time period goal for reviewing an application does not begin until the last sectionof the NDA or BLA is submitted. Additionally, the fast track designation may be withdrawn by the FDA if the FDA believes thatthe designation is no longer supported by data emerging in the clinical trial process.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Anyproduct submitted to the FDA for marketing, including under a fast track program, may be eligible for other types of FDA programsintended to expedite development and review, such as accelerated approval. Drug or biological products studied for their safetyand effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existingtreatments may receive accelerated approval, which means the FDA may approve the product based upon a surrogate endpoint thatis reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidityor mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit,taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 21; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         18         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Inclinical trials, a surrogate endpoint is a measurement of laboratory or clinical signs of a disease or condition that substitutesfor a direct measurement of how a patient feels, functions, or survives. Surrogate endpoints can often be measured more easilyor more rapidly than clinical endpoints. A drug or biologic candidate approved on this basis is subject to rigorous post-marketingcompliance requirements, including the completion of Phase 4 or post-approval clinical trials to confirm the effect on the clinicalendpoint. Failure to conduct required post-approval studies, or confirm a clinical benefit during post-marketing studies, willallow the FDA to withdraw the drug or biologic from the market on an expedited basis. All promotional materials for drug candidatesapproved under accelerated regulations are subject to prior review by the FDA.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           PediatricInformation          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Underthe Pediatric Research Equity Act (“PREA”), NDAs or BLAs or supplements to NDAs or BLAs must contain data to assessthe safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosingand administration for each pediatric subpopulation for which the drug is safe and effective. The FDA may grant full or partialwaivers, or deferrals, for submission of data. Unless otherwise required by regulation, PREA does not apply to any drug for anindication for which orphan designation has been granted.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           EarlyAccess to Medicines Scheme          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Launchedin April 2014 in the United Kingdom by the MHRA, the Early Access to Medicines Scheme (“EAMS”) offers severely illpatients with life-threatening and seriously debilitating conditions the lifeline of trying ground-breaking new medicines earlierthan they would normally be accessible. PIM designation is the first phase of EAMS and is awarded following an assessment of earlynonclinical and clinical data by the MHRA. The criteria product candidates must meet to obtain PIM designation are:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Criterion 1 –    The condition should be life-threatening or seriously debilitating with a high unmet medical need (i.e., there is no method    of treatment, diagnosis or prevention available or existing methods have serious limitations).           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Criterion 2 –    The medicinal product is likely to offer major advantage over methods currently used in the UK.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Criterion 3 –    The potential adverse effects of the medicinal product are likely to be outweighed by the benefits, allowing for the reasonable    expectation of a positive benefit risk balance. A positive benefit risk balance should be based on preliminary scientific    evidence that the safety profile of the medicinal product is likely to be manageable and acceptable in relation to the estimated    benefits.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           FalseClaims Laws          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Thefederal False Claims Act prohibits, among other things, any person or entity from knowingly presenting, or causing to be presented,a false claim for payment to, or approval by, the federal government or knowingly making, using, or causing to be made or useda false record or statement material to a false or fraudulent claim to the federal government. As a result of a modification madeby the Fraud Enforcement and Recovery Act of 2009, a claim includes “any request or demand” for money or propertypresented to the U.S. government.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          Anti-KickbackLaws         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Thefederal Anti-Kickback Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying,soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in returnfor purchasing, leasing, ordering or arranging for the purchase, lease or order of any item or service reimbursable under Medicare,Medicaid or other federal healthcare programs. The term remuneration has been interpreted broadly to include anything of value.The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers,purchasers, and formulary managers on the other.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 22; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         19         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           UnitedStates Healthcare Reform          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         FederalPhysician Payments Sunshine Act and its implementing regulations require that certain manufacturers of drugs, devices, biologicaland medical supplies for which payment is available under Medicare, Medicaid or the Children’s Health Insurance Program(with certain exceptions) to report information related to certain payments or other transfers of value made or distributed tophysicians and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physiciansand teaching hospitals and to report annually certain ownership and investment interests held by physicians and their immediatefamily members.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Inaddition, we may be subject to data privacy and security regulation by both the federal government and the states in which weconduct our business. The Health Insurance Portability and Accountability Act (“HIPAA”), as amended by the HealthInformation Technology for Economic and Clinical Health Act (“HITECH”), and its implementing regulations, imposescertain requirements relating to the privacy, security and transmission of individually identifiable health information. Amongother things, HITECH makes HIPAA’s privacy and security standards directly applicable to “business associates”– independent contractors or agents of covered entities that receive or obtain protected health information in connectionwith providing a service on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties, amendedHIPAA to make civil and criminal penalties directly applicable to business associates and possibly other persons, and gave stateattorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAAlaws and seek attorneys’ fees and costs associated with pursuing federal civil actions. In addition, state laws govern theprivacy and security of health information in certain circumstances, many of which differ from each other in significant waysand may not have the same effect, thus complicating compliance efforts.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         <b>          Third-PartySuppliers and Manufacturers         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Drugsubstance and drug product manufacturing is outsourced to qualified suppliers. We do not have manufacturing capabilities/infrastructureand do not intend to develop the capacity to manufacture drug products substances. We have agreements with third-party manufacturersto supply bulk drug substances for our product candidates and with third parties to formulate, package and distribute our productcandidates. Our employees include professionals with expertise in pharmaceutical manufacturing development, quality assuranceand third party supplier management who oversee work conducted by third-party companies. We believe that we have on hand or caneasily obtain sufficient amounts of product candidates to complete our currently contemplated clinical trials. All of the drugsubstances used in our product candidates currently are manufactured by single suppliers. While we have not experienced any supplydisruptions, the number of manufacturers of the drug substances is limited. In the event it is necessary or advisable to acquiresupplies from alternative suppliers, assuming commercially reasonable terms could be reached, the challenge would be the efficienttransfer of technology and know-how from current manufactures to the new supplier. Formulation and distribution of our finishedproduct candidates also currently are conducted by single suppliers but we believe that alternative sources for these servicesare readily available on commercially reasonable terms, subject to the efficient transfer of technology and know-how from currentsuppliers to the new supplier.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Allof the current agreements for the supply of bulk drug substances for our product candidates and for the formulation or distributionof our product candidates relate solely to the development (including preclinical and clinical) of our product candidates. Underthese contracts, our product candidates are manufactured upon our order of a specific quantity. In the event that we obtain marketingapproval for a product candidate, we will qualify secondary suppliers for all key manufacturing activities supporting the marketingapplication.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          Marketingand Collaboration         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Wedo not currently have any sales and marketing capability, other than to potentially market our biodefense vaccine products directlyto government agencies. With respect to other commercialization efforts, we currently intend to seek distribution and other collaborationarrangements for the sales and marketing of any product candidate that is approved, while also evaluating the potential to commercializeon our own in orphan disease indications. From time to time, we have had and are having strategic discussions with potential collaborationpartners for our biodefense vaccine product candidates, although no assurance can be given that we will be able to enter intoone or more collaboration agreements for our product candidate on acceptable terms, if at all. We believe that both military andcivilian health authorities of the U.S. and other countries will increase their stockpiling of therapeutics and vaccines to treatand prevent diseases and conditions that could ensue following a bioterrorism attack.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 23; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         20         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         OnDecember 20, 2012, we re-acquired the North American and European commercial rights to oral BDP through an amendment of our collaborationand supply agreement with Sigma-Tau Pharmaceuticals, Inc., which is now known as Leadiant Biosciences, Inc. (“Leadiant”).The amendment requires us to make certain approval and commercialization milestone payments to Leadiant which could reach up to$6 million. In addition, we have agreed to pay Leadiant: (a) a royalty amount equal to 3% of all net sales of oral BDP made directlyby us, and any third-party partner and/or their respective affiliates in the U.S., Canada, Mexico and in each country in the EuropeanTerritory for the later to occur of: (i) a period of ten years from the first commercial sale of oral BDP in each country, or(ii) the expiration of our patents and patent applications relating to oral BDP in such country (the “Payment Period”);and (b) 15% of all up-front payments, milestone payments and any other consideration (exclusive of equity payments) received byus and/or a potential partner from us and/or potential partner’s licensees, distributors and agents for oral BDP in eachrelevant country in the territory, which amount will be paid on a product-by-product and a country-by-country basis for the PaymentPeriod.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         OnAugust 25, 2013, we entered into an agreement with SciClone Pharmaceuticals, Inc. (“SciClone”), pursuant to whichSciClone provided us with access to its oral mucositis clinical and regulatory data library in exchange for exclusive commercializationrights for SGX942 in the People’s Republic of China, including Hong Kong and Macau, subject to the negotiation of economicterms. SciClone’s data library was generated from two sequential Phase 2 clinical studies conducted in 2010 and 2012 evaluatingSciClone’s compound, SCV-07, for the treatment of oral mucositis caused by chemoradiation therapy in head and neck cancerpatients, before SciClone terminated its program. By analyzing data available from the placebo subjects in the SciClone trials,we acquired valuable insight into disease progression, along with quantitative understanding of its incidence and severity inthe head and neck cancer patient population. This information assisted us with the design of the SGX942 Phase 2 clinical trial,in which positive preliminary results were announced in December 2015.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         OnSeptember 9, 2016, we and SciClone entered into an exclusive license agreement, pursuant to which we granted rights to SciCloneto develop, promote, market, distribute and sell SGX942 in the People’s Republic of China, including Hong Kong and Macau,as well as Taiwan, South Korea and Vietnam. Under the terms of the license agreement, SciClone will be responsible for all aspectsof development, product registration and commercialization in the territory, having access to data generated by us. In exchangefor exclusive rights, SciClone will pay us royalties on net sales, and we will supply commercial drug product to SciClone on acost-plus basis, while maintaining worldwide manufacturing rights. We also entered into a common stock purchase agreement withSciClone pursuant to which we sold 352,942 shares of our common stock to SciClone for approximately $8.50 per share, for an aggregateprice of $3,000,000.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          Competition         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Ourcompetitors are pharmaceutical and biotechnology companies, most of whom have considerably greater financial, technical, and marketingresources than we do. Universities and other research institutions, including the U.S. Army Medical Research Institute of InfectiousDiseases, also compete in the development of treatment technologies, and we face competition from other companies to acquire rightsto those technologies.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           SGX301Competition          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         TheFDA has approved several treatments for later stages (IIB-IV) of CTCL and/or in conditions that are unresponsive to prior treatment.Three are targeted therapies (Targretin         <sup>          ®         </sup>         -caps, Ontak         <sup>          ®         </sup>         and Adcetris         <sup>          ®         </sup>         ), two are histonedeacetylases inhibitors (Zolina         <sup>          ®         </sup>         and Istodax         <sup>          ®         </sup>         ) and the remaining two are topical therapies (Valchor         <sup>          ®         </sup>         and Targretin         <sup>          ®         </sup>         -gel). There are currently no FDA approved therapies for the treatment of front-line, earlystage (I-IIA) CTCL; however certain topical chemotherapies and topical, radiation, photodynamic and other therapies which areapproved for indications other than CTCL are prescribed off-label for the treatment of early stage CTCL. These include narrow-bandultraviolet B (NB-UVB) light therapy and psoralen combined with ultraviolet A (UVA) light therapy (“PUVA”); however,PUVA treatments are usually limited to three times per week and 200 times in total due to the potentially carcinogenic side effect,while NB UVB is known to be effective against patches but less so against plaque lesions, common in early stage CTCL. There areother drugs currently in development that may have the potential to be used in early stage (I-IIA) CTCL – two topical therapiesare in phase 2 (sirolimus and SHAPE gelled solution), one photodynamic therapy (Silicon Phthalocyanine 4) in Phase 1 and one systemictherapy for stage IB, II or III CTCL completing Phase 2 (cobomarsen). Other treatments for later stage disease are not considereddirect competitors.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 24; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         21         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           SGX94/942Competition          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         BecauseSGX94 (dusquetide) uses a novel mechanism of action in combating bacterial infections, there are no direct competitors at thistime. Bacterial infections are routinely treated with antibiotics and SGX94 treatment is anticipated to be utilized primarilywhere antibiotics are insufficient (e.g., due to antibiotic resistance) or contra-indicated (e.g., in situations where the developmentof antibiotic resistance is a significant concern). Many groups are working on the antibiotic resistance problem and researchinto the innate immune system is intensifying, making emerging competition likely (from companies such as Celtaxsys Inc., InnaxonTherapeutics and Innate Pharma SA).        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Thereis currently one drug approved for the treatment of oral mucositis in hematological cancer (palifermin). There are currently noapproved drugs for treatment of oral mucositis in cancers with solid tumors (e.g., head and neck cancer). There are several drugsin clinical development for oral mucositis – five in Phase 3 (an epidermal growth factor under development by Daewoong PharmaceuticalCo. Ltd. a protease inhibitor under investigation at a Chinese hospital, daily infused GC4419 by Galera Therapeutics Inc. mucobuccaltablet by Monopar Therapeutics LLC, and topical MOB-015 by Moberg Pharma), one in Phase 2 (under development by Innovation Pharmaceuticals)and various natural products in small and/or open label studies (including sage, turmeric, honey and olive oil). In addition,there are medical devices approved for the treatment of oral mucositis including MuGard,         <sup>          ®         </sup>         GelClair,         <sup>          ®         </sup>         Episil         <sup>          ®         </sup>         and Caphosol.         <sup>          ®         </sup>         These devices attempt to create a protective barrier around the oral ulcerationwith no biologic activity in treating the underlying disease.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           OralBDP Competition          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Thereare a number of approved treatments for Crohn’s disease and additional compounds are in late-stage development.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Remicade         <sup>          ®         </sup>         (infliximab) and Humira         <sup>          ®         </sup>         (adalimumab) are currently approved for the treatment of pediatric Crohn’s disease; however, both carry significant BlackBox warnings in their labeling for increased risk of serious infection and malignancy, and therefore are approved for treatmentof moderate to severe patients. Entocort         <sup>          ®         </sup>         (enteric-coated budesonide) is currently approved for the treatment ofmild to moderate active Crohn’s disease involving the lower GI tract (ileum and/or the ascending colon) in patients eightyears of age and older who weigh more than 25 kilograms. There is one other marketed biologic, Tysabri         <sup>          ®         </sup>         (natalizumab),in a Phase 2 study for pediatric Crohn’s.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           ThermoVax           <sup>            ®           </sup>           Competition          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Multiplegroups and companies are working to address the unmet need of vaccine thermostability using a variety of technologies. In addition,other organizations, such as the Bill and Melinda Gates Foundation and PATH, have programs designed to advance technologies toaddress this need.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Severalstabilization technologies currently being developed involve mixing vaccine antigen +/- adjuvant with various proprietary excipientsor co-factors that either serve to stabilize the vaccine or biological product in a liquid or dried (lyophilized) form. Examplesof these approaches include the use of various plant-derived sugars and macromolecules being developed by companies such as StabilitechLtd. Variation Biotechnologies, Inc. (“VBI”) is developing a lipid system (resembling liposomes) to stabilize viralantigens, including virus-like particles (“VLPs”), and for potential application to a conventional influenza vaccineamong others.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Otherapproaches involve process variations to freeze-dry live virus vaccines. For example, PaxVax, Inc. is seeking to employ aspray drying technology in concert with enteric coating to achieve formulations for room temperature stability of live virus vaccinesusing adenovirus vectors. VBI is seeking to utilize their proprietary stabilization technology for a number of vaccines (asa co-development service, similar to the business model being developed by Stabilitech Ltd.), whereas PaxVax is applying the technologyto their own proprietary vaccine development programs. Stabilitech uses combinations of excipients, which include glassifyingsugars similar to the ThermoVax         <sup>          ®         </sup>         technology, and variations in drying cycles during lyophilization, as does theThermoVax         <sup>          ®         </sup>         technology.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Additionally,companies like Pharmathene, Inc., Panacea Biotec Ltd., and Compass Biotech Inc. are developing proprietary vaccines with the applicationof some form of stabilization technology.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 25; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         22         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           PublicHealth Solutions Competition          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Weface competition in the area of biodefense product development from various public and private companies, universities and governmentalagencies, such as the U.S. Army, some of whom may have their own proprietary technologies which may directly compete with ourtechnologies.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         TheU.S. Army Medical Research Institute of Infectious Diseases, the DoD’s lead laboratory for medical research to counter biologicalthreats is also developing a ricin vaccine candidate, RVEc™. RVEc™ has been shown to be fully protective in mice exposedto lethal doses of ricin toxin by the aerosol route. Further studies, in both rabbits and nonhuman primates, were conducted toevaluate RVEc™’s safety as well as its immunogenicity, with positive results observed. A monoclonal antibody is alsobeing developed by Mapp Biopharmaceutical Inc. as a ricin therapeutic, with administration 4 hours after exposure demonstratingefficacy while administration 12 hours after ricin exposure was not protective in animal models.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          Patentsand Other Proprietary Rights         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Ourgoal is to obtain, maintain and enforce patent protection for our products, formulations, processes, methods and other proprietarytechnologies, preserve our trade secrets, and operate without infringing on the proprietary rights of other parties, both in theU.S. and in other countries. Our policy is to actively seek to obtain, where appropriate, the broadest intellectual property protectionpossible for our product candidates, proprietary information and proprietary technology through a combination of contractual arrangementsand patents, both in the U.S. and elsewhere in the world.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Wealso depend upon the skills, knowledge and experience of our scientific and technical personnel, as well as that of our advisors,consultants and other contractors, none of which is patentable. To help protect our proprietary knowledge and experience thatis not patentable, and for inventions for which patents may be difficult to enforce, we rely on trade secret protection and confidentialityagreements to protect our interests. To this end, we require all employees, consultants, advisors and other contractors to enterinto confidentiality agreements, which prohibit the disclosure of confidential information and, where applicable, require disclosureand assignment to us of the ideas, developments, discoveries and inventions important to our business.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         In2014, we acquired a novel photodynamic therapy that utilizes safe visible light for activation, which we refer to as SGX301. Theactive ingredient in SGX301 is synthetic hypericin, a photosensitizer which is topically applied to skin lesions and then activatedby fluorescent light 16 to 24 hours later. As part of the acquisition, we acquired a license agreement relating to the use ofphoto-activated hypericin, composition of matter patent for SGX301 (U.S. patent 8,629,302) and additional issued and pending applications,both in the U.S. and abroad. U.S. patent 8,629,302 is expected to expire in September 2030. In August 2018, we were granted aU.S. patent (No. 10,053,513) titled “Systems and Methods for Producing Synthetic Hypericin”. This newly issued patent,expected to expire in 2036, broadens the production around synthetic hypericin. Our proprietary formulation of synthetic hypericinalso has been granted a European patent for the treatment of psoriasis, EP 2571507, and complements the method of treatment claimscovered by the previously issued U.S. patent 6001882, Photoactivated hypericin and the use thereof. Further, on January 7, 2020,Soligenix was also granted a U.S. patent (No. 10,526,268) titled “Systems and Methods for Producing Synthetic Hypericin”,which further expanded protection for the composition of purified synthetic hypericin. This patent is also expected to expirein 2036. On January 29, 2020, we also were granted a Hong Kong Registrar of patents (No. 16102842.8) titled “Formulationsand Methods of Treatment of Skin Conditions.” The grant is directed to the therapeutic use of synthetic hypericin in thetreatment of CTCL, similar to those granted in Europe in 2020. This patent is set to expire in 2031.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 26; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         23         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Inaddition to issued and pending patents, we also have “Orphan Drug” designations for SGX301 in the U.S. and the EUfor CTCL, SGX203 in the U.S. for pediatric Crohn’s disease, as well as for RiVax         <sup>          ®         </sup>         in the U.S. and EU. OurOrphan Drug designations provide for seven years of post-approval marketing exclusivity in the U.S. and ten years exclusivityin Europe. We have pending patent applications for this indication that, if granted, may extend our anticipated marketing exclusivitybeyond the U.S. seven year or EU ten year post-approval exclusivity provided by Orphan Drug legislation.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         In2013, we expanded our patent portfolio to include innate defense regulation through the acquisition of the novel drug technology,known as SGX94. By binding to the pivotal regulatory protein p62, also known as sequestosome-1, SGX94 regulates the innate immunesystem to reduce inflammation, eliminate infection and enhance healing. As part of the acquisition, we acquired all rights, includingcomposition of matter patents for SGX94 as well as other analogs and crystal structures of SGX94 with its protein target p62,including U.S. patent 8,124,721 and additional pending applications, both in the U.S. and abroad. SGX94 was developed pursuantto discoveries made by Professors B. Brett Finlay and Robert Hancock of University of British Columbia (“UBC”). U.S.patent 8,124,721 is expected to expire in April 2028. The U.S. Patent Office has granted the patent entitled “Novel Peptidesand Analogs for Use in the Treatment of Oral Mucositis”. The newly issued patent claims therapeutic use of dusquetide andrelated IDR analogs, and adds to composition of matter claims for dusquetide and related analogs that have been granted in theU.S. and worldwide. In January 2019, the European Patent Office granted the patent entitled “Novel Peptides for Treatingand Preventing Immune-Related Disorders, Including Treating and Preventing Infection by Modulating Innate Immunity”. Thisnewly issued patient claims composition of matter of IDR analogs, expanding patent protection around our lead IDR, dusquetide.In 2019, we further expanded protection for dusquetide and related IDR analogs with patents granted in Canada (composition ofmatter) and in New Zealand and the U.S. (No. 10,526,268; protecting therapeutic use in oral mucositis).        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Wehave issued U.S. patents 8,263,582 that cover the use of oral BDP for treating inflammatory disorders of the gastrointestinaltract, which patent is expected to expire in March 2022. We also have European patent EP 1392321 claiming the use of topicallyactive corticosteroids in orally administered dosage forms that act concurrently to treat inflammation in the upper and lowergastrointestinal tract, as well as European patent EP 2242477 claiming the use of orally ingested BDP for treatment of interstitiallung disease. European patents EP 1392321 and EP 2242477 are expected to expire in March 2022 and January 2029.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Thesubject of U.S. patent application number 12/633,631 filed December 8, 2009 and continued into patent application 15/495,798 filedApril 24, 2017 and corresponding European patent application number 09836727.9, which was granted as patent 2373160 in October2017 and pursued in multiple European countries, is the use of topically active BDP in radiation and chemotherapeutics injury.Additionally, we have numerous patent filings currently issued or pending in foreign jurisdictions covering this subject matter,including Australia, Canada, China, Hong Kong, Israel, Japan, South Korea and New Zealand.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         ThermoVax         <sup>          ®         </sup>         is the subject of U.S. patent 8,444,991 issued on May 21, 2013 titled “Method of Preparing an Immunologically-ActiveAdjuvant-Bound Dried Vaccine Composition” and licensed to us by VitriVax, Inc. ThermoVax         <sup>          ®         </sup>         is also U.S. patentapplication number 13/474,661 filed May 17, 2012 titled “Thermostable Vaccine Compositions and Methods of Preparing Same”and jointly invented by the UC and the Company. The patent application and the corresponding foreign filings are pending or grantedand they address the use of adjuvants in conjunction with vaccines that are formulated to resist thermal inactivation. The licenseagreement covers thermostable vaccines for biodefense. U.S. patent 8,444,991 is expected to expire in February 2030. An additionalpatent, covering vaccine combinations such as ricin toxin and anthrax, was filed in 2015 and granted on May 21, 2019 in the U.S.(No. 10,293,041, titled “Multivalent Stable Vaccine Composition and Methods of Making Same”) and is expected to expirein 2035.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        RiVax        <sup>         ®        </sup>        is the subject ofthree issued U.S. patent numbers 6,566,500, 6,960,652, and 7,829,668, all titled “Compositions and methods for modifyingtoxic effects of proteinaceous compounds.” This patent family includes composition of matter claims for the modified ricintoxin A chain which is the immunogen contained in RiVax        <sup>         ®        </sup>        , and issued in 2003, 2005 and 2010 respectively. The initialfiling date of these patents was March 2000 and they expired on March 30, 2020. The issued patents contain claims that describealteration of sequences within the ricin A chain that affect vascular leak, one of the deadly toxicities caused by ricin toxin.Another U.S. patent number 7,175,848 titled “Ricin A chain mutants lacking enzymatic activity as vaccines to protect againstaerosolized ricin,” was filed in October of 2000 and expired in September 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 27; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         24         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           SGX301License Agreement          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In September 2014, we acquired a worldwide exclusive licenseagreement with New York University and Yeda Research and Development Company Ltd. for the rights to a novel photodynamic therapythat utilizes safe visible light for activation, which we refer to as SGX301. To maintain this license we are obligated to pay$25,000 in annual license fees. In addition, we will pay the licensors: (a) a royalty amount equal to 3% of all net sales of SGX301made directly by us and/or any affiliates; (b) a royalty amount equal to 2.5% of all net sales of SGX301 made by our sublicensees,subject to stated maximums and (c) 20% of all payments, not based on net sales, received by us from our sublicensees. This licensemay be terminated by either party upon notice of a material breach by the other party that is not cured within the applicable cureperiod. The exclusive license includes rights to several issued U.S. patents, including U.S. patent numbers 6,867,235 and 7,122,518,among other domestic and foreign patent applications. U.S. Patent numbers 6,867,235 and 7,122,518 expired in January 2020 and isexpected to expire in November 2023, respectively.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Weacquired the license agreement for SGX301 and related intangible assets, including U.S. patent 8,629,302, properties and rightspursuant to an asset purchase agreement with Hy Biopharma Inc. (“Hy Biopharma”). As consideration for the assets acquired,we initially paid $275,000 in cash and issued 184,912 shares of common stock with a market value of $3,750,000, and in March 2020we issued 1,956,182 shares of common stock at a value of $5,000,000 (based upon an effective per share price of $2.56) as a resultof SGX301 demonstrating statistical significant treatment response in the Phase 3 clinical trial. Provided the final success-orientatedmilestone is attained, we will be required to make a payment of up to $5.0 million, if and when achieved, payable in our commonstock.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           SGX94License Agreements          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         OnDecember 18, 2012, we announced the acquisition of a first in class drug technology, known as SGX94 (dusquetide), representinga novel approach to modulation of the innate immune system. SGX94 is an IDR that regulates the innate immune system to reduceinflammation, eliminate infection and enhance tissue healing by binding to the pivotal regulatory protein p62, also known as sequestosome-1.As part of the acquisition, we acquired all rights, including composition of matter patents, preclinical and Phase 1 clinicalstudy datasets for SGX94. We also assumed a license agreement with UBC to advance the research and development of the SGX94 technology.The license agreement with UBC provides us with exclusive worldwide rights to manufacture, distribute, market sell and/or licenseor sublicense products derived or developed from this technology. Under the license agreement we are obligated to pay UBC (i)an annual license maintenance fee of CAN $1,000, and (ii) milestone payments which could reach up to CAN $1.2 million. This licenseagreement (a) will automatically terminate if we file, or become subject to an involuntary filing, for bankruptcy, and (b) maybe terminated by UBC in the event of, among other things, our insolvency, dissolution, grant of a security interest in the technologylicensed to us pursuant to the license agreement, or material breach of or failure to perform material obligations under the licenseagreement or other research agreements between us and UBC.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           OralBDP License Agreement          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         OnNovember 24, 1998, the Company, known at the time as Enteron Pharmaceuticals, Inc. (“Enteron”) and George B. McDonald(“Dr. McDonald”) entered into an exclusive license agreement for the rights to intellectual property, including know-how,relating to oral BDP. We have an exclusive license to commercially exploit the covered products worldwide, subject to Dr. McDonald’sright to make and use the technology for research purposes and the U.S. Government’s right to use the technology for governmentpurposes. Pursuant to the license agreement, as amended, we are is required to (i) reimburse Dr. McDonald for certain out-of-pocketexpenses incurred by Dr. McDonald in connection with the patent applications and issued patents, (ii) pay Dr. McDonald$300,000 upon approval by the FDA of our first NDA incorporating oral BDP; (iii) pay Dr. McDonald royalty payments equalto 3% of net sales of the covered products and (iv) pay Dr. McDonald $400,000 in cash upon an approval of oral BDP by the EuropeanMedicines Agency.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 28; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         25         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Additionally,in the event that sublicenses our rights under the license agreement, we will be required to pay Dr. McDonald 10% of any sublicensefees and royalty payments paid by the sublicense to us.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Theterm of the license agreement expires upon the expiration of the licensed patent applications or patents. Dr. McDonald has theright to terminate the license agreement in its entirety or to terminate exclusivity under the agreement if we or its sublicenseshave not commercialized or are not actively attempting to commercialize a covered product.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Additionally,the agreement terminates: (i) automatically upon us becoming insolvent; (ii) upon 30 days’ notice, if we breach any obligationunder the agreement without curing such breach during the notice period; and (iii) upon 90 days’ notice by us. After anytermination, we will have the right to sell our inventory for a period not to exceed three months following the date of termination,subject to the payment of the amounts owed under the agreement.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           ThermoVax           <sup>            ®           </sup>           License Agreement          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         OnDecember 21, 2010, we executed a worldwide exclusive license agreement with the UC for ThermoVax         <sup>          ®         </sup>         , which is thesubject of U.S. patent number 8,444,991 issued on May 21, 2013 titled “Method of Preparing an Immunologically-Active Adjuvant-BoundDried Vaccine Composition.” This patent and its corresponding foreign filings are licensed to us by the UC and they addressthe use of adjuvants in conjunction with vaccines that are formulated to resist thermal inactivation. U.S. Patent 8,444,991 isexpected to expire in December 2031. The license agreement also covers thermostable vaccines for biodefense as well as other potentialvaccine indications. In addition, we, in conjunction with UC, filed domestic and foreign patent applications claiming priorityback to a provisional application filed on May 17, 2011 titled: “Thermostable Vaccine Compositions and Methods of PreparingSame.” In April 2018, the UC delivered a notice of termination of our license agreement based upon our failure to achieveone of the development milestones: initiation of the Phase 1 clinical trial of the heat stabilization technology by March 31,2018. After negotiating with the UC, we and the UC agreed to extend the termination date to October 31, 2018 in order to allowus time to agree upon a potential agreement that would allow us to keep the rights to, and to continue to develop, the heat stabilizationtechnology or a product candidate containing the heat stabilization technology in our field of use.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         OnOctober 31, 2018, in a series of related transactions, (a) we and the UC agreed to terminate the original license agreement, (b)the UC and VitriVax executed a worldwide exclusive license agreement for the heat stabilization technology for all fields of use,and (c) we and VitriVax executed a worldwide exclusive sublicense agreement, which was amended and restated in October 2020, forthe heat stabilization technology for use in the fields of ricin and Ebola vaccines. We paid a $100,000 sublicense fee on theeffective date of the sublicense agreement. Under the amended sublicense agreement to maintain the sublicense we are obliged topay a minimum annual royalty of $20,000 until first commercial sale of a sublicensed product, upon which point, we will be requiredto pay an earned royalty of 2% of net sales subject to a minimum royalty of $50,000 each year. We are also required to pay royaltieson any sub-sublicense income based on a declining percentage of all sub-sublicense income calculated within the contractual perioduntil reaching a minimum of 15% after two years. In addition, we are required to pay VitriVax milestone fees of: (a) $25,000 uponinitiation of a Phase 2 clinical trial of the sublicensed product, (b) $100,000 upon initiation of a Phase 3 clinical trial ofthe sublicensed product, (c) $100,000 upon regulatory approval of a sublicensed product, and (c) $1 million upon achieving $10million in aggregate net sales of a sublicensed product in the U.S. or equivalent. To date none of these milestones have beenmet.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           RiVax           <sup>            ®           </sup>           License Agreement          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         InJune 2003, we executed a worldwide exclusive option to license patent applications with UTSW for the nasal, pulmonary and oraluses of a non-toxic ricin vaccine. In June 2004, we entered into a license agreement with UTSW for the injectable rights to thericin vaccine and, in October 2004, we negotiated the remaining oral rights to the ricin vaccine. To maintain this license weare obligated to pay $50,000 in annual license fees. Through this license, we have rights to the issued patent number 7,175,848titled “Ricin A chain mutants lacking enzymatic activity as vaccines to protect against aerosolized ricin.” This patentincludes methods of use and composition claims for RiVax         <sup>          ®         </sup>         .        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 29; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         26         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           CoVaccineHT™ License Agreement          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         In April 2020, we executed an agreement for the exclusive worldwidelicense of CoVaccine HT™, a novel vaccine adjuvant, from BTG, a division of Boston Scientific Corporation (NYSE: BSX),for the fields of SARS-CoV-2, the cause of COVID-19 and pandemic flu. The agreement was executed with Protherics Medicines Development,one of the companies that make up the BTG specialty pharmaceuticals business, which owns the CoVaccine HT™ intellectualproperty.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          Researchand Development Expenditures         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Wespent approximately $10.1 million and $8.1 million in the years ended December 31, 2020 and 2019, respectively, on research anddevelopment. The amounts we spent on research and development per product during the years ended December 31, 2020 and 2019 areset forth in “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in thisAnnual Report on Form 10-K.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Human Capital        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We are committed to a work environmentthat is welcoming, inclusive and encouraging.  To achieve our plans and goals, it is imperative that we attract and retaintop talent.  In order to do so, we aim to have a safe and encouraging workplace, with opportunities for our employees to growand develop professionally, supported by strong compensation, benefits, and other incentives.  In addition to competitivebase salaries, we offer every full-time employee a cash target bonus, a comprehensive benefits package and equity compensation.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">        Historically, we have experienced a low turnover of employees.During 2020, our voluntary turnover rate was less than 12%.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         As of December 31, 2020, we employed a total of 18 persons,including 1 part-time employee and 17 full-time employees, six of whom are MDs/PhDs.  In addition to our employees, we contractwith third-parties for the conduct of certain clinical development, manufacturing, accounting and administrative activities. We anticipate increasing the number of our employees.  We have no collective bargaining agreements with our employees, andnone are represented by labor unions.  We consider our relationships with our employees to be good.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Throughout the COVID-19 pandemic, mostof our employees have been working remotely.  We implemented a number of significant safety measures based on current guidelinesrecommended by the Centers for Disease Control for employees who choose to work at the Company’s facilities. These include,but are not limited to, social distancing, capacity limitations, mask requirements in common areas, weekly deep cleaning and dailysanitation procedures.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          AvailableInvestor Information         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Wefile electronically with the Securities and Exchange Commission (“SEC”) our annual reports on Form 10-K, quarterlyreports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a)of 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). We make available through our website,free of charge, copies of these reports as soon as reasonably practicable after we electronically file or furnish them to theSEC. Our website is located at www.soligenix.com. You can also request copies of such documents by contacting the company at (609)538-8200 or sending an email to info@soligenix.com.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <a name="a_018">          </a>          Item1A. Risk factors         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <i>         </i>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <i>          Aninvestment in our securities involves a high degree of risk. You should carefully consider the following information about theserisks, together with the other information about these risks contained in this Annual Report, as well as the other informationcontained in this Annual Report generally, before deciding to buy our securities. Any of the risks we describe below could adverselyaffect our business, financial condition, operating results or prospects. The market prices for our securities could decline ifone or more of these risks and uncertainties develop into actual events and you could lose all or part of your investment. Additionalrisks and uncertainties that we do not yet know of, or that we currently think are immaterial, may also impair our business operations.You should also refer to the other information contained in this Annual Report, including our financial statements and the relatednotes.         </i>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 30; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         27         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          Summaryof Risk Factors         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Ourbusiness is subject to a number of risks and uncertainties that you should understand before making an investment decision. Theserisks include, but are not limited to, the following:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           RisksRelated to our Business          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            We    have had significant losses and anticipate future losses; if additional funding cannot be obtained, we may reduce or discontinue    our product development and commercialization efforts or not be able to repay the Convertible Notes.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            If    we are unable to develop our product candidates, our ability to generate revenues and viability as a company will be significantly    impaired.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            We    have no approved products on the market and therefore do not expect to generate any revenues from product sales in the foreseeable    future, if at all.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Our    business is subject to extensive governmental regulation, which can be costly, time consuming and subjects us to unanticipated    delays.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            There    may be unforeseen challenges in developing our biodefense products.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            We    are dependent on government funding, which is inherently uncertain, for the success of our biodefense operations.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The    terms of our loan and security agreement with Pontifax Medison Finance require, and any future debt financing may require,    us to meet certain operating covenants and place restrictions on our operating and financial flexibility.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            If    the parties we depend on for supplying our drug substance raw materials and certain manufacturing-related services do not    timely supply these products and services, it may delay or impair our ability to develop, manufacture and market our products.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            If    we are not able to maintain or secure agreements with third parties for pre-clinical and clinical trials of our product candidates    on acceptable terms, if these third parties do not perform their services as required, or if these third parties fail to timely    transfer any regulatory information held by them to us, we may not be able to obtain regulatory approval for, or commercialize,    our product candidates.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The    manufacturing of our products is a highly exacting process, and if we or one of our materials suppliers encounter problems    manufacturing our products, our business could suffer.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            We    may use our financial and human resources to pursue a particular research program or product candidate and fail to capitalize    on programs or product candidates that may be more profitable or for which there is a greater likelihood of success.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Even    if approved, our products will be subject to extensive post-approval regulation.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Even    if we obtain regulatory approval to market our product candidates, our product candidates may not be accepted by the market.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            We    do not have extensive sales and marketing experience and our lack of experience may restrict our success in commercializing    some of our product candidates.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Our    products, if approved, may not be commercially viable due to change in health care practice and third party reimbursement    limitations.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Our    product candidates may cause serious adverse events or undesirable side effects which may delay or prevent marketing approval,    or, if approval is received, require them to be taken off the market, require them to include safety warnings or otherwise    limit their sales.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            If    we fail to obtain or maintain orphan drug exclusivity for our product candidates, our competitors may sell products to treat    the same conditions and our revenue will be reduced.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Federal    and/or state health care reform initiatives could negatively affect our business.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">       </p>       <!-- Field: Page; Sequence: 31; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         28         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            We    may not be able to retain rights licensed to us by third parties to commercialize key products or to develop the third party    relationships we need to develop, manufacture and market our products.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            We    may suffer product and other liability claims; we maintain only limited product liability insurance, which may not be sufficient.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            We    may use hazardous chemicals in our business. Potential claims relating to improper handling, storage or disposal of these    chemicals could affect us and be time consuming and costly.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            We    may not be able to compete with our larger and better-financed competitors in the biotechnology industry.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Competition    and technological change may make our product candidates and technologies less attractive or obsolete.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Our    business could be harmed if we fail to retain our current personnel or if they are unable to effectively run our business.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Instability    and volatility in the financial markets could have a negative impact on our business, financial condition, results of operations,    and cash flows.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            We    may not be able to utilize all of our net operating loss carryforwards.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Global    pathogens could have an impact on financial markets, materials sourcing, patients, governments and population (e.g. COVID-19).           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           RisksRelated to our Intellectual Property          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            We    may be unable to commercialize our products if we are unable to protect our proprietary rights, and we may be liable for significant    costs and damages if we face a claim of intellectual property infringement by a third party.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            We    may be involved in lawsuits to protect or enforce our patents, which could be expensive and time consuming.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            If    we infringe the rights of third parties we could be prevented from selling products, forced to pay damages, and defend against    litigation.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 32; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         29         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           RisksRelated to our Securities          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The    price of our common stock and warrants may be highly volatile.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            If    we fail to remain current with our listing requirements, we could be removed from The Nasdaq Capital Market, which would limit    the ability of broker-dealers to sell our securities and the ability of shareholders to sell their securities in the secondary    market.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Shareholders    may suffer substantial dilution related to issued stock warrants, options and convertible notes.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Our    shares of common stock and warrants are thinly traded, so stockholders may be unable to sell at or near ask prices or at all    if they need to sell shares or warrants to raise money or otherwise desire to liquidate their shares.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            We    do not currently intend to pay dividends on our common stock in the foreseeable future, and consequently, our stockholders’    ability to achieve a return on their investment will depend on appreciation in the price of our common stock.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Upon    our dissolution, our stockholders may not recoup all or any portion of their investment.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The    issuance of our common stock pursuant to the terms of the asset purchase agreement with Hy Biopharma Inc. may cause dilution    and the issuance of such shares of common stock, or the perception that such issuances may occur, could cause the price of    our common stock to fall.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         <b>          RisksRelated to our Business         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           Wehave had significant losses and anticipate future losses; if additional funding cannot be obtained, we may reduce or discontinueour product development and commercialization efforts.          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We have experienced significant lossessince inception and, at December 31, 2020, had an accumulated deficit of approximately $193 million. We expect to incur additionaloperating losses in the future and expect our cumulative losses to increase. As of December 31, 2020, we had approximately $18.7million in cash and cash equivalents available, and as of March 30, 2021 we had approximately $30.4 million in cash and cash equivalentsavailable. Based on our projected budgetary needs, funding from existing contracts and grants over the next two years, our loanand security agreement with Pontifax Medison Finance and sales pursuant to our At Market Issuance Sales Agreement (“FBR SalesAgreement”) with B. Riley FBR, Inc. (“FBR”), we expect to be able to maintain the current level of our operationsthrough at least March 31, 2022.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In September 2014, we entered into a contract with the NIH forthe development of RiVax        <sup>         ®        </sup>        to protect against exposure to ricin toxin that would provide up to $24.7 million of fundingin the aggregate over six years if options to extend the contract are exercised by the NIH. In 2017, we were awarded two separategrants from the NIH of approximately $1.5 million each to support our pivotal Phase 3 trials of SGX301 for the treatment of CTCLand SGX942 for the treatment of oral mucositis in head and neck cancer. In December 2020, we were awarded Direct to Phase II SBIRgrant from NIAID of approximately $1.5 million to support manufacture, formulation (including thermostabilization) and characterizationof COVID-19 and EVD vaccine candidates in conjunction with the CoVaccine HT™ adjuvant. Our biodefense grants have an overheadcomponent that allows us an agency-approved percentage over our incurred costs. We estimate that the overhead component associatedwith our existing contracts and grants will fund some fixed costs for direct employees working on these contracts and grants aswell as other administrative costs. As of December 31, 2020, we had approximately $2.16 million in awarded contract and grant fundingavailable.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Our product candidates are positioned foror are currently in clinical trials, and we have not yet generated any significant revenues from sales or licensing of these productcandidates. From inception through December 31, 2020, we have expended approximately $99 million developing our current productcandidates for pre-clinical research and development and clinical trials, and we currently expect to spend approximately $10.7million for the year ending December 31, 2021 in connection with the development of our therapeutic and vaccine products, licenses,employment agreements, and consulting agreements, of which approximately $0.8 million is expected to be reimbursed through ourexisting government contracts and grants.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Wehave no control over the resources and funding NIH, BARDA and NIAID may devote to our programs, which may be subject to periodicrenewal and which generally may be terminated by the government at any time for convenience. Any significant reductions in thefunding of U.S. government agencies or in the funding areas targeted by our business could materially and adversely affect ourbiodefense program and our results of operations and financial condition. If we fail to satisfy our obligations under the governmentcontracts, the applicable Federal Acquisition Regulations allow the government to terminate the agreement in whole or in part,and we may be required to perform corrective actions, including but not limited to delivering to the government any incompletework. If NIH, BARDA or NIAID do not exercise future funding options under the contracts or grants, terminate the funding or failto perform their responsibilities under the agreements or grants, it could materially impact our biodefense program and our financialresults.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 33; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         30         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Unlessand until we are able to generate sales or licensing revenue from one of our product candidates, we will require additional fundingto meet these commitments, sustain our research and development efforts, provide for future clinical trials, and continue ouroperations. There can be no assurance we can raise such funds. If additional funds are raised through the issuance of equity securities,stockholders may experience dilution of their ownership interests, and the newly issued securities may have rights superior tothose of the common stock. If additional funds are raised by the issuance of debt, we may be subject to limitations on our operations.If we cannot raise such additional funds, we may have to delay or stop some or all of our drug development programs.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           Ifwe are unable to develop our product candidates, our ability to generate revenues and viability as a company will be significantlyimpaired.          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Inorder to generate revenues and profits, our organization must, along with corporate partners and collaborators, positively research,develop and commercialize our technologies or product candidates. Our current product candidates are in various stages of clinicaland pre-clinical development and will require significant further funding, research, development, pre-clinical and/or clinicaltesting, regulatory approval and commercialization, and are subject to the risks of failure inherent in the development of productsbased on innovative or novel technologies. Specifically, each of the following is possible with respect to any of our productcandidates:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 0.25in; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            we    may not be able to maintain our current research and development schedules;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 0.25in; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            we    may be unable to secure procurement contracts on beneficial economic terms or at all from the U.S. government or others for    our biodefense products;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 0.25in; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            we    may encounter problems in clinical trials; or           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 0.25in; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the    technology or product may be found to be ineffective or unsafe, or may fail to obtain marketing approval.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Ifany of the risks set forth above occur, or if we are unable to obtain the necessary regulatory approvals as discussed below, wemay be unable to develop our technologies and product candidates and our business will be seriously harmed. Furthermore, for reasonsincluding those set forth below, we may be unable to commercialize or receive royalties from the sale of any other technologywe develop, even if it is shown to be effective, if:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 0.25in; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            it    is not economical or the market for the product does not develop or diminishes;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 0.25in; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            we    are not able to enter into arrangements or collaborations to manufacture and/or market the product;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 0.25in; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the    product is not eligible for third-party reimbursement from government or private insurers;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 0.25in; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            others    hold proprietary rights that preclude us from commercializing the product;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 0.25in; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            we    are not able to manufacture the product reliably;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 0.25in; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            others    have brought to market similar or superior products; or           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 0.25in; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the    product has undesirable or unintended side effects that prevent or limit its commercial use.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 34; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         31         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           Weexpect a number of factors to cause our operating results to fluctuate on a quarterly and annual basis, which may make it difficultto predict our future performance.          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Weare a late-stage biopharmaceutical company. Our operations to date have been primarily limited to developing our technology andundertaking pre-clinical studies and clinical trials of our product candidates in our two active business segments, SpecializedBioTherapeutics and Public Health Solutions. We have not yet obtained regulatory approvals for any of our product candidates.Consequently, any predictions made about our future success or viability may not be as accurate as they could be if we had commercializedproducts. Our financial condition has varied significantly in the past and will continue to fluctuate from quarter-to-quarteror year-to-year due to a variety of factors, many of which are beyond our control. Factors relating to our business that may contributeto these fluctuations include other factors described elsewhere in this Annual Report and also include:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 0.25in; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our    ability to obtain additional funding to develop our product candidates;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our    ability to repay existing debt in accordance with its terms;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            delays    in the commencement, enrollment and timing of clinical trials;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the    success of our product candidates through all phases of clinical development;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            any    delays in regulatory review and approval of product candidates in clinical development;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our    ability to obtain and maintain regulatory approval for our product candidates in the U.S. and foreign jurisdictions;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            potential    side effects of our product candidates that could delay or prevent commercialization, limit the indications for any approved    drug, require the establishment of risk evaluation and mitigation strategies, or cause an approved drug to be taken off the    market;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our    dependence on third-party contract manufacturing organizations to supply or manufacture our products;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our    dependence on contract research organizations to conduct our clinical trials;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our    ability to establish or maintain collaborations, licensing or other arrangements;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            market    acceptance of our product candidates;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our    ability to establish and maintain an effective sales and marketing infrastructure, either through the creation of a commercial    infrastructure or through strategic collaborations;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            competition    from existing products or new products that may emerge;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the    ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for our products;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our    ability to discover and develop additional product candidates;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our    ability and our licensors’ abilities to successfully obtain, maintain, defend and enforce intellectual property rights    important to our business;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our    ability to attract and retain key personnel to manage our business effectively;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our    ability to build our finance infrastructure and improve our accounting systems and controls;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            potential    product liability claims;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            potential    liabilities associated with hazardous materials; and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our    ability to obtain and maintain adequate insurance policies.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Accordingly,the results of any quarterly or annual periods should not be relied upon as indications of future operating performance.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 35; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         32         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           Wehave no approved products on the market and therefore do not expect to generate any revenues from product sales in the foreseeablefuture, if at all.          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Todate, we have no approved product on the market and have not generated any significant product revenues. We have funded our operationsprimarily from sales of our securities and from government contracts and grants. We have not received, and do not expect to receivefor at least the next several years, if at all, any revenues from the commercialization of our product candidates. To obtain revenuesfrom sales of our product candidates, we must succeed, either alone or with third parties, in developing, obtaining regulatoryapproval for, manufacturing and marketing drugs with commercial potential or successfully obtain government procurement or stockpilingagreements. We may never succeed in these activities, and we may not generate sufficient revenues to continue our business operationsor achieve profitability.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           Ourbusiness is subject to extensive governmental regulation, which can be costly, time consuming and subjects us to unanticipateddelays.          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Ourbusiness is subject to very stringent federal, foreign, state and local government laws and regulations, including the FederalFood, Drug and Cosmetic Act, the Environmental Protection Act, the Occupational Safety and Health Act, and state and local counterpartsto these acts. These laws and regulations may be amended, additional laws and regulations may be enacted, and the policies ofthe FDA and other regulatory agencies may change.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Theregulatory process applicable to our products requires pre-clinical and clinical testing of any product to establish its safetyand efficacy. This testing can take many years, is uncertain as to outcome, and requires the expenditure of substantial capitaland other resources. We estimate that the clinical trials of our product candidates that we have planned will take at least severalyears to complete. Furthermore, failure can occur at any stage of the trials, and we could encounter problems that cause us toabandon or repeat clinical trials. Favorable results in early studies or trials, if any, may not be repeated in later studiesor trials. Even if our clinical trials are initiated and completed as planned, we cannot be certain that the results will supportour product candidate claims. Success in preclinical testing, Phase 1 and Phase 2 clinical trials does not ensure that later Phase2 or Phase 3 clinical trials will be successful. In addition, we, the FDA or other regulatory authorities may suspend clinicaltrials at any time if it appears that we are exposing participants to unacceptable health risks or the FDA or other regulatoryauthorities find deficiencies in our submissions or conduct of our trials.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Wemay not be able to obtain, or we may experience difficulties and delays in obtaining, necessary domestic and foreign governmentalclearances and approvals to market a product (for example, the FDA may not recognize fast track designation upon a NDA submission,resulting in no priority review and subjecting us to longer potential review times than originally anticipated). Also, even ifregulatory approval of a product is granted, that approval may entail limitations on the indicated uses for which the productmay be marketed.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Followingany regulatory approval, a marketed product and its manufacturer are subject to continual regulatory review. Later discovery ofproblems with a product or manufacturer may result in restrictions on such product or manufacturer. These restrictions may includeproduct recalls and suspension or withdrawal of the marketing approval for the product. Furthermore, the advertising, promotionand export, among other things, of a product are subject to extensive regulation by governmental authorities in the U.S. and othercountries. If we fail to comply with applicable regulatory requirements, we may be subject to fines, suspension or withdrawalof regulatory approvals, product recalls, seizure of products, operating restrictions and/or criminal prosecution.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           Theremay be unforeseen challenges in developing our biodefense products.          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Fordevelopment of biodefense vaccines and therapeutics, the FDA has instituted policies that are expected to result in acceleratedapproval. This includes approval for commercial use using the results of animal efficacy trials, rather than efficacy trials inhumans, referred to as the Animal Rule. However, we will still have to establish that the vaccines we are developing are safein humans at doses that are correlated with the beneficial effect in animals. Such clinical trials will also have to be completedin distinct populations that are subject to the countermeasures; for instance, the very young and the very old, and in pregnantwomen, if the countermeasure is to be licensed for civilian use. Other agencies will have an influence over the risk benefit scenariosfor deploying the countermeasures and in establishing the number of doses utilized in the Strategic National Stockpile. We maynot be able to sufficiently demonstrate the animal correlation to the satisfaction of the FDA, as these correlates are difficultto establish and are often unclear. Invocation of the Animal Rule may raise issues of confidence in the model systems even ifthe models have been validated. For many of the biological threats, the animal models are not available and we may have to developthe animal models, a time-consuming research effort. There are few historical precedents, or recent precedents, for the developmentof new countermeasures for bioterrorism agents. Despite the Animal Rule, the FDA may require large clinical trials to establishsafety and immunogenicity before licensure and it may require safety and immunogenicity trials in additional populations. Approvalof biodefense products may be subject to post-marketing studies, and could be restricted in use in only certain populations. Thegovernment’s biodefense priorities can change, which could adversely affect the commercial opportunity for the productswe are developing. Further, other countries have not, at this time, established criteria for review and approval of these typesof products outside their normal review process, i.e., there is no Animal Rule equivalent, and consequently there can be no assurancethat we will be able to make a submission for marketing approval in foreign countries based on such animal data.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 36; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         33         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Additionally,few facilities in the U.S. and internationally have the capability to test animals with ricin, or otherwise assist us in qualifyingthe requisite animal models. We have to compete with other biodefense companies for access to this limited pool of highly specializedresources. We therefore may not be able to secure contracts to conduct the testing in a predictable timeframe or at all.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           Weare dependent on government funding, which is inherently uncertain, for the success of our biodefense operations.          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Weare subject to risks specifically associated with operating in the biodefense industry, which is a new and unproven business area.We do not anticipate that a significant commercial market will develop for our biodefense products. Because we anticipate thatthe principal potential purchasers of these products, as well as potential sources of research and development funds, will bethe U.S. government and governmental agencies, the success of our biodefense division will be dependent in large part upon governmentspending decisions. The funding of government programs is dependent on budgetary limitations, congressional appropriations andadministrative allotment of funds, all of which are inherently uncertain and may be affected by changes in U.S. government policiesresulting from various political and military developments. Our receipt of government funding is also dependent on our abilityto adhere to the terms and provisions of the original grant and contract documents and other regulations. We can provide no assurancethat we will receive or continue to receive funding for grants and contracts we have been awarded. The loss of government fundscould have a material adverse effect on our ability to progress our biodefense business.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           Theterms of our loan and security agreement with Pontifax Medison Finance require, and any future debt financing may require, usto meet certain operating covenants and place restrictions on our operating and financial flexibility.          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         InDecember 2020, we entered into a loan and security agreement with Pontifax Medison Finance (the “Loan and Security Agreement”),that is secured by a lien covering substantially all of our assets, other than our intellectual property and licenses for intellectualproperty. The Loan and Security Agreement contains customary affirmative and negative covenants and events of default. Affirmativecovenants include, among others, covenants requiring us to protect and maintain our intellectual property and comply with allapplicable laws, deliver certain financial reports, maintain a minimum cash balance and maintain insurance coverage. Negativecovenants include, among others, covenants restricting us from transferring any material portion of our assets, incurring additionalindebtedness, engaging in mergers or acquisitions, changing foreign subsidiary voting rights, repurchasing shares, paying dividendsor making other distributions, making certain investments, and creating other liens on our assets, including our intellectualproperty, in each case subject to customary exceptions. If we raise any additional debt financing, the terms of such additionaldebt could further restrict our operating and financial flexibility. These restrictions may include, among other things, limitationson borrowing and specific restrictions on the use of our assets, as well as prohibitions on our ability to create liens, pay dividends,redeem capital stock or make investments. If we default under the terms of the Loan and Security Agreement or any future debtfacility, the lender may accelerate all of our repayment obligations and take control of our pledged assets, potentially requiringus to renegotiate our agreement on terms less favorable to us or to immediately cease operations. Further, if we are liquidated,the lender’s right to repayment would be senior to the rights of the holders of our common stock. The lender could declarea default upon the occurrence of any event that it interprets as a material adverse effect as defined under the Loan and SecurityAgreement. Any declaration by the lender of an event of default could significantly harm our business and prospects and couldcause the price of our common stock to decline.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 37; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         34         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           Ifthe parties we depend on for supplying our drug substance raw materials and certain manufacturing-related services do not timelysupply these products and services, it may delay or impair our ability to develop, manufacture and market our products. We donot have or anticipate having internal manufacturing capabilities.          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Werely on suppliers for our drug substance raw materials and third parties for certain manufacturing-related services to producematerial that meets appropriate content, quality and stability standards, which material will be used in clinical trials of ourproducts and, after approval, for commercial distribution. To succeed, clinical trials require adequate supplies of drug substanceand drug product, which may be difficult or uneconomical to procure or manufacture. We and our suppliers and vendors may not beable to (i) produce our drug substance or drug product to appropriate standards for use in clinical studies, (ii) perform underany definitive manufacturing, supply or service agreements with us or (iii) remain in business for a sufficient time to be ableto develop, produce, secure regulatory approval of and market our product candidates. If we do not maintain important manufacturingand service relationships, we may fail to find a replacement supplier or required vendor or develop our own manufacturing capabilitieswhich could delay or impair our ability to obtain regulatory approval for our products and substantially increase our costs ordeplete profit margins, if any. If we do find replacement manufacturers and vendors, we may not be able to enter into agreementswith them on terms and conditions favorable to us and, there could be a substantial delay before a new facility could be qualifiedand registered with the FDA and foreign regulatory authorities.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           Werely on third parties for pre-clinical and clinical trials of our product candidates and, in some cases, to maintain regulatoryfiles for our product candidates. If we are not able to maintain or secure agreements with such third parties on acceptable terms,if these third parties do not perform their services as required, or if these third parties fail to timely transfer any regulatoryinformation held by them to us, we may not be able to obtain regulatory approval for, or commercialize, our product candidates.          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Werely on academic institutions, hospitals, clinics and other third-party collaborators for preclinical and clinical trials of ourproduct candidates. Although we monitor, support, and/or oversee our pre-clinical and clinical trials, because we do not conductthese trials ourselves, we have less control over the timing and cost of these studies and the ability to recruit trial subjectsthan if we conducted these trials wholly by ourselves. If we are unable to maintain or enter into agreements with these thirdparties on acceptable terms, or if any such engagement is terminated, we may be unable to enroll patients on a timely basis orotherwise conduct our trials in the manner we anticipate. In addition, there is no guarantee that these third parties will devoteadequate time and resources to our studies or perform as required by a contract or in accordance with regulatory requirements,including maintenance of clinical trial information regarding our product candidates. If these third parties fail to meet expecteddeadlines, fail to timely transfer to us any regulatory information, fail to adhere to protocols or fail to act in accordancewith regulatory requirements or our agreements with them, or if they otherwise perform in a substandard manner or in a way thatcompromises the quality or accuracy of their activities or the data they obtain, then preclinical and/or clinical trials of ourproduct candidates may be extended, delayed or terminated, or our data may be rejected by the FDA or regulatory agencies.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           Themanufacturing of our products is a highly exacting process, and if we or one of our materials suppliers encounter problems manufacturingour products, our business could suffer.          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         TheFDA and foreign regulators require manufacturers to register manufacturing facilities. The FDA and foreign regulators also inspectthese facilities to confirm compliance with current Good Manufacturing Practice (“cGMP”) or similar requirements thatthe FDA or foreign regulators establish. We, or our materials suppliers, may face manufacturing or quality control problems causingproduct production and shipment delays or a situation where we or the supplier may not be able to maintain compliance with theFDA’s cGMP requirements, or those of foreign regulators, necessary to continue manufacturing our drug substance. Any failureto comply with cGMP requirements or other FDA or foreign regulatory requirements could adversely affect our clinical researchactivities and our ability to market and develop our products.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 38; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         35         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           Wemay use our financial and human resources to pursue a particular research program or product candidate and fail to capitalizeon programs or product candidates that may be more profitable or for which there is a greater likelihood of success.          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Becausewe have limited financial and human resources, we are currently focusing on the regulatory approval of certain product candidates.As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that laterprove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercialproducts or profitable market opportunities. Our spending on existing and future product candidates for specific indications maynot yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particularproduct candidate, we may relinquish valuable rights to that product candidate through strategic alliance, licensing or otherroyalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercializationrights to such product candidate, or we may allocate internal resources to a product candidate in an area in which it would havebeen more advantageous to enter into a partnering arrangement.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           Evenif approved, our products will be subject to extensive post-approval regulation.          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Oncea product is approved, numerous post-approval requirements apply. Among other things, the holder of an approved NDA is subjectto periodic and other FDA monitoring and reporting obligations, including obligations to monitor and report adverse events andinstances of the failure of a product to meet the specifications in the NDA. Application holders must submit new or supplementalapplications and obtain FDA approval for certain changes to the approved product, product labeling, or manufacturing process.Application holders must also submit advertising and other promotional material to the FDA and report on ongoing clinical trials.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Dependingon the circumstances, failure to meet these post-approval requirements can result in criminal prosecution, fines, injunctions,recall or seizure of products, total or partial suspension of production, denial or withdrawal of pre-marketing product approvals,or refusal to allow us to enter into supply contracts, including government contracts. In addition, even if we comply with FDAand other requirements, new information regarding the safety or effectiveness of a product could lead the FDA to modify or withdrawproduct approval.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           Evenif we obtain regulatory approval to market our product candidates, our product candidates may not be accepted by the market.          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Evenif the FDA approves one or more of our product candidates, physicians and patients may not accept it or use it. Even if physiciansand patients would like to use our products, our products may not gain market acceptance among healthcare payors such as managedcare formularies, insurance companies or government programs such as Medicare or Medicaid. Acceptance and use of our productswill depend upon a number of factors including: perceptions by members of the health care community, including physicians, aboutthe safety and effectiveness of our drug product; cost-effectiveness of our product relative to competing products; availabilityof reimbursement for our product from government or other healthcare payers; and effectiveness of marketing and distribution effortsby us and our licensees and distributors, if any.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         Thedegree of market acceptance of any product that we develop will depend on a number of factors, including:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            cost-effectiveness;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the    safety and effectiveness of our products, including any significant potential side effects, as compared to alternative products    or treatment methods;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the    timing of market entry as compared to competitive products;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the rate of adoption    of our products by doctors and nurses;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            product labeling    or product insert required by the FDA for each of our products;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 39; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         36         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            reimbursement policies    of government and third-party payors;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            effectiveness of    our sales, marketing and distribution capabilities and the effectiveness of such capabilities of our collaborative partners,    if any; and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 48px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            unfavorable publicity    concerning our products or any similar products.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Ourproduct candidates, if successfully developed, will compete with a number of products manufactured and marketed by major pharmaceuticalcompanies, biotechnology companies and manufacturers of generic drugs. Our products may also compete with new products currentlyunder development by others. Physicians, patients, third-party payors and the medical community may not accept and utilize anyof our product candidates. If our products do not achieve market acceptance, we will not be able to generate significant revenuesor become profitable.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Becausewe expect sales of our current product candidates, if approved, to generate substantially all of our product revenues for theforeseeable future, the failure of these products to find market acceptance would harm our business and could require us to seekadditional financing.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           Wedo not have extensive sales and marketing experience and our lack of experience may restrict our success in commercializing someof our product candidates.          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Wedo not have extensive experience in marketing or selling pharmaceutical products whether in the U.S. or internationally. To obtainthe expertise necessary to successfully market and sell any of our products, the development of our own commercial infrastructureand/or collaborative commercial arrangements and partnerships will be required. Our ability to make that investment and also executeour current operating plan is dependent on numerous factors, including, the performance of third party collaborators with whomwe may contract.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           Ourproducts, if approved, may not be commercially viable due to change in health care practice and third party reimbursement limitations.          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Initiativesto reduce the federal deficit and to change health care delivery are increasing cost-containment efforts. We anticipate that Congress,state legislatures and the private sector will continue to review and assess alternative benefits, controls on health care spendingthrough limitations on the growth of private health insurance premiums and Medicare and Medicaid spending, price controls on pharmaceuticals,and other fundamental changes to the health care delivery system. Any changes of this type could negatively impact the commercialviability of our products, if approved. Our ability to successfully commercialize our product candidates, if they are approved,will depend in part on the extent to which appropriate reimbursement codes and authorized cost reimbursement levels of these productsand related treatment are obtained from governmental authorities, private health insurers and other organizations, such as healthmaintenance organizations. In the absence of national Medicare coverage determination, local contractors that administer the Medicareprogram may make their own coverage decisions. Any of our product candidates, if approved and when commercially available, maynot be included within the then current Medicare coverage determination or the coverage determination of state Medicaid programs,private insurance companies or other health care providers. In addition, third-party payers are increasingly challenging the necessityand prices charged for medical products, treatments and services.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           Ourproduct candidates may cause serious adverse events or undesirable side effects which may delay or prevent marketing approval,or, if approval is received, require them to be taken off the market, require them to include safety warnings or otherwise limittheir sales.          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Seriousadverse events or undesirable side effects from any of our product candidates could arise either during clinical development or,if approved, after the approved product has been marketed. The results of future clinical trials may show that our product candidatescause serious adverse events or undesirable side effects, which could interrupt, delay or halt clinical trials, resulting in delayof, or failure to obtain, marketing approval from the FDA and other regulatory authorities.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 40; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         37         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Ifany of our product candidates cause serious adverse events or undesirable side effects:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            regulatory authorities    may impose a clinical hold which could result in substantial delays and adversely impact our ability to continue development    of the product;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            regulatory authorities    may require the addition of labeling statements, specific warnings, a contraindication or field alerts to physicians and pharmacies;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            we may be required    to change the way the product is administered, conduct additional clinical trials or change the labeling of the product;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            we may be required    to implement a risk minimization action plan, which could result in substantial cost increases and have a negative impact    on our ability to commercialize the product;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            we may be required    to limit the patients who can receive the product;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            we may be subject    to limitations on how we promote the product;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            sales of the product    may decrease significantly;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            regulatory authorities    may require us to take our approved product off the market;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            we may be subject    to litigation or product liability claims; and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our reputation may    suffer.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Anyof these events could prevent us from achieving or maintaining market acceptance of the affected product or could substantiallyincrease commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenues fromthe sale of our products.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           Ifwe fail to obtain or maintain orphan drug exclusivity for our product candidates, our competitors may sell products to treat thesame conditions and our revenue will be reduced.          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Underthe Orphan Drug Act, the FDA may designate a product as an orphan drug if it is intended to treat a rare disease or condition,defined as a patient population of fewer than 200,000 in the U.S., or a patient population greater than 200,000 in the U.S. wherethere is no reasonable expectation that the cost of developing the drug will be recovered from sales in the U.S. In the EU, theEuropean Medicines Agency’s Committee for Orphan Medicinal Products grants orphan drug designation to promote the developmentof products that are intended for the diagnosis, prevention, or treatment of a life-threatening or chronically debilitating conditionaffecting not more than five in 10,000 persons in the EU. Additionally, designation is granted for products intended for the diagnosis,prevention, or treatment of a life-threatening, seriously debilitating or serious and chronic condition when, without incentives,it is unlikely that sales of the drug in the EU would be sufficient to justify the necessary investment in developing the drugor biological product or where there is no satisfactory method of diagnosis, prevention, or treatment, or, if such a method exists,the medicine must be of significant benefit to those affected by the condition.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Inthe U.S., orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinicaltrial costs, tax advantages, and user-fee waivers. In addition, if a product receives the first FDA approval for the indicationfor which it has orphan designation, the product is entitled to orphan drug exclusivity, which means the FDA may not approve anyother application to market the same drug for the same indication for a period of seven years, except in limited circumstances,such as a showing of clinical superiority over the product with orphan exclusivity or where the manufacturer is unable to assuresufficient product quantity. In the EU, orphan drug designation entitles a party to financial incentives such as reduction offees or fee waivers and ten years of market exclusivity following drug or biological product approval. This period may be reducedto six years if the orphan drug designation criteria are no longer met, including where it is shown that the product is sufficientlyprofitable not to justify maintenance of market exclusivity.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 41; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         38         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Eventhough we have orphan drug designation for SGX301 in the U.S. and Europe, and SGX203, RiVax         <sup>          ®         </sup>         in the U.S., we maynot be the first to obtain marketing approval for any particular orphan indication due to the uncertainties associated with developingdrugs or biologic products. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectivelyprotect the product from competition because different drugs with different active moieties can be approved for the same condition.Absent patent or other intellectual property protection, even after an orphan drug is approved, the FDA or European MedicinesAgency may subsequently approve the same drug with the same active moiety for the same condition if the FDA or European MedicinesAgency concludes that the later drug is safer, more effective, or makes a major contribution to patient care.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           Federaland/or state health care reform initiatives could negatively affect our business.          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Theavailability of reimbursement by governmental and other third-party payers affects the market for any pharmaceutical product.These third-party payers continually attempt to contain or reduce the costs of healthcare. There have been a number of legislativeand regulatory proposals to change the healthcare system and further proposals are likely. Medicare’s policies may decreasethe market for our products. Significant uncertainty exists with respect to the reimbursement status of newly approved healthcareproducts.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Third-partypayers are increasingly challenging the price and cost-effectiveness of medical products and services. Once approved, we mightnot be able to sell our products profitably or recoup the value of our investment in product development if reimbursement is unavailableor limited in scope, particularly for product candidates addressing small patient populations. On July 15, 2008, the MedicareImprovements for Patients and Providers Act of 2008 became law with a number of Medicare and Medicaid reforms to establish a bundledMedicare payment rate that includes services and drug/labs that were separately billed at that time. Bundling initiatives thathave been implemented in other healthcare settings have occasionally resulted in lower utilization of services that had not previouslybeen a part of the bundled payment.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Inaddition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. Therequirements governing drug pricing vary widely from country to country. We expect that there will continue to be a number ofU.S. federal and state proposals to implement governmental pricing controls. While we cannot predict whether such legislativeor regulatory proposals will be adopted, the adoption of such proposals could have a material adverse effect on our business,financial condition and profitability.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           Wemay not be able to retain rights licensed to us by third parties to commercialize key products or to develop the third party relationshipswe need to develop, manufacture and market our products.          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Wecurrently rely on license agreements from New York University, Yeda Research and Development Company Ltd., the University of TexasSouthwestern Medical Center, the University of British Columbia, Harvard University and George B. McDonald, MD as well as sublicenseagreement from VitriVax for the rights to commercialize key product candidates. We may not be able to retain the rights grantedunder these agreements or negotiate additional agreements on reasonable terms, if at all. Our existing license agreements impose,and we expect that future license agreements will impose, various diligence, milestone payment, royalty, and other obligationson us. If we fail to comply with our obligations under these agreements, or we are subject to a bankruptcy, we may be requiredto make certain payments to the licensor, we may lose the exclusivity of our license, or the licensor may have the right to terminatethe license, in which event we would not be able to develop or market products covered by the license.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         Additionally,the milestone and other payments associated with these licenses will make it less profitable for us to develop our drug candidates.See “Business - Patents and Other Proprietary Rights” for a description of our license agreements.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Licensingof intellectual property is of critical importance to our business and involves complex legal, business, and scientific issues.Disputes may arise regarding intellectual property subject to a licensing agreement, including but not limited to:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the scope of rights    granted under the license agreement and other interpretation-related issues;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 42; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         39         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the extent to which    our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the sublicensing    of patent and other rights;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our diligence obligations    under the license agreement and what activities satisfy those diligence obligations;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the ownership of    inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our    collaborators; and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the priority of    invention of patented technology.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Ifdisputes over intellectual property and other rights that we have licensed prevent or impair our ability to maintain our currentlicensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Additionally,the research resulting in certain of our licensed patent rights and technology was funded by the U.S. government. As a result,the government may have certain rights, or march-in rights, to such patent rights and technology. When new technologies are developedwith government funding, the government generally obtains certain rights in any resulting patents, including a non-exclusive licenseauthorizing the government to use the invention for non-commercial purposes. The government can exercise its march-in rights ifit determines that action is necessary because we fail to achieve practical application of the government-funded technology, becauseaction is necessary to alleviate health or safety needs, to meet requirements of federal regulations or to give preference toU.S. industry. In addition, our rights in such inventions may be subject to certain requirements to manufacture products embodyingsuch inventions in the U.S. Any exercise by the government of such rights could harm our competitive position, business, financialcondition, results of operations and prospects.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Furthermore,we currently have very limited product development capabilities and no manufacturing, marketing or sales capabilities. For usto research, develop and test our product candidates, we need to contract or partner with outside researchers, in most cases withor through those parties that did the original research and from whom we have licensed the technologies. If products are successfullydeveloped and approved for commercialization, then we will need to enter into additional collaboration and other agreements withthird parties to manufacture and market our products. We may not be able to induce the third parties to enter into these agreements,and, even if we are able to do so, the terms of these agreements may not be favorable to us. Our inability to enter into theseagreements could delay or preclude the development, manufacture and/or marketing of some of our product candidates or could significantlyincrease the costs of doing so. In the future, we may grant to our development partners rights to license and commercialize pharmaceuticaland related products developed under the agreements with them, and these rights may limit our flexibility in considering alternativesfor the commercialization of these products. Furthermore, third-party manufacturers or suppliers may not be able to meet our needswith respect to timing, quantity and quality for the products.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Additionally,if we do not enter into relationships with additional third parties for the marketing of our products, if and when they are approvedand ready for commercialization, we would have to build our own sales force or enter into commercialization agreements with othercompanies. Development of an effective sales force in any part of the world would require significant financial resources, timeand expertise. We may not be able to obtain the financing necessary to establish a sales force in a timely or cost effective manner,if at all, and any sales force we are able to establish may not be capable of generating demand for our product candidates, ifthey are approved.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 43; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         40         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           Wemay suffer product and other liability claims; we maintain only limited product liability insurance, which may not be sufficient.          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Theclinical testing, manufacture and sale of our products involves an inherent risk that human subjects in clinical testing or consumersof our products may suffer serious bodily injury or death due to side effects, allergic reactions or other unintended negativereactions to our products. As a result, product and other liability claims may be brought against us. We currently have clinicaltrial and product liability insurance with limits of liability of $10 million, which may not be sufficient to cover our potentialliabilities. Because liability insurance is expensive and difficult to obtain, we may not be able to maintain existing insuranceor obtain additional liability insurance on acceptable terms or with adequate coverage against potential liabilities. Furthermore,if any claims are brought against us, even if we are fully covered by insurance, we may suffer harm such as adverse publicity.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           Wemay use hazardous chemicals in our business. Potential claims relating to improper handling, storage or disposal of these chemicalscould affect us and be time consuming and costly.          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Ourresearch and development processes and/or those of our third party contractors involve the controlled use of hazardous materialsand chemicals. These hazardous chemicals are reagents and solvents typically found in a chemistry laboratory. Our operations alsomay produce hazardous waste products. Federal, state and local laws and regulations govern the use, manufacture, storage, handlingand disposal of hazardous materials. While we attempt to comply with all environmental laws and regulations, including those relatingto the outsourcing of the disposal of all hazardous chemicals and waste products, we cannot eliminate the risk of contaminationfrom or discharge of hazardous materials and any resultant injury. In the event of such an accident, we could be held liable forany resulting damages and any liability could materially adversely affect our business, financial condition and results of operations.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Compliancewith environmental laws and regulations may be expensive. Current or future environmental regulations may impair our research,development or production efforts. We might have to pay civil damages in the event of an improper or unauthorized release of,or exposure of individuals to, hazardous materials. We are not insured against these environmental risks. We may agree to indemnifyour collaborators in some circumstances against damages and other liabilities arising out of development activities or productsproduced in connection with these collaborations.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Inaddition, the federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal ofhazardous or radioactive materials and waste products may require us to incur substantial compliance costs that could materiallyadversely affect our business, financial condition and results of operations.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           Wemay not be able to compete with our larger and better financed competitors in the biotechnology industry.          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Thebiotechnology industry is intensely competitive, subject to rapid change and sensitive to new product introductions or enhancements.Most of our existing competitors have greater financial resources, larger technical staffs, and larger research budgets than wehave, as well as greater experience in developing products and conducting clinical trials. Our competition is particularly intensein the gastroenterology and transplant areas and is also intense in the therapeutic area of inflammatory bowel diseases. We faceintense competition in the biodefense area from various public and private companies and universities as well as governmentalagencies, such as the U.S. Army, which may have their own proprietary technologies that may directly compete with our technologies.In addition, there may be other companies that are currently developing competitive technologies and products or that may in thefuture develop technologies and products that are comparable or superior to our technologies and products. We may not be ableto compete with our existing and future competitors, which could lead to the failure of our business.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         Additionally,if a competitor receives FDA approval before we do for a drug that is similar to one of our product candidates, FDA approval forour product candidate may be precluded or delayed due to periods of non-patent exclusivity and/or the listing with the FDA bythe competitor of patents covering its newly-approved drug product. Periods of non-patent exclusivity for new versions of existingdrugs such as our current product candidates can extend up to three and one-half years. See “Business - The Drug ApprovalProcess.”        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Thesecompetitive factors could require us to conduct substantial new research and development activities to establish new product targets,which would be costly and time consuming. These activities would adversely affect our ability to commercialize products and achieverevenue and profits.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           Competitionand technological change may make our product candidates and technologies less attractive or obsolete.          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Wecompete with established pharmaceutical and biotechnology companies that are pursuing other forms of treatment for the same indicationswe are pursuing and that have greater financial and other resources. Other companies may succeed in developing products earlierthan us, obtaining FDA approval for products more rapidly, or developing products that are more effective than our product candidates.Research and development by others may render our technology or product candidates obsolete or noncompetitive, or result in treatmentsor cures superior to any therapy we develop. We face competition from companies that internally develop competing technology oracquire competing technology from universities and other research institutions. As these companies develop their technologies,they may develop competitive positions that may prevent, make futile, or limit our product commercialization efforts, which wouldresult in a decrease in the revenue we would be able to derive from the sale of any products.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 44; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         41         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Therecan be no assurance that any of our product candidates will be accepted by the marketplace as readily as these or other competingtreatments. Furthermore, if our competitors’ products are approved before ours, it could be more difficult for us to obtainapproval from the FDA. Even if our products are successfully developed and approved for use by all governing regulatory bodies,there can be no assurance that physicians and patients will accept our product(s) as a treatment of choice.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Furthermore,the pharmaceutical research industry is diverse, complex, and rapidly changing. By its nature, the business risks associated therewithare numerous and significant. The effects of competition, intellectual property disputes, market acceptance, and FDA regulationspreclude us from forecasting revenues or income with certainty or even confidence.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           Ourbusiness could be harmed if we fail to retain our current personnel or if they are unable to effectively run our business.          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Wecurrently have 18 employees and we depend upon these employees, in particular Dr. Christopher Schaber, our President and ChiefExecutive Officer, to manage the day-to-day activities of our business. Because we have such limited personnel, the loss of anyof them or our inability to attract and retain other qualified employees in a timely manner would likely have a negative impacton our operations. We may be unable to effectively manage and operate our business, and our business may suffer, if we lose theservices of our employees.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           Instabilityand volatility in the financial markets could have a negative impact on our business, financial condition, results of operations,and cash flows.          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Duringrecent years, there has been substantial volatility in financial markets due at least in part to the uncertainty with regard tothe global economic environment. In addition, there has been substantial uncertainty in the capital markets and access to additionalfinancing is uncertain. Moreover, customer spending habits may be adversely affected by current and future economic conditions.These conditions could have an adverse effect on our industry and business, including our financial condition, results of operations,and cash flows.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Tothe extent that we do not generate sufficient cash from operations, we may need to issue stock or incur indebtedness to financeour plans for growth. Recent turmoil in the credit markets and the potential impact on the liquidity of major financial institutionsmay have an adverse effect on our ability to fund our business strategy through borrowings, under either existing or newly createdinstruments in the public or private markets on terms we believe to be reasonable, if at all.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           Wemay not be able to utilize all of our net operating loss carryforwards.          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The State of New Jersey’s Technology Business Tax CertificateProgram allows certain high technology and biotechnology companies to sell unused net operating loss (“NOL”) carryforwardsto other New Jersey-based corporate taxpayers. During the year ended December 31, 2020 in accordance with this program, we soldNew Jersey NOL carry forwards resulting in the recognition of $863,893 of income tax benefit, net of transaction costs. Due toa delay in the program, these funds were not recognized or received until April 2020. We have applied for and received confirmationthat we have NOLs for the year ended December 31, 2019 that qualify for an income tax benefit in the amount of $864,742. The programhas been delayed again this year, and we will therefore not recognize this benefit until we receive our certificate for the funds.We have not yet sold our 2020 New Jersey NOLs but may do so in the future. If there is an unfavorable change in the State of NewJersey’s Technology Business Tax Certificate Program (whether as a result of a change in law, policy or otherwise) that terminatesthe program or eliminates or reduces our ability to use or sell our NOL carryforwards or if we are unable to find a suitable buyerto utilize our New Jersey NOL carryforwards to the extent the NOLs expire before we are able to utilize them against our taxableincome, our cash taxes may increase which may have an adverse effect on our financial condition.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 45; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         42         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           Globalpathogens that could have an impact on financial markets, materials sourcing, patients, governments and population (e.g. COVID-19).          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Basedon the current outbreak of the Coronavirus SARS-CoV-2, the pathogen responsible for COVID-19, which has already had an impacton financial markets, there could be additional repercussions to our operating business, including but not limited to, the sourcingof materials for our product candidates, manufacture of supplies for our preclinical and/or clinical studies, delays in clinicaloperations, which may include the availability or the continued availability of patients for our trials due to such things asquarantines, our conduct of patient monitoring and clinical trial data retrieval at investigational study sites.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Thefuture impact of the outbreak is highly uncertain and cannot be predicted, and we cannot provide any assurance that the outbreakwill not have a material adverse impact on our operations or future results or filings with regulatory health authorities. Theextent of the impact to us, if any, will depend on future developments, including actions taken to contain the coronavirus.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          RisksRelated to our Intellectual Property         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           Wemay be unable to commercialize our products if we are unable to protect our proprietary rights, and we may be liable for significantcosts and damages if we face a claim of intellectual property infringement by a third party.          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Ournear and long-term prospects depend in part on our ability to obtain and maintain patents, protect trade secrets and operate withoutinfringing upon the proprietary rights of others. In the absence of patent and trade secret protection, competitors may adverselyaffect our business by independently developing and marketing substantially equivalent or superior products and technology, possiblyat lower prices. We could also incur substantial costs in litigation and suffer diversion of attention of technical and managementpersonnel if we are required to defend ourselves in intellectual property infringement suits brought by third parties, with orwithout merit, or if we are required to initiate litigation against others to protect or assert our intellectual property rights.Moreover, any such litigation may not be resolved in our favor.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Althoughwe and our licensors have filed various patent applications covering the uses of our product candidates, patents may not be issuedfrom the patent applications already filed or from applications that we might file in the future. Moreover, the patent positionof companies in the pharmaceutical industry generally involves complex legal and factual questions, and has been the subject ofmuch litigation. Any patents we own or license, now or in the future, may be challenged, invalidated or circumvented. To date,no consistent policy has been developed in the U.S. Patent and Trademark Office (the “PTO”) regarding the breadthof claims allowed in biotechnology patents.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Inaddition, because patent applications in the U.S. are maintained in secrecy until patent applications publish or patents issue,and because publication of discoveries in the scientific or patent literature often lags behind actual discoveries, we cannotbe certain that we and our licensors are the first creators of inventions covered by any licensed patent applications or patentsor that we or they are the first to file. The PTO may commence interference proceedings involving patents or patent applications,in which the question of first inventorship is contested. Accordingly, the patents owned or licensed to us may not be valid ormay not afford us protection against competitors with similar technology, and the patent applications licensed to us may not resultin the issuance of patents.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Itis also possible that our owned and licensed technologies may infringe on patents or other rights owned by others, and licensesto which may not be available to us. We may be unable to obtain a license under such patent on terms favorable to us, if at all.We may have to alter our products or processes, pay licensing fees or cease activities altogether because of patent rights ofthird parties.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Inaddition to the products for which we have patents or have filed patent applications, we rely upon unpatented proprietary technologyand may not be able to meaningfully protect our rights with regard to that unpatented proprietary technology. Furthermore, tothe extent that consultants, key employees or other third parties apply technological information developed by them or by othersto any of our proposed projects, disputes may arise as to the proprietary rights to this information, which may not be resolvedin our favor.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 46; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         43         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           Wemay be involved in lawsuits to protect or enforce our patents, which could be expensive and time consuming.          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Thepharmaceutical industry has been characterized by extensive litigation regarding patents and other intellectual property rights,and companies have employed intellectual property litigation to gain a competitive advantage. We may become subject to infringementclaims or litigation arising out of patents and pending applications of our competitors, or additional interference proceedingsdeclared by the PTO to determine the priority of inventions. The defense and prosecution of intellectual property suits, PTO proceedings,and related legal and administrative proceedings are costly and time-consuming to pursue, and their outcome is uncertain. Litigationmay be necessary to enforce our issued patents, to protect our trade secrets and know-how, or to determine the enforceability,scope, and validity of the proprietary rights of others. An adverse determination in litigation or interference proceedings towhich we may become a party could subject us to significant liabilities, require us to obtain licenses from third parties, orrestrict or prevent us from selling our products in certain markets. Although patent and intellectual property disputes mightbe settled through licensing or similar arrangements, the costs associated with such arrangements may be substantial and couldinclude our paying large fixed payments and ongoing royalties. Furthermore, the necessary licenses may not be available on satisfactoryterms or at all.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Competitorsmay infringe our patents, and we may file infringement claims to counter infringement or unauthorized use. This can be expensive,particularly for a company of our size, and time-consuming. In addition, in an infringement proceeding, a court may decide thata patent of ours is not valid or is unenforceable or may refuse to stop the other party from using the technology at issue onthe grounds that our patents do not cover its technology. An adverse determination of any litigation or defense proceedings couldput one or more of our patents at risk of being invalidated or interpreted narrowly.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Also,a third party may assert that our patents are invalid and/or unenforceable. There are no unresolved communications, allegations,complaints or threats of litigation related to the possibility that our patents are invalid or unenforceable. Any litigation orclaims against us, whether or not merited, may result in substantial costs, place a significant strain on our financial resources,divert the attention of management and harm our reputation. An adverse decision in litigation could result in inadequate protectionfor our product candidates and/or reduce the value of any license agreements we have with third parties.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Interferenceproceedings brought before the PTO may be necessary to determine priority of invention with respect to our patents or patent applications.During an interference proceeding, it may be determined that we do not have priority of invention for one or more aspects in ourpatents or patent applications and could result in the invalidation in part or whole of a patent or could put a patent applicationat risk of not issuing. Even if successful, an interference proceeding may result in substantial costs and distraction to ourmanagement.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Furthermore,because of the substantial amount of discovery required in connection with intellectual property litigation or interference proceedings,there is a risk that some of our confidential information could be compromised by disclosure. In addition, there could be publicannouncements of the results of hearings, motions or other interim proceedings or developments. If investors perceive these resultsto be negative, the price of our common stock could be adversely affected.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           Ifwe infringe the rights of third parties we could be prevented from selling products, forced to pay damages, and defend againstlitigation.          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Ifour products, methods, processes and other technologies infringe the proprietary rights of other parties, we could incur substantialcosts and we may have to: obtain licenses, which may not be available on commercially reasonable terms, if at all; abandon aninfringing product candidate; redesign our products or processes to avoid infringement; stop using the subject matter claimedin the patents held by others; pay damages; and/or defend litigation or administrative proceedings which may be costly whetherwe win or lose, and which could result in a substantial diversion of our financial and management resources.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">       </p>       <!-- Field: Page; Sequence: 47; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         44         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <u>           RisksRelated to our Securities          </u>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           Theprice of our common stock and warrants may be highly volatile.          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Themarket price of our securities, like that of many other research and development public pharmaceutical and biotechnology companies,has been highly volatile and the price of our common stock and warrants may be volatile in the future due to a wide variety offactors, including:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            announcements by    us or others of results of pre-clinical testing and clinical trials;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            announcements of    technological innovations, more important bio-threats or new commercial therapeutic products by us, our collaborative partners    or our present or potential competitors;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            failure of our common    stock or warrants to continue to be listed or quoted on a national exchange or market system, such as The Nasdaq Stock Market    (“NASDAQ”) or NYSE Amex LLC;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our quarterly operating    results and performance;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            developments or    disputes concerning patents or other proprietary rights;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            acquisitions;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            litigation and government    proceedings;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            adverse legislation;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            changes in government    regulations;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            our available working    capital;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            economic and other    external factors;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            general market conditions.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Since January 1, 2021, the closing stock price of our commonstock has fluctuated between a high of $2.48 per share to a low of $1.26 per share. Since January 1, 2021, the closing price ofour common stock warrants has fluctuated between a high of $0.65 per warrant to a low of $0.16 per warrant. On March 23, 2021,the last reported sales prices of our common stock and our common stock warrant on The Nasdaq Capital Market were $1.59 per shareand $0.40 per warrant. The fluctuation in the price of our common stock and warrants has sometimes been unrelated or disproportionateto our operating performance. In addition, potential dilutive effects of future sales of shares of common stock and warrants byus, as well as potential sale of common stock by the holders of warrants and options, could have an adverse effect on the marketprice of our shares.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           Ifwe fail to remain current with our listing requirements, we could be removed from The Nasdaq Capital Market, which would limitthe ability of broker-dealers to sell our securities and the ability of shareholders to sell their securities in the secondarymarket.          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Companiestrading on The Nasdaq Stock Market, such as our Company, must be reporting issuers under Section 12 of the Exchange Act, as amended,and must meet the listing requirements in order to maintain the listing of common stock on The Nasdaq Capital Market. If we donot meet these requirements, the market liquidity for our securities could be severely adversely affected by limiting the abilityof broker-dealers to sell our securities and the ability of shareholders to sell their securities in the secondary market.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">       </p>       <!-- Field: Page; Sequence: 48; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         45         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           Thewarrants may not have any value.          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Theoutstanding warrants do not confer any rights of common stock ownership on their holders, such as voting rights or the right toreceive dividends, but rather merely represent the right to acquire shares of common stock at a fixed price for a limited periodof time. Specifically, the holders of the outstanding warrants may exercise their right to acquire the common stock and pay theper share exercise price, prior to the expiration date, after which date any unexercised warrants will expire and have no furthervalue. In the event our common stock does not exceed the exercise price of the warrants during the period when the warrants areexercisable, the warrants may not have any value.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           Shareholdersmay suffer substantial dilution related to issued stock warrants, options and convertible notes.          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Asof December 31, 2020, we had a number of agreements or obligations that may result in dilution to investors. These include:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            warrants to purchase    a total of approximately 5,731,477 shares of our common stock at a current weighted average exercise price of approximately    $2.96;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            options    to purchase approximately 1,933,804 shares of our common stock at a current weighted average exercise price of approximately    $2.96;           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the FBR Sales Agreement pursuant to which we may, but have noobligation to, sell up to an additional $2.1 million worth of our common stock as of March 30, 2021; and           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>         </tr>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            convertible    promissory notes issued to Pontifax Medison Finance, which may be converted into up to 4,878,048 shares of common stock at    a price of $4.10 per share assuming we were to borrow the full $20 million under the loan and security agreement.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Wealso have an incentive compensation plan for our management, employees and consultants. We have granted, and expect to grant inthe future, options to purchase shares of our common stock to our directors, employees and consultants. To the extent that warrantsor options are exercised, our stockholders will experience dilution and our stock price may decrease.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           Ourshares of common stock and warrants are thinly traded, so stockholders may be unable to sell at or near ask prices or at all ifthey need to sell shares or warrants to raise money or otherwise desire to liquidate their shares.          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Ourcommon stock and warrants have from time to time been “thinly-traded,” meaning that the number of persons interestedin purchasing our common stock or warrants at or near ask prices at any given time may be relatively small or non-existent. Thissituation is attributable to a number of factors, including the fact that we are a small company that is relatively unknown tostock analysts, stock brokers, institutional investors and others in the investment community that generate or influence salesvolume, and that even if we came to the attention of such persons, they tend to be risk-averse and would be reluctant to followan unproven company such as ours or purchase or recommend the purchase of our shares until such time as we become more seasonedand viable. As a consequence, there may be periods of several days or more when trading activity in our shares is minimal or non-existent,as compared to a seasoned issuer which has a large and steady volume of trading activity that will generally support continuoussales without an adverse effect on share price. We cannot give stockholders any assurance that a broader or more active publictrading market for our common shares and warrants will develop or be sustained, or that current trading levels will be sustained.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           Wedo not currently intend to pay dividends on our common stock in the foreseeable future, and consequently, our stockholders’ability to achieve a return on their investment will depend on appreciation in the price of our common stock.          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Wehave never declared or paid cash dividends on our common stock and do not anticipate paying any cash dividends to holders of ourcommon stock in the foreseeable future. Consequently, our stockholders must rely on sales of their common stock and warrants afterprice appreciation, which may never occur, as the only way to realize any future gains on their investments. There is no guaranteethat shares of our common stock or warrants will appreciate in value or even maintain the price at which our stockholders havepurchased their shares.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">       </p>       <!-- Field: Page; Sequence: 49; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         46         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           Uponour dissolution, our stockholders may not recoup all or any portion of their investment.          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Inthe event of our liquidation, dissolution or winding-up, whether voluntary or involuntary, the proceeds and/or our assets remainingafter giving effect to such transaction, and the payment of all of our debts and liabilities will be distributed to the holdersof common stock on a pro rata basis. There can be no assurance that we will have available assets to pay to the holders of commonstock, or any amounts, upon such a liquidation, dissolution or winding-up. In this event, our stockholders could lose some orall of their investment.         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           Theissuance of our common stock pursuant to the terms of the asset purchase agreement with Hy Biopharma Inc. may cause dilution andthe issuance of such shares of common stock, or the perception that such issuances may occur, could cause the price of our commonstock to fall.          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On April 1, 2014, we entered into an option agreement pursuantto which Hy Biopharma granted us an option to purchase certain assets, properties and rights (the “Hypericin Assets”)related to the development of Hy Biopharma’s synthetic hypericin product candidate for the treatment of CTCL, which we referto as SGX301, from Hy Biopharma. In exchange for the option, we paid $50,000 in cash and issued 4,307 shares of common stock inthe aggregate to Hy Biopharma and its assignees. We subsequently exercised the option, and on September 3, 2014, we entered intoan asset purchase agreement with Hy Biopharma, pursuant to which we purchased the Hypericin Assets. Pursuant to the purchase agreement,we initially paid $275,000 in cash and issued 184,912 shares of common stock in the aggregate to Hy Biopharma and its assignees,and the licensors of the license agreement acquired from Hy Biopharma. Also on September 3, 2014, we entered into a RegistrationRights Agreement with Hy Biopharma, pursuant to which we may be required to file a registration statement with the SEC. In March2020, we issued 1,956,182 shares of common stock at a value of $5,000,000 (based upon an effective per share price of $2.56) asa result of SGX301 demonstrating statistically significant treatment response in the Phase 3 clinical trial. We will be requiredto issue up to $5.0 million worth of our common stock (subject to a cap equal to 19.99% of our issued and outstanding common stock)in the aggregate, if SGX301 is approved for the treatment of CTCL by either the FDA or the EMA.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Thenumber of shares that we may issue under the purchase agreement will fluctuate based on the market price of our common stock.Depending on market liquidity at the time, the issuance of such shares may cause the trading price of our common stock to fall.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Wemay ultimately issue all, some or none of the additional shares of our common stock that may be issued pursuant to the purchaseagreement. We are required to register any shares issued pursuant to the purchase agreement for resale under the Securities Actof 1933, as amended (the “Securities Act”). After any such shares are registered, the holders will be able to sellall, some or none of those shares. Therefore, issuances by us under the purchase agreement could result in substantial dilutionto the interests of other holders of our common stock. Additionally, the issuance of a substantial number of shares of our commonstock pursuant to the purchase agreement, or the anticipation of such issuances, could make it more difficult for us to sell equityor equity-related securities in the future at a time and at a price that we might otherwise wish to effect sales.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           Repaymentof certain convertible notes, if they are not otherwise converted, will require a significant amount of cash, and we may not havesufficient cash flow from our business to make payments on our indebtedness.          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Ourability to pay the principal of and/or interest on the convertible notes issued pursuant to the Loan and Security Agreement withPontifax Medison Finance (the “Convertible Notes”) depends on our future performance, which is subject to economic,financial, competitive and other factors beyond our control. Our business may not generate cash flow from operations in the futuresufficient to service the Convertible Notes or other future indebtedness and make necessary capital expenditures. If we are unableto generate such cash flow, we may be required to adopt and implement one or more alternatives, such as selling assets, restructuringindebtedness or obtaining additional debt financing or equity financing on terms that may be onerous or highly dilutive. Our abilityto refinance the Convertible Notes or other future indebtedness will depend on the capital markets and our financial conditionat such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, whichcould result in a default on our debt obligations, including the Convertible Notes.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>          The issuance of shares of commonstock upon conversion of the Convertible Notes could substantially dilute shareholders’ investments and could impede ourability to obtain additional financing.         </i>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         <i>         </i>        </b>        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         TheConvertible Notes are convertible into shares of our common stock and give the holders an opportunity to profit from a rise inthe market price of our common stock such that conversion or exercise thereof could result in dilution of the equity interestsof our shareholders. We have no control over whether the holders will exercise their right to convert their Convertible Notes.While the Convertible Notes are convertible at a minimum price of $4.10 per share which is higher than our current market price,we cannot predict the market price of our common stock at any future date, and therefore, cannot predict whether the ConvertibleNotes will be converted. The existence and potentially dilutive impact of the Convertible Notes may prevent us from obtainingadditional financing in the future on acceptable terms, or at all.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 50; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         47         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <a name="a_002">          </a>          Item1B. Unresolved Staff Comments         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         None.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <a name="a_003">          </a>          Item2. Properties         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We currently lease approximately 6,200 square feet of officespace at 29 Emmons Drive, Suite B-10 in Princeton, New Jersey pursuant to a lease that expires in to October 2022. This officespace currently serves as our corporate headquarters, and both of our business segments (Specialized BioTherapeutics and PublicHealth Solutions), operate from this space. Our office space is sufficient to satisfy our current needs. We may add new space orexpand existing space as we add employees, and we believe that suitable additional or substitute space will be available as neededto accommodate any such expansion of our operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <a name="a_004">          </a>          Item3. Legal Proceedings         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Fromtime to time, we are a party to claims and legal proceedings arising in the ordinary course of business. Our management evaluatesour exposure to these claims and proceedings individually and in the aggregate and allocates additional monies for potential losseson such litigation if it is possible to estimate the amount of loss and if the amount of the loss is probable.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         OnJuly 1, 2020, we filed a demand for arbitration against Emergent BioSolutions, Inc. (or EBS); Emergent Product Development Gaithersburg,Inc. (or EPDG); and Emergent Manufacturing Operations Baltimore LLC (or EMOB and, together with EBS and EPDG, Emergent) with theAmerican Arbitration Association in Mercer County, New Jersey in which we have alleged that (a) EPDG breached the EPDG Subcontract(defined in the following paragraph), the EPDG Quality Agreement (defined in the following paragraph), an express warranty, awarranty of merchantability, and a warranty of fitness for a particular purpose, (b) EMOB breached the EMOB Quality Agreement(defined in the following paragraph); (c) EPDG was unjustly enriched; (d) EPDG and EMOB were negligent in the performance of theirwork; and (e) EBS fraudulently induced us into entering into the contracts with EPDG and EMOB. Emergent has answered that demandfor arbitration denying the allegations and asserting affirmative defenses.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Afterseveral months of negotiations and based on representations Emergent made related to its capabilities in developing upstream anddownstream processes for vaccines and its designation as a Center for Innovation in Advanced Development and Manufacturing, inMay 2015, we entered into a subcontract (the “EPDG Subcontract”) with EPDG, pursuant to which EPDG agreed to manufacture,and provide to the us, RiVax         <sup>          ®         </sup>         bulk drug substance (“BDS”). In March 2017, we entered into a qualityagreement (the “EPDG Quality Agreement”) with EPDG for the purpose of defining and allocating the quality-relatedresponsibilities between EPDG and us with respect to the production of the RiVax         <sup>          ®         </sup>         BDS under the EPDG Subcontract.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Afternearly three years of EPDG failing to meet the scope of work set forth in the EPDG Subcontract, Emergent recommended that bothdevelopment and manufacturing work under the EPDG Subcontract be transferred to EMOB. On July 9, 2018, we entered into a qualityagreement (the “EMOB Quality Agreement”) with EMOB, which agreement allocated various defined responsibilities betweenEMOB and us with respect to the manufacture, supply, and testing of the RiVax         <sup>          ®         </sup>         BDS. Under the EMOB Quality Agreement,EMOB assumed sole responsibility for, inter alia, (i) employee training; (ii) providing adequate and qualified personnel; (iii)notifying us of out-of-specification results within two (2) business days of identification of the out of-specification results;(iv) performing testing using agreed-to testing procedures, test methods, specifications, and required compendia requirements;(v) ensuring that EMOB-generated data was accurate, controlled and safe from manipulation or loss; (vi) ensuring that the procedures,the state of automation and/or management controls were in place to assure data integrity; (vii) apprising us of any significantchanges to analytical methodology for intermediaries, in-process or final product; and (viii) assuring that samples were storedin appropriate, continuously monitored conditions.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         OnJanuary 8, 2020, EMOB informed us (a) of the existence of a questionable test result that could result in a determination thatthe RiVax         <sup>          ®         </sup>         BDS manufactured, tested and released by EMOB was out-of-specification and should never have been releasedby Emergent (b) that the validity of “initial release” test results for such BDS was faulty because Emergent usedan improper test method. We immediately suspended the Phase 1c trial to evaluate RiVax         <sup>          ®         </sup>         in healthy adults, endingboth further enrollment and further dosing. Emergent conducted an internal review of this deviation and found multiple internalfailures including an “Inadequate analytical method transfer process,” an “Inability to comply with standardoperating procedures around method transfer and data review,” and an “Inability to comply with test method procedures,”We quickly initiated a “for-cause” audit of the Emergent facility and confirmed the failures Emergent identified andadmitted to in its own internal investigation.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Weare seeking to recover damages in excess of $19 million from Emergent. While we intend to vigorously pursue this arbitration,we cannot offer any assurances that we will recover any damages from Emergent.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 51; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         48         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <a name="pa_002">          </a>          PARTII         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <a name="a_005">          </a>          Item5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Ourcommon stock is traded on The Nasdaq Capital Market under the symbol “SNGX.” The following table sets forth the highand low sales prices per share of our common stock for the periods indicated, as reported by The Nasdaq Capital Market.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">        <tbody>         <tr style="vertical-align: bottom">          <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            Price    Range           </font>          </td>          <td style="font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="border-bottom: Black 1.5pt solid; padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            Period           </font>          </td>          <td style="font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            High           </font>          </td>          <td style="font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            Low           </font>          </td>          <td style="font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; font-style: italic">           <font style="font-family: Times New Roman, Times, Serif">            Year    Ended December 31, 2019:           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td colspan="2" style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td colspan="2" style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-indent: -0.125in; padding-left: 0.25in; width: 76%; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">            First    Quarter           </font>          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="width: 9%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            1.32           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="width: 9%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            0.85           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">            Second    Quarter           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            0.96           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            0.65           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">            Third    Quarter           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            1.39           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            0.71           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">            Fourth    Quarter           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            1.49           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            0.85           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; font-style: italic; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">            Year    Ended December 31, 2020:           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">            First    Quarter           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            3.54           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            1.33           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">            Second    Quarter           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            2.47           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            1.32           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">            Third    Quarter           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            2.99           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            1.65           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">            Fourth    Quarter           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            2.80           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            1.21           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On March 23, 2021, the last reported price of our common stockquoted on The Nasdaq Capital Market was $1.59 per share. The Nasdaq Capital Market prices set forth above represent inter-dealerquotations, without adjustment for retail mark-up, mark-down or commission, and may not represent the prices of actual transactions.Our stock is listed on The Nasdaq Capital Market under the under the symbol “SNGX.” On December 13, 2016, certain ofour common stock warrants began trading on The Nasdaq Capital Market under the symbol “SNGXW”. For the period fromJanuary 1, 2019 through December 31, 2020, the high and low sales price per warrant as reported by Nasdaq were $1.12 and $0.16respectively. On March 23, 2021, the last reported price of our common stock warrants on Nasdaq was $0.40 per warrant.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          TransferAgent         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Thetransfer agent and registrar for our common stock and warrants is American Stock Transfer &amp; Trust Company, LLC. The addressis 6201 15         <sup>          th         </sup>         Avenue, Brooklyn, NY 11219 and the telephone number is (718) 921-8200.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          Holdersof Common Stock         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        As of March 23, 2021, there were 97 holdersof record of our common stock. As of such date, 40,020,461 shares of our common stock were issued and outstanding.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 52; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         49         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          Dividends         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Wehave never declared nor paid any cash dividends, and currently intend to retain all our cash and any earnings for use in our businessand, therefore, do not anticipate paying any cash dividends in the foreseeable future. Any future determination to pay cash dividendswill be at the discretion of the Board of Directors and will be dependent upon our consolidated financial condition, results ofoperations, capital requirements and such other factors as the Board of Directors deems relevant.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <a name="a_006">          </a>          Item6. Selected Financial Data         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Notapplicable.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <a name="a_007">          </a>          Item7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <u>           OurBusiness Overview          </u>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Weare a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where thereis an unmet medical need. We maintain two active business segments: Specialized BioTherapeutics and Public Health Solutions.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         OurSpecialized BioTherapeutics business segment is developing and moving toward potential commercialization of SGX301 as a novelphotodynamic therapy utilizing safe visible light for the treatment of CTCL. With a successful Phase 3 study completed, regulatoryapproval is being sought and commercialization activities for this product candidate are being advanced initially in the U.S.Development programs in this business segment also include our first-in-class IDR technology, dusquetide (SGX942) for the treatmentof inflammatory diseases, including oral mucositis in head and neck cancer, and proprietary formulations of oral BDP for the prevention/treatmentof GI disorders characterized by severe inflammation including pediatric Crohn's disease (SGX203) and acute radiation enteritis(SGX201).        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Our Public Health Solutions business segment includes activedevelopment programs for RiVax        <sup>         ®        </sup>        , our ricin toxin vaccine candidate and SGX943, our therapeutic candidate for antibioticresistant and emerging infectious disease and our vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax        <sup>         TM        </sup>        ,our vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of our vaccine programs incorporatesthe use of our proprietary heat stabilization platform technology, known as ThermoVax        <sup>         ®        </sup>        . To date, this business segmenthas been supported with government grant and contract funding from NIAID, BARDA and DTRA.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Anoutline of our business strategy follows:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">            <font style="font-family: Times New Roman, Times, Serif">             Following        positive primary endpoint results for the Phase 3 clinical trial of SGX301, as well as further statistically significant        improvement in response rates with longer treatment (18 weeks compared to 12 and 6 weeks of treatment), pursue New Drug        Application (“NDA”) filing and commercialization in the U.S. while continuing to explore ex-U.S.        partnership.            </font>           </p>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px">           <font style="font: 10pt Times New Roman, Times, Serif">            ●           </font>          </td>          <td style="text-align: justify">           Continue to analyze the full dataset from the Phase 3 clinicaltrial of SGX942 to better understand why the study did not achieve the statistically significant benefit expected, despite demonstratingclinically meaningful reductions in oral mucositis consistent with the previous Phase 2 study. Any clarity gained from furtheranalysis, especially with respect to specific subsets of patients that may benefit from SGX942 therapy, will be communicated toand discussed with the United States Food and Drug Administration and the EMA.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 53; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         50         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Continue development    of RiVax            <sup>             ®            </sup>            (ricin toxin vaccine) and CiVax            <sup>             TM            </sup>            (COVID-19 vaccine) in combination with our ThermoVax            <sup>             ®            </sup>            technology to develop a new heat stable vaccine in biodefense with NIAID funding support.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Continue development    of our therapeutic SGX943 and our vaccine programs targeting filoviruses (such as Marburg and Ebola) with DTRA and NIAID funding    support.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Continue to apply    for and secure additional government funding for each of our Specialized BioTherapeutics and Public Health Solutions programs    through grants, contracts and/or procurements.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Pursue businessdevelopment opportunities for our pipeline programs, as well as explore merger/acquisition strategies.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Acquire or in-license    new clinical-stage compounds for development.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <u>           CorporateInformation          </u>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Wewere incorporated in Delaware in 1987 under the name Biological Therapeutics, Inc. In 1987, we merged with Biological Therapeutics,Inc., a North Dakota corporation, pursuant to which we changed our name to “Immunotherapeutics, Inc.” We changed ourname to “Endorex Corp.” in 1996, to “Endorex Corporation” in 1998, to “DOR BioPharma, Inc.”in 2001, and finally to “Soligenix, Inc.” in 2009. Our principal executive offices are located at 29 Emmons Drive,Suite B-10, Princeton, New Jersey 08540 and our telephone number is (609) 538-8200.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <u>           OurProduct Candidates in Development          </u>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Thefollowing tables summarize our product candidates under development:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <u>           SpecializedBioTherapeutics Product Candidates*          </u>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: bottom">          <td style="border-bottom: black 1.5pt solid; width: 25%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Soligenix    Product Candidate            </b>           </font>          </td>          <td style="width: 1%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: black 1.5pt solid; width: 25%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Therapeutic    Indication            </b>           </font>          </td>          <td style="width: 1%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: black 1.5pt solid; width: 48%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Stage    of Development            </b>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            SGX301           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Cutaneous T-Cell    Lymphoma           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">            <font style="font-family: Times New Roman, Times, Serif">             Phase        2 trial completed; demonstrated significantly higher response rate compared to placebo; Phase 3 demonstrated statistical        significance in primary endpoint in March 2020 (Cycle 1); and demonstrated continued improvement in treatment response        with extended treatment in April 2020 (Cycle 2) and October (Cycle 3)            </font>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <font style="font-family: Times New Roman, Times, Serif">             <b>             </b>            </font>           </p>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            SGX942           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Oral Mucositis in    Head and Neck Cancer           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">            <font style="font-family: Times New Roman, Times, Serif">             Phase        2 trial completed; demonstrated significant response compared to placebo with positive long-term (12 month) safety also        reported; Phase 3 clinical trial results announced December 2020: The primary endpoint of median duration of severe oral        mucositis (“SOM”) did not achieve the pre-specified criterion for statistical significance (p≤0.05), although        biological activity was observed with a 56% reduction in the median duration of SOM from 18 days in the placebo group        to 8 days in the SGX942 treatment group            </font>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">            <font style="font-family: Times New Roman, Times, Serif">            </font>           </p>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            SGX203            <b>             †            </b>           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Pediatric Crohn’s    disease           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">            <font style="font-family: Times New Roman, Times, Serif">             Phase        1/2 clinical trial completed; efficacy data, pharmacokinetic (PK)/pharmacodynamic (PD) profile and safety profile demonstrated;        Phase 3 clinical trial initiation contingent upon additional funding, such as through partnership            </font>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <font style="font-family: Times New Roman, Times, Serif">            </font>           </p>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            SGX201            <b>             †            </b>           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Acute Radiation Enteritis           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Phase 1/2 clinical    trial completed; safety profile and preliminary efficacy demonstrated; further clinical development contingent upon additional    funding, such as through partnership           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 54; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         51         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <u>           PublicHealth Solutions*†          </u>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr>          <td style="border-bottom: black 1.5pt solid; width: 25%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Soligenix    Product Candidate            </b>           </font>          </td>          <td style="width: 1%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: black 1.5pt solid; width: 25%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Indication            </b>           </font>          </td>          <td style="width: 1%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: black 1.5pt solid; width: 48%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Stage    of Development            </b>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ThermoVax            <sup>             ®            </sup>           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Thermostability of    vaccines for Ricin toxin, Ebola, Marburg and SARS-CoV-2 (COVID-19) viruses           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Pre-clinical           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            RiVax            <sup>             ®            </sup>           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <font style="font-family: Times New Roman, Times, Serif">             Vaccine        against            </font>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <font style="font-family: Times New Roman, Times, Serif">             Ricin        Toxin Poisoning            </font>           </p>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Phase 1a and 1b    trials completed, safety and neutralizing antibodies for protection demonstrated; Phase 1c trial initiated December 2019,    closed January 2020           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            SGX943           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Therapeutic against    Emerging Infectious Diseases           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Pre-clinical           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            CiVax™           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Vaccine against COVID-19           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="padding-left: -0.5in; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Pre-clinical           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -1.5in; text-align: left; text-indent: 1.5in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -1.5in; text-align: left; text-indent: 1.5in">       </p>       <!-- Field: Rule-Page -->       <div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%">        <div style="border-top: Black 1.5pt solid; font-size: 1pt">         <font style="font-family: Times New Roman, Times, Serif">         </font>        </div>       </div>       <!-- Field: /Rule-Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -1.5in; text-align: left; text-indent: 1.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            *           </font>          </td>          <td>           <p style="margin-top: 0; margin-bottom: 0">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             <i>              Timelines        subject to potential disruption due to COVID-19 outbreak.             </i>            </font>           </p>           <p style="margin-top: 0; margin-bottom: 0">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             <i>             </i>            </font>           </p>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             †            </b>           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <i>             Contingent upon continued government contract/grant    funding or other funding source.            </i>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          CriticalAccounting Policies         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Our management’s discussion and analysisof financial condition and results of operations is based on our consolidated financial statements, which have been prepared inaccordance with generally accepted accounting principles in the United States. The preparation of our financial statements andrelated disclosures requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, costsand expenses and the disclosure of contingent assets and liabilities in our financial statements. We base our estimates on historicalexperience, known trends and events and various other factors that we believe are reasonable under the circumstances, the resultsof which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparentfrom other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimatesunder different assumptions or conditions.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        While our significant accounting policies are described in moredetail in the notes to our financial statements appearing at the end of this Annual Report on Form 10-K, we believe that the followingaccounting policies are those most critical to the judgments and estimates used in the preparation of our financial statements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <u>          RevenueRecognition         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Ourrevenues are primarily generated from government contracts and grants. The revenue from government contracts and grants is basedupon subcontractor costs and internal costs incurred that are specifically covered by the contracts and grants, plus a facilitiesand administrative rate that provides funding for overhead expenses and management fees. These revenues are recognized when expenseshave been incurred by subcontractors or when we incur reimbursable internal expenses that are related to the government contractsand grants.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <u>          Researchand Development Costs         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        As part of the process of preparing ourfinancial statements, we are required to estimate our accrued research and development expenses. This process involves reviewingopen contract and purchase orders, communicating with our personnel to identify services that have been performed on our behalfand estimating the level of service performed and the associated costs incurred for the services when we have not yet been invoicedor otherwise notified of the actual costs. The majority of our service providers invoice us in arrears for services performed,on a pre-determined schedule or when contractual milestones are met; however, some require advanced payments. We make estimatesof our accrued expenses as of each balance sheet date in our financial statements based on facts and circumstances known to usat that time. Examples of estimated accrued research and development expenses include fees paid to:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           ●          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">            contract research organizations (“CROs”)in connection with performing research activities on our behalf and conducting preclinical studies and clinical trials on our behalf;           </font>          </td>         </tr>        </tbody>       </table>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           ●          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">            investigative sites or other service providersin connection with clinical trials;           </font>          </td>         </tr>        </tbody>       </table>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           ●          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">            vendors in connection with preclinicaland clinical development activities; and           </font>          </td>         </tr>        </tbody>       </table>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           ●          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">            vendors related to product manufacturingand development and distribution of preclinical and clinical supplies.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 55; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         52         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We base our expenses related to preclinicalstudies and clinical trials on our estimates of the services received and efforts expended pursuant to quotes and contracts withmultiple CROs that conduct and manage preclinical studies and clinical trials on our behalf. The financial terms of these agreementsare subject to negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in whichpayments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. Payments undersome of these contracts depend on factors such as the successful enrollment of patients and the completion of clinical trial milestones.In accruing fees, we estimate the time period over which services will be performed, enrollment of patients, number of sites activatedand the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effortvaries from our estimate, we adjust the accrual or amount of prepaid expense accordingly. Although we do not expect our estimatesto be materially different from amounts actually incurred, our understanding of the status and timing of services performed relativeto the actual status and timing of services performed may vary and may result in us reporting amounts that are too high or toolow in any particular period. To date, we have not made any material adjustments to our prior estimates of accrued research anddevelopment expenses.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <u>          Useof Estimates and Assumptions         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Thepreparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires managementto make estimates and assumptions such as the fair value of warrants and stock options and recovery of the useful life of intangiblesthat affect the reported amounts in the financial statements and accompanying notes. Actual results could differ from those estimates.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <u>           MaterialChanges in Results of Operations          </u>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           YearEnded December 31, 2020 Compared to 2019          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        For the year ended December 31, 2020,we had a net loss of $17,688,522 as compared to a net loss of $9,355,592 for the prior year, representing an increased lossof $8,332,930 or 89%. The increase in net loss is primarily due to increased expenditures incurred to support both thepivotal Phase 3 trial of SGX301 in the treatment of CTCL and the pivotal Phase 3 trial of SGX942 in the treatment of oralmucositis in head and neck cancer. In addition, we had additional costs in 2020 relating to the issuance of $5,000,000 worthof fully vested shares of common stock to Hy Biopharma, Inc. (“Hy Biopharma”) in connection with the achievementof a development milestone. For the year ended December 31, 2020, we had revenues of $2,359,447 as compared to $4,629,916 forthe prior year, representing a decrease of $2,270,469 or 49%. The decrease in revenues was primarily a result of thecompletion of the two Phase 3 trials of SGX301 and SGX942.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Weincurred costs related to contract and grant revenues in the year ended December 31, 2020 and 2019 of $1,820,949 and $3,567,415,respectively, representing a decrease of $1,746,466 or 49%. The decrease in costs was primarily the result of grants ending in2020.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Our gross profit for the year ended December31, 2020 was $538,498 or 23% as compared to $1,062,501 or 33% of total revenue for the prior year, representing a decrease of $524,003or 49% in respects to the change in gross profit. The decrease in revenues and gross profit were primarily the result of the closing of the CTCL study.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Research and development expenses increasedby $2,023,168 or 25% to $10,145,778 for the year ended December 31, 2020 as compared to $8,122,610 for the prior year. The increasein research and development spending for the year ended December 31, 2020 was related to expenditures incurred in the Phase 3 ofthe clinical trials of SGX942 and SGX301.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        General and administrative expenses increasedby $498,315 or 14%, to $3,979,227 for the year ended December 31, 2020, as compared to $3,480,912 for the prior year. This increaseis primarily related to employee compensation increases.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Other income for the year ended December31, 2020 was $61,092 as compared to $574,753 for the prior year, reflecting a decrease of $513,661 or 89%. The decrease was primarilydue to a decrease in the UK research and development tax credit, a decrease in interest income earned on our cashbalances due to decreased interest rates on invested cash in 2020 and interest expense in 2020 on the new convertible debt agreement.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The State of New Jersey’s Technology Business Tax CertificateProgram allows certain high technology and biotechnology companies to sell unused net operating loss (“NOL”) carryforwardsto other New Jersey-based corporate taxpayers. We sold NOLs resulting in the recognition of income tax benefits of $836,893 and$610,676 for the years ending December 31, 2020 and 2019, respectively. We have applied for and received preliminary confirmationfor NOLs related to the tax year ended December 31, 2019 in the amount of approximately $865,000, which will not be recognizeduntil a certificate for the refund is received. We have not yet sold our tax year 2020 New Jersey NOLs but may do so in the future.We will continue to explore opportunities to sell unused NOL carryforwards for the tax year ended December 31, 2020. However, therecan be no assurance as to the continuation or magnitude of this program in future years.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 56; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         53         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           BusinessSegments          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Wemaintain two active business segments for the years ended December 31, 2020 and 2019: Public Health Solutions and SpecializedBioTherapeutics.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Revenuesfor the Public Health Solutions business segment for the year ended December 31, 2020 were $2,242,078 as compared to $3,402,014for the year ended December 31, 2019, representing a decrease of $1,159,936 or 34%. The decrease in revenues was primarily theresult of grants and contracts coming to an end during the year ended December 31, 2020.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Revenuesfor the Specialized BioTherapeutics business segment for the year ended December 31, 2020 were $117,369 as compared to $1,227,902for the year ended December 31, 2019, representing a decrease of $1,110,533 or 90%. The decrease was due to less reimbursabledevelopment activity under the oral mucositis juvenile toxicology grant to support the evaluation of SGX942 (dusquetide) in pediatricindications during the year ended December 31, 2020.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Loss from operations for the Public Health Solutions businesssegment for the year ended December 31, 2020 was $435,028 as compared to income of $153,969 for the year ended December 31, 2019,representing an increased loss of $588,997 or 383%. The loss for the year ended December 31, 2020 is attributable to the expirationof grants and contracts. Loss from operations for the Specialized BioTherapeutics business segment for the year ended December31, 2020 was $13,610,715 as compared to $6,738,284 for the year ended December 31, 2019, representing an increased loss of $6,872,431or 102%. This is primarily attributed to the additional expense incurred in patient enrollments in the Phase 3 clinical trial ofSGX301 and the $5,000,000 HyBiopharma milestone expense.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <u>           FinancialCondition and Liquidity          </u>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           Cashand Working Capital          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        As of December 31, 2020, we had cash and cashequivalents of $18,676,663 as compared to $5,420,708 as of December 31, 2019, representing an increase of $13,255,955 or 245%.As of December 31, 2020, we had working capital of $13,386,485, representing an increase of $12,205,236 as compared to workingcapital of $1,181,249 for the prior year. The increase in cash and cash equivalents was primarily related to our usage of the AtMarket Issuance Sales Agreement (“FBR Sales Agreement”) with B. Riley FBR, Inc. (“FBR”) and the loan proceedsfrom Pontifax Medison Finance.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Basedon our current rate of cash outflows, cash on hand, proceeds from government contract and grant programs, cash available fromthe loan from Pontifax Medison Finance, and proceeds available from the FBR Sales Agreement, management believes that itscurrent cash will be sufficient to meet the anticipated cash needs for working capital and capital expenditures for at least thenext twelve months from issuance of the financial statements.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Ourplans with respect to our liquidity management include, but are not limited to, the following:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            We have up to $2.16    million in active government contract funding still available as of December 31, 2020 to support our associated research programs    through 2021 and beyond, provided the federal agencies do not elect to terminate the contracts for convenience. We plan to    submit additional contract and grant applications for further support of our programs with various funding agencies;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            We have continued    to use equity instruments to provide a portion of the compensation due to vendors and collaboration partners and expect to    continue to do so for the foreseeable future;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            We will continue    to pursue Net Operating Loss (“NOL”) sales in the state of New Jersey pursuant to its Technology Business Tax    Certificate Transfer Program if the program is available;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 57; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         54         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px">           <font style="font: 10pt Times New Roman, Times, Serif">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font: 10pt Times New Roman, Times, Serif">            We plan to pursue potential partnerships for pipeline programs; however, there can be no assurances that we can consummate such transactions;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font: 10pt Times New Roman, Times, Serif">            ●           </font>          </td>          <td style="text-align: justify">           We have up to $10.0 million remaining available from the loan and security agreement with Pontifax Medison Finance as of March 30, 2021, which includes an immediately available $5 million line of credit and a $5 million late withdrawal loan that is contingent upon the initial filing of the NDA for CTCL;          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">          <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            We have up to $2.1    million remaining from the FBR Sales Agreement as of March 30, 2021 under the prospectus supplement updated August 28, 2020;    and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            We may seek additional    capital in the private and/or public equity markets, pursue government contracts and grants as well as business development    activities, to continue our operations, respond to competitive pressures, develop new products and services, and to support    new strategic partnerships. We are currently evaluating additional equity/debt financing opportunities on an ongoing    basis and may execute them when appropriate. However, there can be no assurances that we can consummate such a transaction,    or consummate a transaction at favorable pricing.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           Expenditures          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Underour budget and based upon our existing product development agreements and license agreements pursuant to letters of intent andoption agreements, we expect our total research and development expenditures for the year ending December 31, 2021 to be approximately$10.7 million before any contract or grant reimbursements, of which $9.8 million relates to the Specialized BioTherapeutics businessand $0.9 million relates to the Public Health Solutions business. We anticipate contract and grant reimbursements for thesame period of approximately $0.8 million to offset research and development expenses in the Specialized BioTherapeutics and PublicHealth Solutions business segments.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Thetable below details our costs for research and development by program and amounts reimbursed for the years ended December 31,2020 and 2019:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: center">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2020          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-weight: bold; font-style: italic; text-align: justify">           Research &amp; Development Expenses          </td>          <td>          </td>          <td colspan="2" style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td colspan="2" style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 76%; text-align: justify; padding-left: 9pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            RiVax            <sup>             ®            </sup>            &amp; ThermoVax            <sup>             ®            </sup>            Vaccines           </font>          </td>          <td style="width: 1%; font-weight: bold">          </td>          <td style="width: 1%; font-weight: bold; text-align: left">           $          </td>          <td style="width: 9%; font-weight: bold; text-align: right">           915,007          </td>          <td style="width: 1%; font-weight: bold; text-align: left">          </td>          <td style="width: 1%; font-weight: bold">          </td>          <td style="width: 1%; font-weight: bold; text-align: left">           $          </td>          <td style="width: 9%; font-weight: bold; text-align: right">           466,899          </td>          <td style="width: 1%; font-weight: bold; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-left: 9pt">           SGX942 (Dusquetide)          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           4,275,326          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           5,550,746          </td>          <td style="font-weight: bold; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify; padding-left: 9pt">           SGX301          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           4,393,838          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           1,620,707          </td>          <td style="font-weight: bold; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">           Other          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">           561,538          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">           484,258          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0.25in">           Total          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">           10,145,709          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">           8,122,610          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-weight: bold; font-style: italic; text-align: justify">           Reimbursed under Government Contracts and Grants          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-left: 9pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            RiVax            <sup>             ®            </sup>            &amp; ThermoVax            <sup>             ®            </sup>            Vaccines           </font>          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           1,663,297          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           2,746,877          </td>          <td style="font-weight: bold; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify; padding-left: 9pt">           SGX942          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           78,860          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           412,572          </td>          <td style="font-weight: bold; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-left: 9pt">           SGX943          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           78,792          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           13,058          </td>          <td style="font-weight: bold; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">           SGX301          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">           394,908          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0.25in">           Total          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">           1,820,949          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">           3,567,415          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify; padding-bottom: 4pt; padding-left: 27pt">           Grand Total          </td>          <td style="font-weight: bold; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">           11,933,439          </td>          <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">           11,690,025          </td>          <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <u>           ContractualObligations          </u>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Wehave licensing fee commitments of approximately $500,000 for the next five years for several licensing agreements with entities,consultants and universities. Additionally, we have collaboration and license agreements, which upon clinical or commercializationsuccess may require the payment of milestones of up to $7.9 million and/or royalties up to 6% of net sales of covered products,if and when achieved. However, there can be no assurance that clinical or commercialization success will occur.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        We currently lease approximately 6,200 square feet of officespace at 29 Emmons Drive, Suite B-10 in Princeton, New Jersey pursuant to a lease that expires in to October 2022. This officespace currently serves as our corporate headquarters, and both of our business segments (Specialized BioTherapeutics and PublicHealth Solutions), operate from this space. The rent for the remainder of the term will be $11,108, or approximately $21.50 persquare foot. Our office space is sufficient to satisfy our current needs.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 58; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         55         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         OnSeptember 3, 2014, we entered into an asset purchase agreement with Hy Biopharma pursuant to which we acquired certain intangibleassets, properties and rights of Hy Biopharma related to the development of Hy BioPharma’s synthetic hypericin product.As consideration for the assets acquired, we initially paid $275,000 in cash and issued 184,912 shares of common stock with afair value based upon our stock price on the date of grant of $3,750,000. These amounts were charged to research and developmentexpense during the third quarter of 2014 as the assets will be used in our research and development activities and do not havealternative future use pursuant to generally accepted accounting principles in the U.S.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         In January 2020, our Board of Directors authorized an amendmentto Dr. Schaber’s employment agreement to increase the number of shares of common stock from 5,000 to 500,000, issuable toDr. Schaber immediately prior to the completion of a transaction, or series or a combination of related transactions, negotiatedby our Board of Directors whereby, directly or indirectly, a majority of our capital stock or a majority of our assets are transferredfrom us and/or our stockholders to a third party.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         OnMarch 20, 2020, we filed a prospectus supplement covering the offer and sale of up to 1,956,182 shares of our common stock, whichwere issued to Hy Biopharma. We were required to issue the shares to Hy Biopharma as payment following the achievement of a milestoneunder the asset purchase agreement, specifically, the Phase 3 clinical trial of SGX301 being successful in the treatment of CTCL.The number of shares of our common stock issued to Hy Biopharma was calculated using an effective price of $2.56 per share, basedupon a formula set forth in the asset purchase agreement.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Providedthe final success-oriented milestone is attained, we will be required to make a payment of up to $5.0 million, if and when achieved.The potential future payment will be payable in our common stock, not to exceed 19.9% of our outstanding stock.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On December 16, 2020, we entered into a $20 million convertibledebt financing agreement with Pontifax Medison Finance (“Pontifax”), the healthcare-dedicated venture and debt fundof the Pontifax life science funds. Under the terms of the agreement with Pontifax, we have access to up to $20 million in convertibledebt financing in three tranches, which will mature on June 15, 2025 and have an interest only period for the first two years witha rate of 8.47% on borrowed amounts and a 1% rate on amounts available but not borrowed. Upon the closing of this transaction,we borrowed the first tranche of $10 million, and have the option to draw the second tranche of $5 million at any time over thenext 12 months and the third tranche of $5 million upon filing of the SGX301 new drug application, subject to certain conditions.Interest expense incurred and paid in 2020 totaled $34,406.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Pontifaxmay elect to convert the outstanding loan drawn under the first two tranches into shares of our common stock at any time priorto repayment at a conversion price of $4.10 per share. We also have the ability to force the conversion of the loan into sharesof our common stock, subject to certain conditions.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Asa result of the above agreements, we have future contractual obligations over the next five years as follows:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: left; border-bottom: Black 1.5pt solid">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">            <font style="font-family: Times New Roman, Times, Serif">             <b>             </b>            </font>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">            <font style="font-family: Times New Roman, Times, Serif">             <b>              Year             </b>            </font>           </p>          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Licensing Fee          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Property and           <br/>           Other Leases          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Principal           <br/>           and Interest          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <font style="font-family: Times New Roman, Times, Serif">             <b>             </b>            </font>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">            <font style="font-family: Times New Roman, Times, Serif">             <b>              Total             </b>            </font>           </p>          </td>          <td style="padding-bottom: 1.5pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 52%; text-align: left">           2021          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           100,000          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           139,708          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           897,000          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           1,136,708          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left">           2022          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           100,000          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           111,083          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           897,000          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           1,108,083          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left">           2023          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           100,000          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           4,769,138          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           4,869,138          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left">           2024          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           100,000          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           4,430,338          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           4,530,338          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-bottom: 1.5pt">           2025          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           100,000          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           2,110,566          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           2,210,566          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 4pt">           Total          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           500,000          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           250,791          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           13,104,042          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           13,854,833          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <u>          CARESAct Loan         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         OnApril 13, 2020, we were advised that one of our principal banks, JPMorgan Chase Bank, N.A., had approved a $417,830 loan (the“Loan”) under the Paycheck Protection Program (“PPP”) pursuant to the Coronavirus Aid, Relief and EconomicSecurity Act that was signed into law on March 27, 2020.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 59; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         56         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Asa U.S. small business, we qualified for the PPP, which allows businesses and nonprofits with fewer than 500 employees to obtainloans of up to $10 million to incentivize companies to maintain their workers as they manage the business disruptions caused bythe COVID-19 pandemic. The PPP provides for loans for amounts up to 2.5 times of the average monthly payroll expenses of the qualifyingbusiness. The PPP loan proceeds may be used for eligible purposes, including payroll, benefits, rent and utilities.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Loan, has a term of two years, is unsecured, and is guaranteedby the Small Business Administration. The short –term portion of the Loan is $324,979 and the long-term portion of the Loan is $92,851with accrued interest expense of $2,730 as of December 31, 2020. The Loan bears interest at a fixed rate of 0.98% per annum, withthe first ten months of interest and principal deferred. Some or all of the Loan may be forgiven if at least 60% of the Loan proceedsare used by us to cover payroll costs, including benefits and if we maintain our employment and compensation within certain parametersduring the eight-week or twenty-four-week period following the Loan origination date and comply with other relevant conditions.We used the proceeds for purposes consistent with the PPP and expect to meet the conditions when we apply for forgiveness of the Loan,although forgiveness is not guaranteed.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <u>          Contingencies         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Wefollow subtopic 450-20 of the FASB Accounting Standards Codification to report accounting for contingencies. Certain conditionsmay exist as of the date the financial statements are issued, which may result in a loss to but which will only be resolved whenone or more future events occur or fail to occur. We assess such contingent liabilities, and such assessment inherently involvesan exercise of judgment. A liability is only recorded if management determines that it is both probable and reasonably estimable.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         <u>          COVID-19         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Basedon the current outbreak of SARS-CoV-2, the pathogen responsible for COVID-19, which has already had an impact on financial markets,there could be additional repercussions to our operating business, including but not limited to, the sourcing of materials forproduct candidates, manufacture of supplies for preclinical and/or clinical studies, delays in clinical operations, which mayinclude the availability or the continued availability of patients for trials due to such things as quarantines, conduct of patientmonitoring and clinical trial data retrieval at investigational study sites.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Thefuture impact of the outbreak is highly uncertain and cannot be predicted, and we cannot provide any assurance that the outbreakwill not have a material adverse impact on our operations or future results or filings with regulatory health authorities. Theextent of the impact to us, if any, will depend on future developments, including actions taken to contain the coronavirus.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         <u>          EmergentBioSolutions Legal Proceedings         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         OnJuly 1, 2020, we filed a demand for arbitration against Emergent BioSolutions, Inc. and certain of its subsidiaries with the AmericanArbitration Association in Mercer County, New Jersey. We allege in the arbitration various breaches of contracts and warrantiesas well as acts of fraud. Emergent has answered that demand for arbitration denying the allegations and asserting affirmativedefenses. (see Part I, Item 3 – Legal Proceedings).        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Weare seeking to recover damages in excess of $19 million from Emergent. While we intend to vigorously pursue this arbitration,we cannot offer any assurances that it will recover any damages from Emergent.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Wehave received invoices from Emergent related to the above matter. No accrual has been made for these invoices as management deemsthem invalid and not probable of being required to pay them based on the numerous breaches sited in the pending arbitration. Theseinvoices total approximately $331,000.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <a name="a_008">          </a>          Item8. Financial Statements and Supplementary Data         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Theinformation required by this Item 8 is contained on pages F-1 through F-23 of this Annual Report on Form 10-K and is incorporatedherein by reference.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 60; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         57         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <a name="a_009">          </a>          Item9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         None.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <a name="a_010">          </a>          Item9A. Controls and Procedures         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <u>           Evaluationof Disclosure Controls and Procedures          </u>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Disclosurecontrols and procedures are our controls and other procedures that are designed to ensure that information required to be disclosedby us in the reports that we file or submit under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosurecontrols and procedures include, without limitation, controls and procedures designed to ensure that information required to bedisclosed by us in the reports that we file under the Exchange Act is accumulated and communicated to our management, includingour principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding requireddisclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can only providereasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the possiblecontrols and procedures.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Ourmanagement has evaluated, with the participation of our principal executive officer and principal financial officer, the effectivenessof our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) asof the end of the period covered by this report. Based upon that evaluation, our management, including our principal executiveofficer and principal financial officer, has concluded that, as of the end of the period covered by this report, our disclosurecontrols and procedures were effective at the reasonable assurance level.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         <b>          Management’sAnnual Report on Internal Control         </b>         over         <b>          Financial Reporting         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Companymanagement is responsible for establishing and maintaining adequate internal control over financial reporting. Internal controlover financial reporting is a process designed by, or under the supervision of, our principal executive and principal financialofficers and effected by our Board of Directors, management and other personnel to provide reasonable assurance regarding thereliability of financial reporting and the preparation of financial statements for external purposes in accordance with generallyaccepted accounting principles and includes those policies and procedures that:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            pertain to the maintenance    of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            provide reasonable    assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally    accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations    of management and directors; and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            provide reasonable    assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could    have a material effect on the financial statements.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Becauseof inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of anyevaluation of effectiveness to future periods are subject to the risks that controls may become inadequate because of changesin conditions, or that the degree of compliance with the policies or procedures may deteriorate.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Managementassessed the effectiveness of our internal control over financial reporting as of December 31, 2020. In making this assessment,management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”)in         <i>          Internal Control-Integrated Framework, 2013         </i>         .        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Basedon our assessment, management has concluded that, as of December 31, 2020, our internal control over financial reporting is effective.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          Changesin Internal Control over Financial Reporting         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Therewere no changes in our internal control over financial reporting identified in connection with the evaluation of such internalcontrol that occurred during our last fiscal quarter that have materially affected, or are reasonably likely to materially affect,our internal control over financial reporting.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <a name="a_011">          </a>          Item9B. Other Information         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 61; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         58         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <a name="pa_003">          </a>          PARTIII         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <a name="a_012">          </a>          Item10. Directors, Executive Officers and Corporate Governance         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Thetable below contains information regarding the current members of the Board of Directors and executive officers. The ages of individualsare provided as of March 23, 2021.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr>          <td style="border-bottom: black 1.5pt solid; vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Name            </b>           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Age            </b>           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: black 1.5pt solid; vertical-align: top; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Position            </b>           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: bottom; width: 30%; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Christopher    J. Schaber, PhD            </b>           </font>          </td>          <td style="vertical-align: bottom; width: 1%">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="vertical-align: bottom; width: 10%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            54           </font>          </td>          <td style="vertical-align: bottom; width: 1%">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="vertical-align: top; width: 58%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Chairman    of the Board, Chief Executive Officer and President           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: bottom; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Gregg    A. Lapointe, CPA, MBA            </b>           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            62           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Director           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: bottom; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Diane    L Parks, MBA            </b>           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            68           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Director           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: bottom; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Robert    J. Rubin, MD            </b>           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            75           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Director           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: bottom; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Jerome    B. Zeldis, MD, PhD            </b>           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            70           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Director           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Jonathan Guarino,    CPA, CGMA            </b>           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            48           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Chief Financial    Officer, Senior Vice President and Corporate Secretary           </font>          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="vertical-align: bottom; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Oreola    Donini, PhD            </b>           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            49           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Chief Scientific    Officer and Senior Vice President           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="vertical-align: bottom; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Richard    Straube, MD            </b>           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            69           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Chief Medical Officer    and Senior Vice President           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          ChristopherJ. Schaber, PhD         </b>         has over 30 years of experience in the pharmaceutical and biotechnology industry. Dr. Schaber has been ourPresident and Chief Executive Officer and a director since August 2006. He was appointed Chairman of the Board on October 8, 2009.He also has served on the board of directors of the Biotechnology Council of New Jersey (“BioNJ”) since January 2009and the Alliance for Biosecurity since October 2014, and has been a member of the corporate councils of both the National Organizationfor Rare Diseases (“NORD”) and the American Society for Blood and Marrow Transplantation (“ASBMT”) sinceOctober 2009 and July 2009, respectively. He also serves on the scientific advisory board for private start-up medical devicecompany, Simphotek, Inc. Prior to joining Soligenix, Dr. Schaber served from 1998 to 2006 as Executive Vice President and ChiefOperating Officer of Discovery Laboratories, Inc., where he was responsible for overall pipeline development and key areas ofcommercial operations, including regulatory affairs, quality control and assurance, manufacturing and distribution, pre-clinicaland clinical research, and medical affairs, as well as coordination of commercial launch preparation activities. From 1996 to1998, Dr. Schaber was a co-founder of Acute Therapeutics, Inc., and served as its Vice President of Regulatory Compliance andDrug Development. From 1994 to 1996, Dr. Schaber was employed by Ohmeda PPD, Inc., as Worldwide Director of Regulatory Affairsand Operations. From 1989 to 1994, Dr. Schaber held a variety of regulatory, development and operations positions with The LiposomeCompany, Inc., and Elkins-Sinn Inc., a division of Wyeth-Ayerst Laboratories. Dr. Schaber received his BA degree from WesternMaryland College, his MS degree in Pharmaceutics from Temple University School of Pharmacy and his PhD degree in PharmaceuticalSciences from the Union Graduate School. Dr. Schaber was selected to serve as a member of our Board of Directors becauseof his extensive experience in drug development and pharmaceutical operations, including his experience as an executive seniorofficer with our Company and Discovery Laboratories, Inc., and as a member of the board of directors of BioNJ; because of hisproven ability to raise funds and provide access to capital; and because of his advanced degrees in science and business.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 62; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         59         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          GreggA. Lapointe, CPA, MBA         </b>         has been a director since March 2009. Mr. Lapointe is currently CEO of Cerium Pharmaceuticals, Inc.and serves on the Board of Directors of Rigel Pharmaceuticals, Inc., Cytori Therapeutics, Inc. and Catabasis Pharmaceuticals,Inc. Mr. Lapointe has previously served on the Board of Directors of ImmunoCellular Therapeutics Ltd., Raptor Pharmaceuticals,Inc., SciClone Pharmaceuticals, Inc., the Pharmaceuticals Research and Manufacturers of America (PhRMA), Questcor Pharmaceuticals,Inc. and the Board of Trustees of the Keck Graduate Institute of Applied Life Sciences. He previously served in varying rolesfor Sigma-Tau Pharmaceuticals, Inc. (now known as Leadiant Biosciences, Inc.), a private biopharmaceutical company, from September2001 through February 2012, including Chief Operating Officer from November 2003 to April 2008 and Chief Executive Officer fromApril 2008 to February 2012. From May, 1996 to August 2001, he served as Vice President of Operations and Vice President, Controllerof AstenJohnson, Inc. (formerly JWI Inc.). Prior to that, Mr. Lapointe spent several years in the Canadian medical products industryin both distribution and manufacturing. Mr. Lapointe began his career at Price Waterhouse. Mr. Lapointe received his B.A. degreein Commerce from Concordia University in Montreal, Canada, a graduate diploma in Accountancy from McGill University and his M.B.A.degree from Duke University. He is a C.P.A. in the state of Illinois. Mr. Lapointe was selected to serve as a member of our Boardof Directors because of his significant experience in the areas of global strategic planning and implementation, business development,corporate finance, and acquisitions, and his experience as an executive officer and board member in the pharmaceutical and medicalproducts industries.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Diane L. Parks, MBA        </b>        has been a directorsince July 2019. From February 2016 until July 2018, she served as Head of U.S. Commercial and Senior Vice President of Marketing,Sales &amp; Market Research at Kite Pharma, Inc., a biopharma company developing cancer immunotherapy products with a primary focuson genetically engineered autologous T cell therapy with chimeric antigen receptors. From October 2014 to October 2015, Ms. Parksserved as Vice President of Global Marketing at Pharmacyclics LLC, a biopharmaceutical company primarily focused on the developmentof cancer therapies. Prior to Pharmacyclics LLC, Ms. Parks held senior leadership roles as Vice President of Sales for Amgen, Inc.,a biopharmaceutical company, representing oncology and nephrology products, and Senior Vice President of Specialty Biotherapeuticsand Managed Care at Genentech, Inc., a biotechnology company that discovers, develops, manufactures and commercializes medicinesto treat patients with serious or life-threatening medical conditions that was acquired by Roche Holding AG in 2009. At Genentech,she led the launches of multiple products as well as commercial development of Lucentis® and Rituxan®. Since May 2019,she has been a member of the board of directors of Calliditas Therapeutics AB (publ), a biopharmaceutical company, the shares ofwhich are traded on the Nasdaq Stockholm Exchange, that is developing and commercializing pharmaceutical products for patientswith significant unmet medical needs in niche indications. From July 2018 to November 2019, Ms. Parks has been a member of theboard of managers of Healogix LLC, a global marketing research-based consultancy that helps pharmaceutical and biotechnology companiesachieve successful product development and commercial clarity. Since November 2019, she has been a member of the board of directorsof Kura Oncology, Inc., a clinical-stage biopharmaceutical company, the shares of which are traded on the Nasdaq Stockholm Exchange,which focuses on the discovery and development of precision medicines for cancer treatments. Since September 2020, Ms. Parks hasbeen a member of the board of directors for a non-profit company called Lymphoma Research Foundation, which is devoted exclusivelyto funding lymphoma research and serving those impacted by the blood cancer. Ms. Parks holds a BS from Kansas State Universityand an MBA in marketing from Georgia State University. She has been a commercial leader in the biotech and pharma industry forover 30 years. Ms. Parks was selected to serve as a member of our Board of Directors because of her over 30 years’ experienceas a businesswoman and commercial executive with an extensive record of driving profitable growth for large pharmaceutical andbiotech companies.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Robert J. Rubin, MD        </b>        has been a directorsince October 2009. Dr. Rubin was a clinical professor of medicine at Georgetown University from 1995 until 2012 when he was appointeda Distinguished Professor of Medicine. From 1987 to 2001, he was president of the Lewin Group (purchased by Quintiles TransnationalCorp. in 1996), an international health policy and management consulting firm. From 1994 to 1996, Dr. Rubin served as Medical Directorof ValueRx, a pharmaceutical benefits company. From 1992 to 1996, Dr. Rubin served as President of Lewin-VHI, a health care consultingcompany. From 1987 to 1992, he served as President of Lewin-ICF, a health care consulting company. From 1984 to 1987, Dr. Rubinserved as a principal of ICF, Inc., a health care consulting company. From 1981 to 1984, Dr. Rubin served as the Assistant Secretaryfor Planning and Evaluation at the Department of Health and Human Services and as an Assistant Surgeon General in the U.S. PublicHealth Service. Dr. Rubin has served on the Board of BioTelemetry, Inc. (formerly known as CardioNet, Inc.) from 2007 to February2021. He is a board certified nephrologist and internist. Dr. Rubin received an undergraduate degree in Political Science fromWilliams College and his medical degree from Cornell University Medical College. Dr. Rubin was selected to serve as a member ofour Board of Directors because of his vast experience in the health care industry, including his experience as a nephrologist,internist, clinical professor of medicine and Assistant Surgeon General, and his business experience in the pharmaceutical industry.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 63; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         60         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          JeromeB. Zeldis, MD, PhD         </b>         has been a director since June 2011. Dr. Zeldis is currently Chief Medical Officer and President of ClinicalResearch, Drug Safety and Regulatory of Sorrento Therapeutics, Inc. He is also Chief Medical Officer and Principal at Celularity,Inc. Previously, Dr. Zeldis was Chief Executive Officer of Celgene Global Health and Chief Medical Officer of Celgene Corporation,a publicly traded, fully integrated biopharmaceutical company. He was employed by Celegene from 1997 to 2016. From September 1994to February 1997, Dr. Zeldis worked at Sandoz Research Institute and the Janssen Research Institute in both clinical researchand medical development. He has been a board member of several biotechnology companies and is currently on the boards of Metastat,Inc., PTC Therapeutics Inc., BioSig Technologies, Inc., the Castleman’s Disease Organization and Alliqua, Inc. He has previouslyserved on the boards of the NJ Chapter of the Arthritis Foundation and PTC Therapeutics, Inc. Additionally, he has served as AssistantProfessor of Medicine at the Harvard Medical School (from July 1987 to September 1988), Associate Professor of Medicine at Universityof California, Davis from (September 1988 to September 1994), Clinical Associate Professor of Medicine at Cornell Medical School(January 1995 to December 2003) and Professor of Clinical Medicine at the Robert Wood Johnson Medical School (July 1998 to June2010). Dr. Zeldis received a BA and an MS from Brown University, and an MD, and a PhD in Molecular Biophysics and Biochemistryfrom Yale University. Dr. Zeldis trained in Internal Medicine at the UCLA Center for the Health Sciences and in Gastroenterologyat the Massachusetts General Hospital and Harvard Medical School. Dr. Zeldis was selected to serve as a member of our Board ofDirectors because of his experience as an executive officer of a publicly traded biopharmaceutical company and in clinical researchand medical development, and his experience in the health care industry, including his experience as an internist, gastroenterologistand professor of medicine.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <b>         Jonathan Guarino, CPA, CGMA        </b>        has beenwith our company since September 2019 and is currently our Senior Vice President and Chief Financial Officer. Mr. Guarino has hadsignificant experience with both development-stage and commercial companies. From September 2016 to July 2019, he served as CorporateController for Hepion Pharmaceuticals, Inc. (formerly ContraVir Pharmaceuticals, Inc.), a New Jersey-based public biotechnologycompany, where he contributed to the establishment of the financial infrastructure, as well as assisted with capital fund-raisingand debt financings. He worked as Controller for Suite K Value Added Services LLC from August 2015 to September 2016 and as a seniormanager of technical accounting for Covance, Inc., from June 2014 to May 2015. Prior to these positions, he held accounting andfinance positions of increasing importance with several companies, including PricewaterhouseCoopers LLP, BlackRock, Inc. and Barnes&amp; Noble, Inc. Mr. Guarino is a CPA (certified public accountant) and CGMA (chartered global management accountant), who receivedhis BS in Business from Montclair State University.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          OreolaDonini, PhD         </b>         , has been with our company since August 15, 2013 and is currently our Chief Scientific Officer and Senior VicePresident, a position she has held since December 5, 2014. Dr. Donini served as our Vice President of Preclinical Research andDevelopment from August 15, 2013 until December 4, 2014. She has more than 15 years’ experience in drug discovery and preclinicaldevelopment with start-up biotechnology companies. From 2012 to 2013, Dr. Donini worked with ESSA Pharma Inc. as Vice PresidentResearch and Development. From 2004 to 2013, Dr. Donini worked with Inimex Pharmaceuticals Inc. (“Inimex”), lastlyas Senior Director of Preclinical R&amp;D from 2007-2013. Prior to joining Inimex, she worked with Kinetek Pharmaceuticals Inc.,developing therapies for infectious disease, cancer and cancer supportive care. Dr. Donini is a co-inventor and leader of ourSGX94 innate defense regulator technology, developed by Inimex and subsequently acquired by us. She was responsible for overseeingthe manufacturing and preclinical testing of SGX94, which demonstrated efficacy in combating bacterial infections and mitigatingthe effects of tissue damage due to trauma, infection, radiation and/or chemotherapy treatment. These preclinical studies resultedin a successful Phase 1 clinical study and clearance of Phase 2 protocols for oral mucositis in head and neck cancer and acutebacterial skin and skin structure infections. While with ESSA Pharma Inc. as the Vice President of Research and Development, Dr.Donini led the preclinical testing of a novel N-terminal domain inhibitor of the androgen receptor for the treatment of prostatecancer. While with Kinetek Pharmaceuticals Inc., her work related to the discovery of novel kinase and phosphatase inhibitorsfor the treatment of cancer. Dr. Donini received her PhD from Queen’s University in Kinston, Ontario, Canada and completedher post-doctoral work at the University of California, San Francisco. Her research has spanned drug discovery, preclinical development,manufacturing and clinical development in infectious disease, cancer and cancer supportive care.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 64; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         61         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          RichardStraube, MD         </b>         has been with our company since January 2014 and is currently our Senior Vice President and Chief Medical Officer.Dr. Straube is a board-certified pediatrician with 36 years’ experience in both academia and industry, including clinicalresearch experience in host-response modulation. From 2009 until joining our company, he was Chief Medical Officer of StealthPeptides Incorporated, a privately-held, clinical stage, biopharmaceutical company. Prior to joining us, Dr. Straube servedfrom 1988 to 1993 in various capacities, including most recently as Senior Director, Infectious Diseases and Immunology, ClinicalResearch, for Centocor, Inc., a privately-held biopharmaceutical company focused on developing monoclonal antibody-based diagnostics.While at Centocor, Inc., Dr. Straube was responsible for the initial anti-cytokine and anti-endotoxin programs targeted at amelioratinginappropriate host responses to infectious and immunologic challenges. Programs that he managed at Centocor, Inc. include assessmentsof immunomodulation using monoclonal removal of inciting molecular triggers, removal of internal immune-messengers, augmentationof normal host defenses, and maintenance of normal sub-cellular function in the face of injury. From 1993 to 1995, Dr. Straubewas Director of Medical Affairs at T-cell Sciences, Inc., a privately-held biotechnology company. From 1995 to 1997, he was Directorof Clinical Investigations of the Pharmaceutical Products Division of Ohmeda Corp., a privately-held biopharmaceutical company.He served from 1998 to 2007 as Executive Vice President of Research and Development and Chief Scientific Officer at INO TherapeuticsLLC, a privately-held biotherapeutics company, where he was responsible for the clinical trials and subsequent approval of inhalednitric oxide for the treatment of persistent pulmonary hypertension of the newborn. From 2007 to 2009, Dr. Straube was the ChiefMedical Officer at Critical Biologics Corporation, a privately-held biotechnology company. Dr. Straube received his medical degreeand residency training at the University of Chicago, completed a joint adult and pediatrician infectious diseases fellowship atthe University of California, San Diego (“UCSD”), and as a Milbank Scholar completed training in clinical trial designat the London School of Hygiene and Tropical Medicine. While on the faculty at the UCSD Medical Center, his research focused oninterventional studies for serious viral infections.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          BoardLeadership Structure         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         OurBoard of Directors believes that Dr. Schaber’s service as both the Chairman of our Board of Directors and our Chief ExecutiveOfficer is in the best interest of our Company and our stockholders. Dr. Schaber possesses detailed and in-depth knowledge ofthe issues, opportunities and challenges facing our Company and our business and, therefore, is best positioned to develop agendasthat ensure that the Board of Directors’ time and attention are focused on the most important matters. His combined roleenables decisive leadership, ensures clear accountability, and enhances our ability to communicate our message and strategy clearlyand consistently to our stockholders, employees, and collaborative partners.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Mr.Lapointe, Ms. Parks, Dr. Rubin, and Dr. Zeldis are independent and the Board of Directors believes that the independent directorsprovide effective oversight of management. Moreover, in addition to feedback provided during the course of meetings of the Boardof Directors, the independent directors hold executive sessions. Following an executive session of independent directors, theindependent directors’ report back to the full Board of Directors regarding any specific feedback or issues, provide theChairman with input regarding agenda items for Board of Directors and Committee meetings, and coordinate with the Chairman regardinginformation to be provided to the independent directors in performing their duties. The Board of Directors believes that thisapproach appropriately and effectively complements the combined Chairman/Chief Executive Officer structure.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Althoughwe believe that the combination of the Chairman and Chief Executive Officer roles is appropriate under the current circumstances,our corporate governance guidelines do not establish this approach as a policy, and the Board of Directors may determine thatit is more appropriate to separate the roles in the future.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         <b>          Committeesof the Board of Directors         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         OurBoard of Directors has the following three committees: (1) Compensation, (2) Audit and (3) Nominating and CorporateGovernance. Our Board of Directors has adopted a written charter for each of these committees, which are available on our websiteat www.soligenix.com under the “Investors” section.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 65; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         62         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td style="border-bottom: black 1.5pt solid; width: 25%; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Director            </b>           </font>          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: black 1.5pt solid; width: 24%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Audit             <br/>             Committee            </b>           </font>          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: black 1.5pt solid; width: 24%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Compensation             <br/>             Committee            </b>           </font>          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: black 1.5pt solid; width: 24%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Nominating    and             <br/>             Corporate Governance             <br/>             Committee            </b>           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Gregg A. Lapointe,    CPA           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 9pt">            <b>             <img alt="" src="image_001.jpg"/>            </b>           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            <img alt="" src="image_002.jpg"/>           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            <img alt="" src="image_002.jpg"/>           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Diane L. Parks,    MBA           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <img alt="" src="image_002.jpg"/>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            <img alt="" src="image_002.jpg"/>           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Robert J. Rubin,    MD           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <img alt="" src="image_002.jpg"/>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             <img alt="" src="image_001.jpg"/>            </b>           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Jerome B. Zeldis,    MD, PhD           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">           </font>           <font style="font-family: Times New Roman, Times, Serif; font-size: 9pt">            <b>             <img alt="" src="image_002.jpg"/>            </b>           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 9pt">            <b>             <img alt="" src="image_001.jpg"/>            </b>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 9pt">         <b>          <img alt="" src="image_001.jpg"/>         </b>        </font>        <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">         –Committee Chair        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <img alt="" src="image_002.jpg"/>         –Member        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           AuditCommittee          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         OurBoard of Directors has an Audit Committee, which is comprised of Mr. Lapointe (Chair), Ms. Parks and Dr. Rubin. The Audit Committeeassists our Board of Directors in monitoring the financial reporting process, the internal control structure and the independentregistered public accountants. Its primary duties are to serve as an independent and objective party to monitor the financialreporting process and internal control system, to review and appraise the audit effort of the independent registered public accountantsand to provide an open avenue of communication among the independent registered public accountants, financial and senior management,and our Board of Directors. Our Board of Directors has determined that Mr. Lapointe, Ms. Parks and Dr. Rubin are “independent”directors, within the meaning of applicable listing standards of The Nasdaq Stock Market LLC (“Nasdaq”) and the ExchangeAct and the rules and regulations thereunder. Our Board of Directors has also determined that the members of the Audit Committeeare qualified to serve on the committee and have the experience and knowledge to perform the duties required of the committeeand that Mr. Lapointe qualifies as an “audit committee financial expert” as that term is defined in the applicableregulations of the Exchange Act.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           CompensationCommittee          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         OurBoard of Directors has a Compensation Committee, which is comprised of Dr. Rubin (Chair), Mr. Lapointe and Dr. Zeldis. The CompensationCommittee is responsible for reviewing and approving the executive compensation program, assessing executive performance, settingsalary, making grants of annual incentive compensation and approving certain employment agreements. Our Board of Directors hasdetermined that Dr. Rubin, Mr. Lapointe and Dr. Zeldis are “independent” directors within the meaning of applicablelisting standards of Nasdaq and the Exchange Act and the rules and regulations thereunder.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>           Nominatingand Corporate Governance Committee          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         OurBoard of Directors has a Nominating and Corporate Governance Committee (“Nominating Committee”), which is comprisedof Dr. Zeldis (Chair), Mr. Lapointe and Ms. Parks. The Nominating Committee makes recommendations to the Board of Directors regardingthe size and composition of our Board of Directors, establishes procedures for the nomination process, identifies and recommendscandidates for election to our Board of Directors. Our Board of Directors has determined that Dr. Zeldis, Mr. Lapointe and Ms.Parks are “independent” directors, as such term is defined by the applicable Nasdaq listing standards.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          Codeof Ethics         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Wehave adopted a code of ethics that applies to all of our executive officers and senior financial officers (including our chiefexecutive officer, chief financial officer, chief accounting officer and any person performing similar functions). A copy of ourcode of ethics is publicly available on our website at www.soligenix.com under the “Investors” section. If we makeany substantive amendments to our code of ethics or grant any waiver, including any implicit waiver, from a provision of the codeto our chief executive officer, chief financial officer or chief accounting officer, we will disclose the nature of such amendmentor waiver in a Current Report on Form 8-K.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         <b>          DiversityConsiderations in Identifying Director Nominees         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Wedo not have a formal diversity policy or set of guidelines in selecting and appointing directors that comprise our Board of Directors.However, when making recommendations to our Board of Directors regarding the size and composition of our Board of Directors, ourNominating Committee does consider each individual director’s qualifications, skills, business experience and capacity toserve as a director and the diversity of these attributes for the Board of Directors as a whole.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 66; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         63         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          CompensationCommittee Interlocks and Insider Participation         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Nomember of our Compensation Committee is or has at any time during the past year been one of our officers or employees. None ofour executive officers currently serves or in the past year has served as a member of the Board of Directors or Compensation Committeeof any entity that has one or more executive officers serving on our Board of Directors or Compensation Committee.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <a name="a_013">          </a>          Item11. Executive Compensation         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         In2018, in furtherance of our compensation philosophy and objectives, the Compensation Committee engaged the Setren Smallberg &amp;Associates (“SS&amp;A”), an outside executive compensation consulting firm determined to be independent by the CompensationCommittee, to conduct a review of, and recommend changes to, our compensation program for our most highly compensated executiveofficers. A representative of SS&amp;A attended Compensation Committee meetings at the invitation of the Compensation CommitteeChairman and was also in direct contact with the Compensation Committee and company management from time to time. SS&amp;A providedthe Compensation Committee with assistance and advice in the review of our salary structure, annual and equity incentive awardsand other related executive pay issues. In addition, SS&amp;A provided advice regarding marketplace trends and best practicesrelating to competitive pay levels.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         SS&amp;Adid not provide any services to us other than its services as the Compensation Committee’s independent compensation consultant,and SS&amp;A did not receive any fees or compensation from us other than the fee it received as the independent compensation consultant.Except as described above, SS&amp;A did not provide any services to us in 2018 or 2019. The Compensation Committee confirmed thatSS&amp;A’s work for the Compensation Committee did not create any conflicts of interest.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <u>           SummaryCompensation          </u>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Thefollowing table contains information concerning the compensation paid during each of the two years ended December 31, 2020 and2019, respectively to our Chief Executive Officer and each of the three other most highly compensated executive officers (collectively,the “Named Executive Officers”).        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         <b>          SummaryCompensation         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td style="white-space: nowrap; border-bottom: black 1.5pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Name            </b>           </font>          </td>          <td>          </td>          <td style="border-bottom: black 1.5pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Position            </b>           </font>          </td>          <td>          </td>          <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Year            </b>           </font>          </td>          <td>          </td>          <td>          </td>          <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Salary            </b>           </font>          </td>          <td>          </td>          <td>          </td>          <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Bonus            </b>           </font>          </td>          <td>          </td>          <td>          </td>          <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Option Awards            </b>           </font>          </td>          <td>          </td>          <td>          </td>          <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             All Other Compensation            </b>           </font>          </td>          <td>          </td>          <td>          </td>          <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Total            </b>           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="white-space: nowrap; width: 16%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Christopher J. Schaber             <sup>              (1)             </sup>            </b>           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 11%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            CEO &amp;           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 9%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2020           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="width: 9%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            475,439           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="width: 9%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            306,499           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="width: 9%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            133,466           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="width: 9%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            28,365           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="width: 9%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            943,769           </font>          </td>          <td style="width: 1%">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="white-space: nowrap; text-align: justify">          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            President           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2019           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            466,117           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            111,868           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            83,415           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            26,749           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            688,149           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="white-space: nowrap; text-align: justify">          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="white-space: nowrap; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Jonathan Guarino             <sup>              (2)             </sup>            </b>           </font>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            CFO &amp;           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2020           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            220,000           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            45,788           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            55,707           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            28,296           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            349,791           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="white-space: nowrap; text-align: justify">          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Senior VP           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2019           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            68,750           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            13,041           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            32,255           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            8,437           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            122,483           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="white-space: nowrap; text-align: justify">          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="white-space: nowrap; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Oreola Donini             <sup>              (4)             </sup>            </b>           </font>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            CSO &amp;           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2020           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            248,745           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            127,611           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            97,486           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4,107           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            477,949           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="white-space: nowrap; text-align: justify">          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Senior VP           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2019           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            241,500           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            47,817           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            45,164           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4,619           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            339,100           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: white">          <td style="white-space: nowrap; text-align: justify">          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td>          </td>          <td style="text-align: center">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: right">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="white-space: nowrap; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Richard C. Straube             <sup>              (5)             </sup>            </b>           </font>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            CMO &amp;           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2020           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            173,400           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            121,108           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            55,707           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            -           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            349,791           </font>          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: #CCEEFF">          <td style="white-space: nowrap; text-align: justify">          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Senior VP           </font>          </td>          <td>          </td>          <td>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2019           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            212,352           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            30,090           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            22,582           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            13,636           </font>          </td>          <td>          </td>          <td>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            278,659           </font>          </td>          <td>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (1)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Dr. Schaber deferred    the payment of his 2020 bonus of $306,499 until January 15, 2021. Option awards figure includes the value of Common Stock    option awards at grant date as calculated under FASB ASC 718. Other compensation represents health insurance costs paid by    us.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (2)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Mr. Guarino deferred    the payment of his 2020 bonus of $45,788 until January 15, 2021. Option awards figure includes the value of Common Stock option    awards at grant date as calculated under FASB ASC 718. Other compensation represents health insurance costs paid by us.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 67; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         64         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (3)           </font>          </td>          <td>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">            <font style="font-family: Times New Roman, Times, Serif">             Dr.        Donini deferred the payment of her 2020 bonus of $127,611 until January 15, 2021. Option awards figure includes the value        of Common Stock option awards at grant date as calculated under FASB ASC 718. Other compensation represents health insurance        costs paid by us.            </font>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">            <font style="font-family: Times New Roman, Times, Serif">            </font>           </p>          </td>         </tr>         <tr style="vertical-align: top">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (4)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Dr. Straube deferred    the payment of his 2020 bonus of $121,108 until January 15, 2021. Option awards figure includes the value of Common Stock    option awards at grant date as calculated under FASB ASC 718. Other compensation represents health insurance costs paid by    us.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <u>           Employmentand Severance Agreements          </u>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         InAugust 2006, we entered into a three-year employment agreement with Christopher J. Schaber, PhD. Pursuant to this employment agreementwe agreed to pay Dr. Schaber a base salary of $300,000 per year and a minimum annual bonus of $100,000. Dr. Schaber’s employmentagreement automatically renews every three years, unless otherwise terminated, and was automatically renewed in December 2007,December 2010, December 2013 and December 2016 for an additional term of three years. We agreed to issue him options to purchase12,500 shares of our common stock, with one third immediately vesting and the remainder vesting over three years. Upon terminationwithout “Just Cause” as defined by this agreement, we would pay Dr. Schaber nine months of severance, as well as anyaccrued bonuses, accrued vacation, and we would provide health insurance and life insurance benefits for Dr. Schaber and his dependents.No unvested options shall vest beyond the termination date. Dr. Schaber’s monetary compensation (base salary of $300,000and bonus of $100,000) remained unchanged from 2006 with the 2007 renewal. Upon a change in control of the company due to mergeror acquisition, all of Dr. Schaber’s options shall become fully vested, and be exercisable for a period of five years aftersuch change in control (unless they would have expired sooner pursuant to their terms). In the event of his death during the termof the agreement, all of his unvested options shall immediately vest and remain exercisable for the remainder of their term andbecome the property of Dr. Schaber’s immediate family.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         InJanuary 2020, our Board of Directors authorized an amendment to Dr. Schaber’s employment agreement to increase the numberof shares of common stock from 5,000 to 500,000, issuable to Dr. Schaber immediately prior to the completion of a transactionor series or a combination of related transactions negotiated by our Board of Directors whereby, directly or indirectly, a majorityof our capital stock or a majority of our assets are transferred from us and/or our stockholders to a third party.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         InDecember 2020, our Board of Directors authorized an amendment to Dr. Schaber’s employment agreement to modify the severanceterms. Upon termination without “Just Cause” as defined by this agreement, we would pay Dr. Schaber twelve monthsof severance, as well as a pro rata bonus calculated by the average of his prior two year’s annual bonuses, if any, andbased on the number of months that he was employed during the year in which his employment was terminated; however, in the caseof termination without “Just Cause” within one year following a change in control or the sale or other dispositionof all or substantially all of our assets Dr. Schaber will be entitled 18 months of severance and health insurance and life insurancebenefits for him and his dependents.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         OnJune 22, 2011, the Compensation Committee eliminated his fixed minimum annual bonus payable and revised it to an annual targetedbonus of 40% of his annual base salary. On December 13, 2018, the Compensation Committee approved an increase in salary for Dr.Schaber to $466,117. On December 12, 2019, the Compensation Committee approved an increase in salary for Dr. Schaber to $475,439.On December 10, 2020, the Compensation Committee approved an increase in salary for Dr. Schaber to $484,948.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 68; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         65         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         InJuly 2013, we entered into a one-year employment agreement with Oreola Donini, PhD, our Vice President Preclinical Research &amp;Development. Pursuant to the agreement, we have agreed to pay Dr. Donini $170,000 (CAD) per year and a targeted annual bonus of20% of base salary. We also agreed to issue her options to purchase 40,000 shares of our common stock with one-quarter immediatelyvesting and the remainder vesting over three years. Dr. Donini’s employment agreement automatically renews each year, unlessotherwise terminated, and has automatically renewed each year since execution. Upon termination without “Just Cause”,as defined in Dr. Donini’s employment agreement, we would pay Dr. Donini three months of severance, accrued bonuses andvacation, and health insurance benefits. No unvested options vest beyond the termination date. In December 2014, Dr. Donini wasnamed Chief Scientific Officer and Senior Vice President. Upon Dr. Donini’s promotion to Chief Scientific Officer, the CompensationCommittee increased her targeted bonus to 30% of her annual base salary. On December 13, 2018, the Compensation Committee approvedan increase in salary for Dr. Donini to $241,500. On December 12, 2019, the Compensation Committee approved an increase in salaryfor Dr. Donini to $248,745. On December 10, 2020, the Compensation Committee approved an increase in salary for Dr. Donini to$260,000.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         InDecember 2014, we entered into a one-year employment agreement with Richard C. Straube, MD, our Chief Medical Officer and SeniorVice President. Pursuant to the agreement, we agreed to pay Dr. Straube $300,000 per year and a targeted annual bonus of 30% ofbase salary. We also issued him options to purchase 10,000 shares of our common stock with one-third immediately vesting and theremainder vesting over three years. On March 26, 2019, we entered into an amendment to our employment agreement with Dr. Straube.Pursuant to the amended agreement, which amendment becomes effective as of April 1, 2019, Dr. Straube will be required to devoteat least 20 hours per week to the performance of his duties and we will pay him $170,000 per year. The amended employment agreementautomatically renews each year, unless otherwise terminated. Upon termination without “Just Cause”, as defined inthe amended employment agreement, we would pay Dr. Straube one month of severance. No unvested options vest beyond the terminationdate. On December 13, 2018, the Compensation Committee approved an increase in salary for Dr. Straube to $339,407. On December12, 2019, the Compensation Committee approved an increase in salary for Dr. Straube to $173,400. On December 10, 2020, the CompensationCommittee approved an increase in salary for Dr. Straube to $176,868.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         OnSeptember 9, 2019, we entered into a one-year employment agreement with Jonathan Guarino, CPA, CGMA, our Senior Vice Presidentand Chief Financial Officer. Pursuant to the agreement, we have agreed to pay Mr. Guarino $220,000 per year and a targeted annualbonus of 30% of base salary. We also agreed to issue him options to purchase 40,000 shares of our common stock with one-quarterimmediately vesting and the remainder vesting over three years. Mr. Guarino’s employment agreement automatically renewseach year, unless otherwise terminated. Upon termination without “Just Cause”, as defined in Mr. Guarino’s employmentagreement, we would pay Mr. Guarino three months of severance, accrued salary, bonuses and vacation, and health insurance benefits.No unvested options vest beyond the termination date. On December 10, 2020, the Compensation Committee approved an increase insalary for Mr. Guarino to $224,400.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 69; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         66         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <u>           OutstandingEquity Awards at Fiscal Year-End          </u>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Thefollowing table contains information concerning unexercised options, stock that has not vested, and equity incentive plan awardsfor the Named Executive Officers outstanding at December 31, 2020. We have never issued Stock Appreciation Rights.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            Number    of Securities            <br/>            Underlying Unexercised            <br/>            Options (#)           </font>          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            Equity    Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned           </font>          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            Option            <br/>            Exercise            <br/>            Price           </font>          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            Option    Expiration           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="border-bottom: Black 1.5pt solid; font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif">            Name           </font>          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            Exercisable           </font>          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            Unexercisable           </font>          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            Options    (#)           </font>          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            ($)           </font>          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            Date           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 40%; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">            Christopher J. Schaber           </font>          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 9%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            11,219           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 9%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            -           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 9%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            -           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="width: 9%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            6.40           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 11%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            11/30/2021           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            13,000           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            -           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            -           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            6.80           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            12/04/2022           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            10,000           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            -           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            -           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            20.10           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            12/04/2023           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            10,000           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            -           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            -           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            15.00           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            12/04/2024           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            14,000           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            -           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            -           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            11.30           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            12/30/2025           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            60,000           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            -           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            -           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            2.01           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            12/06/2027           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            45,000           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            15,000           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            15,000           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            0.97           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            12/12/2028           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            41,250           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            18,750           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            18,750           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            0.96           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            01/01/2029           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            30,000           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            30,000           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            30,000           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            1.24           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            12/11/2029           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            26,250           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            33,750           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            33,750           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            1.45           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            01/01/2030           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            15,000           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            45,000           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            45,000           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            2.34           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            12/09/2030           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">            Jonathan Guarino           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            22,500           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            17,500           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            17,500           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            0.97           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            09/08/2029           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            5,000           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            5,000           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            5,000           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            1.24           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            12/11/2029           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            10,000           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            30,000           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            30,000           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            2.34           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            12/09/2030           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">            Oreola Donini           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            4,000           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            -           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            -           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            15.60           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            8/14/2023           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            2,000           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            -           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            -           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            20.10           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            12/4/2023           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            3,000           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            -           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            -           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            15.00           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            12/4/2024           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            7,000           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            -           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            -           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            11.30           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            12/30/2025           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            20,000           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            -           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            -           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            2.67           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            3/30/2027           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            35,000           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            -           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            -           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            2.01           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            12/06/2027           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            30,000           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            10,000           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            10,000           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            0.97           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            12/13/2028           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            30,000           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            30,000           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            30,000           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            1.24           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            12/11/2029           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            17,500           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            52,500           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            52,500           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            2.34           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            12/09/2030           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">            Richard C. Straube           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            10,000           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            -           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            -           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            20.10           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            1/06/2024           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            5,000           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            -           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            -           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            15.00           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            12/04/2024           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            7,000           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            -           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            -           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            11.30           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            12/30/2025           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            20,000           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            -           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            -           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            2.67           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            3/30/2027           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            35,000           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            -           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            -           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            2.01           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            12/06/2027           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            30,000           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            10,000           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            10,000           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            0.97           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            12/13/2028           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            30,000           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            30,000           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            30,000           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            1.24           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            12/11/2029           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            17,500           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            52,500           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            52,500           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            2.34           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            12/09/2030           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 70; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         67         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <u>           Compensationof Directors          </u>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Thefollowing table contains information concerning the compensation of the non-employee directors during the year ended December31, 2020.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">        <tbody>         <tr style="vertical-align: bottom">          <td style="border-bottom: Black 1.5pt solid; font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif">            Name           </font>          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Fees    Earned Paid in Cash             <sup>              (1)             </sup>            </b>           </font>          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Option    Awards             <sup>              (2)             </sup>            </b>           </font>          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            Total           </font>          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 64%; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">            Gregg A. Lapointe           </font>          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="width: 9%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            58,750           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="width: 9%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            30,000           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="width: 9%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            88,750           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">            Diane L. Parks           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            45,625           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            30,000           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            75,625           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Mark Pearson            <sup>             (3)            </sup>           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            11,875           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            -           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            11,875           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">            Robert J. Rubin           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            52,500           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            30,000           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            82,500           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">            Jerome B. Zeldis           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            50,000           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            30,000           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            80,000           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0">          </td>          <td style="width: 0.25in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <sup>             (1)            </sup>           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Directorswho are compensated as full-time employees receive no additional compensation for service on our Board of Directors. Each independentdirector who is not a full-time employee is paid $35,000 annually, on a prorated basis, for their service on our Board of Directors,the chairman of our Audit Committee is paid $15,000 annually, on a prorated basis, and the chairmen of our Compensationand Nominating Committees is paid $10,000 annually, on a prorated basis. Additionally, Audit Committee members are paid $7,500annually and Compensation and Nominating Committee members are paid $5,000 annually. This compensation is paid quarterly.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0">          </td>          <td style="width: 0.25in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <sup>             (2)            </sup>           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Wemaintain a stock option grant program pursuant to the nonqualified stock option plan, whereby members of our Board of Directorsor its committees who are not full-time employees receive an initial grant of fully vested options to purchase 1,500 shares ofcommon stock. Upon re-election to the Board, each Board member will receive stock options with a value of $30,000, calculatedusing the closing price of the common stock on the trading day prior to the date of the annual meeting of our stockholders, whichvest at the rate of 25% per quarter, commencing with the first quarter after each annual meeting of stockholders.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <font style="font-family: Times New Roman, Times, Serif">        </font>        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0">          </td>          <td style="width: 0.25in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <sup>             (3)            </sup>           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Mr.Pearson resigned, for personal reasons, as a member of our Board of Directors, as well as all committees thereof, on March 31,2020.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <u>           StockOwnership Policy          </u>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         InApril 2012, our Board of Directors adopted a stock ownership policy applicable to our non-employee directors to strengthen thelink between director and stockholder interests. Pursuant to the stock ownership policy, each non-employee director is requiredto hold a minimum ownership position in the common stock equal to the annual cash compensation paid for service on the Board ofDirectors, exclusive of cash compensation paid for service as a chair or member of any committees of the Board of Directors.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Stockcounted toward the ownership requirement includes common stock held by the director, unvested and vested restricted stock, andall shares of common stock beneficially owned by the director held in a trust and by a spouse and/or minor children of the director.The policy provides that the ownership requirement must be attained within three years after the later of June 21, 2012 and thedate a director is first elected or appointed to the Board of Directors. To monitor progress toward meeting the requirement, theNominating Committee will review director ownership levels at the end of March of each year. Non-employee directors are prohibitedfrom selling any shares of common stock unless such director is in compliance with the stock ownership policy. A copy of our directorcompensation and stock ownership policy is publicly available on our website at www.soligenix.com under the “Investors”section.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 71; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         68         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <a name="a_014">          </a>          Item12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Thetable below provides information regarding the beneficial ownership of the common stock as of March 23, 2021, of (1) each personor entity who owns beneficially 5% or more of the shares of our outstanding common stock, (2) each of our directors, (3) eachof the Named Executive Officers, and (4) our directors and officers as a group. Except as otherwise indicated, and subject toapplicable community property laws, we believe the persons named in the table have sole voting and investment power with respectto all shares of common stock held by them.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">           Name of Beneficial Owner          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Shares of Common Stock Beneficially Owned **          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <b>             Percent            </b>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <b>             of Class            </b>           </p>          </td>          <td style="padding-bottom: 1.5pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 76%; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Christopher J. Schaber            <sup>             (1)            </sup>           </font>          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           393,569          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           0.98          </td>          <td style="width: 1%; text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Gregg A. Lapointe            <sup>             (2)            </sup>           </font>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           86,684          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           0.22          </td>          <td style="text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Diane L. Parks            <sup>             (3)            </sup>           </font>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           68,482          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           0.17          </td>          <td style="text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Robert J. Rubin            <sup>             (4)            </sup>           </font>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           90,146          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           0.22          </td>          <td style="text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Jerome B. Zeldis            <sup>             (5)            </sup>           </font>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           102,763          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           0.26          </td>          <td style="text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Jonathan Guarino            <sup>             (6)            </sup>           </font>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           43,125          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           0.11          </td>          <td style="text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Oreola Donini            <sup>             (7)            </sup>           </font>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           159,125          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           0.40          </td>          <td style="text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Richard Straube            <sup>             (8)            </sup>           </font>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           138,875          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           0.35          </td>          <td style="text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify">           All directors and executive officers as a group (10 persons)          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           1,082,768          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           2.64          </td>          <td style="text-align: left">           %          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0">          </td>          <td style="width: 0.25in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (1)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Includes53,095 shares of common stock owned by Dr. Schaber, options to purchase 320,719 shares of common stock exercisable within 60 daysof March 23, 2021 and warrants to purchase up to 19,755 shares of common stock exercisable within 60 days of March 23, 2021. Theaddress of Dr. Schaber is c/o Soligenix, 29 Emmons Drive, Suite B-10, Princeton, New Jersey 08540.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (2)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Includes 7,379 shares of Common Stock and options to purchase 79,305 shares of Common Stock exercisable within 60 days of March 23, 2021. The address of Mr. Lapointe is c/o Soligenix, 29 Emmons Drive, Suite B-10, Princeton, New Jersey 08540.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0">          </td>          <td style="width: 0.25in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            (3)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Includes14,940 shares of Common Stock and options to purchase 53,542 shares of Common Stock exercisable within 60 days of March 23, 2021.The address of Ms. Parks is c/o Soligenix, 29 Emmons Drive, Suite B-10, Princeton, New Jersey 08540.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0">          </td>          <td style="width: 0.25in; text-align: left">           (4)          </td>          <td style="text-align: justify">           Includes 4,385 shares of Common Stock, options to purchase81,805 shares of Common Stock exercisable within 60 days of March 23, 2021, and warrants to purchase up to 3,956 shares of CommonStock exercisable within 60 days of March 23, 2021. The address of Dr. Rubin is c/o Soligenix, 29 Emmons Drive, Suite B-10, Princeton,New Jersey 08540.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0">          </td>          <td style="width: 0.25in; text-align: left">           (5)          </td>          <td style="text-align: justify">           Includes 22,917 shares of Common Stock and options to purchase79,846 shares of Common Stock exercisable within 60 days of March 23, 2021. The address of Dr. Zeldis is c/o Soligenix, 29 EmmonsDrive, Suite B-10, Princeton, New Jersey 08540.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0">          </td>          <td style="width: 0.25in; text-align: left">           (6)          </td>          <td style="text-align: justify">           Includes options to purchase 43,125 shares of Common Stockowned by Mr. Guarino exercisable within 60 days of March 23, 2021. The address of Mr. Guarino is c/o Soligenix, 29 Emmons Drive,Suite B-10, Princeton, New Jersey 08540.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0">          </td>          <td style="width: 0.25in; text-align: left">           (7)          </td>          <td style="text-align: justify">           Includes options to purchase 159,125 shares of Common Stockowned by Dr. Donini exercisable within 60 days of March 23, 2021. The address of Dr. Donini is c/o Soligenix, 29 Emmons Drive,Suite B-10, Princeton, New Jersey 08540.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0">          </td>          <td style="width: 0.25in; text-align: left">           (8)          </td>          <td style="text-align: justify">           Includes 138,875 options to purchase shares of Common Stockowned by Dr. Straube exercisable within 60 days of March 23, 2021. The address of Dr. Straube is c/o Soligenix, 29 Emmons Drive,Suite B-10, Princeton, New Jersey 08540.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0">          </td>          <td style="width: 0.25in; text-align: left">           *          </td>          <td style="text-align: justify">           Indicates less than 1%.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0">          </td>          <td style="width: 0.25in; text-align: left">           **          </td>          <td style="text-align: justify">           Beneficial ownership is determined in accordance with therules of the SEC. Shares of Common Stock subject to options or warrants currently exercisable or exercisable within 60 days ofMarch 23, 2021 are deemed outstanding for computing the percentage ownership of the stockholder holding the options or warrants,but are not deemed outstanding for computing the percentage ownership of any other stockholder. Percentage of ownership is basedon 40,020,461 shares of Common Stock outstanding as of March 23, 2021.          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 72; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         69         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          EquityCompensation Plan Information         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         InDecember 2005, our Board of Directors approved the 2005 Equity Incentive Plan, which was approved by stockholders on December29, 2005. The maximum number of shares of our common stock available for issuance under the 2005 Equity Incentive Plan is 300,000shares. In April 2015, our Board of Directors approved the 2015 Equity Incentive Plan, which was approved by stockholders on June18, 2015. The maximum number of shares of our common stock available for issuance under the 2015 Equity Incentive Plan is 2,000,000shares.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Thefollowing table sets forth certain information, as of December 31, 2020, with respect to the following compensation plans (includingindividual compensation arrangements) under which our equity securities are authorized for issuance:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">            all                                         compensation plans previously approved by our security holders; and           </font>          </td>         </tr>        </tbody>       </table>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">        <tbody>         <tr style="vertical-align: top">          <td style="width: 0.25in">          </td>          <td style="width: 0.25in">           <font style="font-family: Times New Roman, Times, Serif">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">            all                                         compensation plans not previously approved by our security holders.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         Allshare numbers in this paragraph and in the following table have been adjusted for the one-for-ten reverse stock split effectiveOctober 7, 2016.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">        <tbody>         <tr style="vertical-align: bottom">          <td style="border-bottom: Black 1.5pt solid; font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif">            Plan    Category           </font>          </td>          <td style="padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <font style="font-family: Times New Roman, Times, Serif">             <b>              Numberof Securities to be Issued upon Exercise of Outstanding Options, Warrants and Rights             </b>            </font>           </p>          </td>          <td style="padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            Weighted-Average    Exercise Price of Outstanding Options, Warrants and Rights           </font>          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <font style="font-family: Times New Roman, Times, Serif">             <b>              Numberof Securities Remaining Available for Future Issuance Under Equity Compensation Plans (excluding securities reflected in the firstcolumn)             </b>            </font>           </p>          </td>          <td style="padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 64%; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Equity    compensation plans approved by security holders            <sup>             (1)            </sup>           </font>          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 9%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            1,933,804           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="width: 9%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            2.96           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 9%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            214,689           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">            Equity compensation    plans not approved by security holders           </font>          </td>          <td style="padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            -           </font>          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            -           </font>          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            -           </font>          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">           <font style="font-family: Times New Roman, Times, Serif">            Total           </font>          </td>          <td style="padding-bottom: 4pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            1,933,804           </font>          </td>          <td style="padding-bottom: 4pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="padding-bottom: 4pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            2.96           </font>          </td>          <td style="padding-bottom: 4pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="padding-bottom: 4pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            214,689           </font>          </td>          <td style="padding-bottom: 4pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">        <tbody>         <tr style="vertical-align: top; text-align: justify">          <td style="width: 0">          </td>          <td style="width: 0.25in; text-align: left">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <sup>             (1)            </sup>           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Includesour 2005 Equity Incentive Plan and our 2015 Equity Incentive Plan. Our 2005 Equity Incentive Plan expired in 2015 and thus nosecurities remain available for future issuance under that plan.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <a name="a_015">          </a>          Item13. Certain Relationships and Related Transactions and Director Independence         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <u>           RelatedParty Transactions          </u>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Ouraudit committee is responsible for the review, approval and ratification of related party transactions. The audit committee reviewsthese transactions under our Code of Ethics, which governs conflicts of interests, among other matters, and is applicable to ouremployees, officers and directors.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Weare party to a registration rights agreement with certain stockholders, including Altamont Pharmaceutical Holdings, LLC and ACTCapital Management, LLLP each of which beneficially owned 5% or more of the shares of our outstanding common stock since January1, 2019. The agreement provides that the stockholders have the right to require that we register its shares under the SecuritiesAct for sale to the public, subject to certain conditions. The stockholders also have piggyback registration rights, which meansthat, if not already registered, they have the right to include their shares in any registration that we effect under the SecuritiesAct, subject to specified exceptions. We must pay all expenses incurred in connection with the exercise of these demand registrationrights.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Weare unable to estimate the dollar value of the registration rights to the holders of these rights. The amount of reimbursableexpenses under the agreements depends on a number of variables, including whether registration rights are exercised incident toa primary offering by us, the form on which we are eligible to register such a transaction, and whether we have a shelf registrationin place at the time of a future offering.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 73; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         70         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Otherthan as described above, the employment agreements and compensation paid to our directors, we did not engage in any transactionswith related parties since January 1, 2019. For a discussion of our employment agreements and compensation paid to our directors,see “Item 11. Executive Compensation”.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <u>           DirectorIndependence          </u>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         TheBoard of Directors has determined that Mr. Lapointe, Ms. Parks, Dr. Rubin, and Dr. Zeldis are “independent” as suchterm is defined by the applicable listing standards of Nasdaq. Our Board of Directors based this determination primarily on areview of the responses of the Directors to questionnaires regarding their employment, affiliations and family and other relationships.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <a name="a_016">          </a>          Item14. Principal Accountant Fees and Services         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Thefollowing table highlights the aggregate fees billed during each of the two years ended December 31, 2020 and December 31, 2019by EisnerAmper LLP.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: center">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2020          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 76%; text-align: justify">           Audit fees          </td>          <td style="width: 1%; font-weight: bold">          </td>          <td style="width: 1%; font-weight: bold; text-align: left">           $          </td>          <td style="width: 9%; font-weight: bold; text-align: right">           173,380          </td>          <td style="width: 1%; font-weight: bold; text-align: left">          </td>          <td style="width: 1%; font-weight: bold">          </td>          <td style="width: 1%; font-weight: bold; text-align: left">           $          </td>          <td style="width: 9%; font-weight: bold; text-align: right">           146,490          </td>          <td style="width: 1%; font-weight: bold; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">           Tax fees          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           12,250          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           12,250          </td>          <td style="font-weight: bold; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify; padding-bottom: 1.5pt">           Other fees          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">           Total          </td>          <td style="font-weight: bold; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">           185,630          </td>          <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">           158,740          </td>          <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          AuditFees         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Thiscategory includes the fees for the examination of our consolidated financial statements, review of our Annual Report on Form 10-Kand quarterly reviews of the interim financial statements included in our Quarterly Reports on Form 10-Q.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          TaxFees         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Thiscategory relates to professional services for tax compliance, tax advice and tax planning.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          OtherFees         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Ourprincipal accountants did not bill us for any services or products other than as reported above in this Item 14 during each ofthe two years.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          Pre-ApprovalPolicies and Procedures         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Theaudit committee has adopted a policy that requires advance approval of all audit services and permitted non-audit services tobe provided by the independent auditor as required by the Exchange Act. The audit committee must approve the permitted servicebefore the independent auditor is engaged to perform it. The audit committee approved all of the services described above in accordancewith its pre-approval policies and procedures.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 74; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         71         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <a name="pa_004">          </a>          PartIV         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <a name="a_017">          </a>          Item15. Exhibits and Financial Statements Schedules         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         a.(1) Consolidated Financial Statements:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Thefinancial statements required to be filed by Item 8 of this Annual Report on Form 10-K and filed in this Item 15, are as follows:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 91%">           <a href="#a_0001">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Consolidated Balance Sheets    as of December 31, 2020 and 2019            </font>           </a>          </td>          <td style="width: 9%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            F-2           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td>           <a href="#a_0002">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Consolidated Statements of Operations for the    Years Ended December 31, 2020 and 2019            </font>           </a>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            F-3           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td>           <a href="#a_0003">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Consolidated Statements of Comprehensive Loss    for the Years Ended December 31, 2020 and 2019            </font>           </a>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            F-4           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td>           <a href="#a_0004">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Consolidated Statements of Shareholders’    Equity for the Years Ended December 31, 2020 and 2019            </font>           </a>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            F-5           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td>           <a href="#a_0005">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Consolidated Statements of Cash Flows for the    Years Ended December 31, 2020 and 2019            </font>           </a>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            F-6           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td>           <a href="#a_0006">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Notes to Consolidated Financial Statements            </font>           </a>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            F-7 - F-23           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td>           <a href="#a_0007">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Report of Independent Registered Public Accounting    Firm            </font>           </a>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            F-24           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         (2)Financial Statement Schedules        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Schedulesare omitted because they are not applicable, or are not required, or because the information is included in the consolidated financialstatements and notes thereto.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         (3)Exhibits:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="width: 10%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2.1           </font>          </td>          <td style="width: 90%; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/812796/000081279606000025/enteronmergeragreements.htm">             Agreement and Plan of Merger, dated May 10, 2006 by and among the Company, Corporate Technology Development, Inc., Enteron Pharmaceuticals, Inc. and CTD Acquisition, Inc. (incorporated by reference to Exhibit 2.1 included in our Registration Statement on Form SB-2 (File No. 333-133975) filed on May 10, 2006).            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>           <font style="font-size: 7pt">           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 7pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3.1           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/812796/000121390012003441/f8k062112ex3i_soligenix.htm">             Second Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 included in our current report on Form 8-K filed on June 22, 2012).            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>           <font style="font-size: 7pt">           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 7pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3.2           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/812796/000095013703004369/c78859sbexv3w1.txt">             Amended    and Restated By-laws (incorporated by reference to Exhibit 3.1 included in our Quarterly Report on Form 10-QSB, as amended,    for the fiscal quarter ended June 30, 2003).            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>           <font style="font-size: 7pt">           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 7pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3.3           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/812796/000121390016014431/f8k061616ex3i_soligenix.htm">             Certificate of Amendment to Second Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 included in our current report on Form 8-K filed on June 22, 2016).            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>           <font style="font-size: 7pt">           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 7pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3.4           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/812796/000121390016017367/f8k100716ex3i_soligenixinc.htm">             Certificate of Amendment to Second Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 included in our current report on Form 8-K filed on October 7, 2016).            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>           <font style="font-size: 7pt">           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 7pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3.5           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/812796/000121390017006494/f8k060817ex3i_soligenixinc.htm">             Certificate of Amendment to Second Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 included in our current report on Form 8-K filed on June 14, 2017).            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>           <font style="font-size: 7pt">           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 7pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3.6           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/812796/000121390018013207/f8k092718ex3-1_soligenixinc.htm">             Certificate of Amendment to Second Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 of our current report on Form 8-K filed on September 28, 2018).            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>           <font style="font-size: 7pt">           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 7pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3.7           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/812796/000121390020040767/ea130873ex3-1_soligenix.htm">             Certificate of Amendment to Second Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 of amendment number 1 to current report on Form 8-K filed on December 3, 2020).            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>           <font style="font-size: 7pt">           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 7pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <p style="margin: 0pt 0">            3.8           </p>          </td>          <td style="text-align: justify">           <p style="margin: 0pt 0">            <a href="http://www.sec.gov/Archives/edgar/data/812796/000121390020012580/f10q0320ex3-1_soligenixinc.htm">             Amendment to Amended and Restated By-laws (incorporated by reference to Exhibit 3.1 included in our Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2020).            </a>           </p>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>           <font style="font-size: 7pt">           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 7pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4.1           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/812796/000121390016019484/f8k121316ex10i_soligenix.htm">             Warrant Agency Agreement by and between the Company and American Stock Transfer &amp; Trust Company, LLC (incorporated by reference to Exhibit 10.1 included in our current report on Form 8-K filed on December 16, 2016).            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>           <font style="font-size: 7pt">           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 7pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4.2           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/812796/000121390016018265/fs11016a1ex4xv_soligenixinc.htm">             Representative’s Warrant (incorporated by reference to Exhibit 4.15 included in our Registration Statement on Form S-1 (File No. 333-214038) filed on November 14, 2016).            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>           <font style="font-size: 7pt">           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 7pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4.3           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/812796/000121390017011103/f8k103117ex4-1_soligenixinc.htm">             Form of Warrant to be issued to Aegis Capital Corp. (incorporated by reference to Exhibit 4.1 included in our current report on Form 8-K filed on October 31, 2017).            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>           <font style="font-size: 7pt">           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 7pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4.4           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/812796/000121390018007967/fs12018a2ex4-8_soligenix.htm">             Form of Warrant to be issued to each investor in the June 2018 registered public offering Form of Warrant to (incorporated by reference to Exhibit 4.8 included in our Amendment No. 2 to Registration Statement on Form S-1 (File No. 333-225226) filed on June 20, 2018).            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>           <font style="font-size: 7pt">           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 7pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4.5           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/812796/000121390018007821/fs12018a1ex4-9_soligenix.htm">             Form of Representative’s Warrant (incorporated by reference to Exhibit 4.9 included in our Amendment No. 1 to Registration Statement on Form S-1 (File No. 333-225226) filed on June 18, 2018).            </a>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="margin: 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 75; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         72         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="width: 10%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4.6           </font>          </td>          <td style="text-align: justify; width: 90%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="f10k2020ex4-6_soligenix.htm">             Description of Securities. *            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4.7           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/812796/000121390020043028/ea131740ex4-1_soligenix.htm">             Registration Rights Agreement, dated December 15, 2020 by and among Soligenix, Inc. and the other parties named therein (incorporated by reference to Exhibit 4.1 included in our current report on Form 8-K filed on December 16, 2020).            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td>          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="width: 10%; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10.1           </font>          </td>          <td style="width: 90%; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/812796/000101540204001290/exhibit10w9.htm">             License Agreement between the Company and the University of Texas Southwestern Medical Center (incorporated by reference to Exhibit 10.9 included in our Annual Report on Form 10-KSB filed March 30, 2004, as amended, for the fiscal year ended December 31, 2004).            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: justify">           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10.2           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/812796/000121390013005475/f8k092513ex10i_soligenixinc.htm">             2005 Equity Incentive Plan, as amended on September 25, 2013 (incorporated by reference to Exhibit 10.1 included in our current report on Form 8-K filed on September 30, 2013). **            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: justify">           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10.3           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/812796/000081279605000035/dor05planinc.htm">             Form S-8 Registration of Stock Options Plan dated December 30, 2005 (incorporated by reference to our registration statement on Form S-8 filed on December 30, 2005).            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: justify">           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10.4           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/812796/000121390014004368/fs82014_soligenixinc.htm">             Form S-8 Registration of Stock Options Plan dated June 20, 2014 (incorporated by reference to our registration statement on Form S-8 filed on June 20, 2014).            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: justify">           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10.5           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/812796/000121390015009444/fs82015_soligenixinc.htm">             Form S-8 Registration of Stock Options Plan dated December 11, 2015 (incorporated by reference to our registration statement on Form S-8 filed on December 14, 2015).            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: justify">           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10.6           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/812796/000081279609000018/clavijoempagree.htm">             Employment Agreement dated December 27, 2007, between Christopher J. Schaber, PhD and the Company (incorporated by reference to Exhibit 10.30 included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2008). **            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: justify">           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10.7           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/812796/000081279609000009/licenseagreementmcdonald.htm">             Exclusive License Agreement dated November 24, 1998, between Enteron Pharmaceuticals, Inc. and George B. McDonald, MD and amendments (incorporated by reference to Exhibit 10.42 included in our Registration Statement on Form S-1 (File No. 333             <b>              -             </b>             157322) filed on February 13, 2009).            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: justify">           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10.8           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/812796/000121390011003682/f8k071211ex10i_soligenix.htm">             First Amendment to Employment Agreement dated as of July 12, 2011, between the Company and Christopher J. Schaber, PhD (incorporated by reference to Exhibit 10.1 of our current report on Form 8-K filed on July 14, 2011).**            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: justify">           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10.9           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/812796/000121390011003926/f8k072611ex10ii_soligenix.htm">             Amendment to the Exclusive License Agreement dated as of July 26, 2011, between George McDonald, MD and the Company (incorporated by reference to Exhibit 10.2 of our current report on Form 8-K filed on July 28, 2011).            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: justify">           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="padding-left: 31.5pt; text-align: justify; text-indent: -31.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10.10           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/812796/000121390012007000/f8k122012ex10i_soligenix.htm">             Amendment No. 2 to the Collaboration and Supply Agreement between the Company, Enteron and Sigma-Tau dated as of December 20, 2012 (incorporated by reference to Exhibit 10.1 of our current report on Form 8-K filed on December 27, 2012). †            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="padding-left: 31.5pt; text-align: justify; text-indent: -31.5pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="padding-left: 31.5pt; text-align: justify; text-indent: -31.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10.11           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/812796/000121390012007000/f8k122012ex10iv_soligenix.htm">             Amendment to Exclusive License Agreement dated as of December 20, 2012 between Enteron and McDonald (incorporated by reference to Exhibit 10.4 of our current report on Form 8-K filed on December 27, 2012).            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: justify">           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="padding-left: 31.5pt; text-align: justify; text-indent: -31.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10.12           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/812796/000121390012007000/f8k122012ex10v_soligenix.htm">             Amendment to Consulting Agreement dated as of December 20, 2012 between Enteron and McDonald (incorporated by reference to Exhibit 10.5 of our current report on Form 8-K filed on December 27, 2012).            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="text-align: justify">           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="padding-left: 31.5pt; text-align: justify; text-indent: -31.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10.13           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/812796/000121390013005354/f8k091813ex10i_soligenix.htm">             Contract HHSO100201300023C dated September 18, 2013 between the Company and the U.S. Department of Health and Human Services Biomedical Advanced Research and Development Authority (incorporated by reference to Exhibit 10.1 of our current report on Form 8-K filed on September 24, 2013). †            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="padding-left: 31.5pt; text-align: justify; text-indent: -31.5pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="padding-left: 31.5pt; text-align: justify; text-indent: -31.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10.14           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/812796/000121390013005475/f8k092513ex10i_soligenixinc.htm">             Contract HHSN272201300030C dated September 24, 2013 by and between the Company and the National Institutes of Health (incorporated by reference to Exhibit 10.1 of our current report on Form 8-K filed on September 30, 2013). †            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="padding-left: 31.5pt; text-align: justify; text-indent: -31.5pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="padding-left: 31.5pt; text-align: justify; text-indent: -31.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10.15           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/812796/000121390014000098/f8k010614ex10i_soligenix.htm">             Employment Agreement dated as of January 6, 2014 between the Company and Richard Straube, M.D. (incorporated by reference to Exhibit 10.1 of our current report on Form 8-K filed on January 8, 2014). **            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="padding-left: 31.5pt; text-align: justify; text-indent: -31.5pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="padding-left: 31.5pt; text-align: justify; text-indent: -31.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10.16           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/812796/000121390014006428/f8k090314ex10i_soligenix.htm">             Asset Purchase Agreement dated September 3, 2014 between the Company and Hy Biopharma, Inc. (incorporated by reference to Exhibit 10.1 of our current report on Form 8-K filed on September 5, 2014). †            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="padding-left: 31.5pt; text-align: justify; text-indent: -31.5pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="padding-left: 31.5pt; text-align: justify; text-indent: -31.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10.17           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/812796/000121390014006428/f8k090314ex10ii_soligenix.htm">             Registration Rights Agreement dated September 3, 2014 between the Company and Hy Biopharma, Inc. (incorporated by reference to Exhibit 10.2 of our current report on Form 8-K filed on September 5, 2014).            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="padding-left: 31.5pt; text-align: justify; text-indent: -31.5pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="padding-left: 31.5pt; text-align: justify; text-indent: -31.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10.18           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/812796/000121390014006848/f8k091714ex10i_soligenix.htm">             Contract HHSN272201400039C dated September 17, 2014 by and between the Company and the National Institutes of Health (incorporated by reference to Exhibit 10.1 of our current report on Form 8-K filed on September 23, 2014). †            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="padding-left: 31.5pt; text-align: justify; text-indent: -31.5pt">           <font style="font-size: 8pt">           </font>          </td>          <td style="text-align: justify">           <font style="font-size: 8pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="padding-left: 31.5pt; text-align: justify; text-indent: -31.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10.19           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/812796/000121390015002035/f10k2014ex10xlii_soligenix.htm">             Lease Agreement dated November 21, 2014, between the Company and CPP II, LLC (incorporated by reference to Exhibit 10.42 included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2014).            </a>           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <!-- Field: Page; Sequence: 76; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         73         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="width: 10%; padding-left: 31.5pt; text-align: justify; text-indent: -31.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10.20           </font>          </td>          <td style="width: 90%; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/812796/000121390017008500/f10q0617ex1i_soligenix.htm">             At Market Issuance Sales Agreement dated August 11, 2017 between Soligenix, Inc. and FBR Capital Markets &amp; Co. (incorporated by reference to Exhibit 1.1 included in our Quarter Report on Form 10-Q for the fiscal quarter ended June 30, 2017).            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="padding-left: 31.5pt; text-align: justify; text-indent: -31.5pt">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="padding-left: 31.5pt; text-align: justify; text-indent: -31.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10.21           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/812796/000121390017011103/f8k103117ex10-3_soligenixinc.htm">             Form of Registration Rights Agreement dated October 31, 2017 (incorporated by reference to Exhibit 10.3 included in our current report on Form 8-K filed on October 31, 2017).            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="padding-left: 31.5pt; text-align: justify; text-indent: -31.5pt">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="padding-left: 31.5pt; text-align: justify; text-indent: -31.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10.22           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/812796/000121390019004865/f10k2018ex10-30_soligenix.htm">             First Amendment to Employment Agreement dated as of April 1, 2019 between the Company and Richard Straube, M.D. (incorporated by reference to Exhibit 10.30 included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2018.**            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="padding-left: 31.5pt; text-align: justify; text-indent: -31.5pt">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="padding-left: 31.5pt; text-align: justify; text-indent: -31.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10.23           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/812796/000121390019017733/f8k090619ex10-1_soligenix.htm">             Soligenix, Inc. 2015 Equity Incentive Plan, as amended on as amended on June 18, 2017 and September 27, 2018 and as proposed to be amended on September 6, 2019 (incorporated by reference to Exhibit 10.1 included in our current report on Form 8-K filed on September 11, 2019).            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="padding-left: 31.5pt; text-align: justify; text-indent: -31.5pt">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="width: 10%; padding-left: 31.5pt; text-align: justify; text-indent: -31.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10.24           </font>          </td>          <td style="width: 90%; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/812796/000121390019017733/f8k090619ex10-2_soligenix.htm">             Employment Agreement dated as of September 6, 2019 between the Company and Jonathan L. Guarino (incorporated by reference to Exhibit 10.2 included in our current report on Form 8-K filed on September 11, 2019).**            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="padding-left: 31.5pt; text-align: justify; text-indent: -31.5pt">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="padding-left: 31.5pt; text-align: justify; text-indent: -31.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10.25           </font>          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/812796/000121390020000155/f8k010220ex10-1_soligenixinc.htm">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Second Amendment to Employment Agreement dated as of January 2, 2020, between Soligenix, Inc. and Christopher J. Schaber, PhD (incorporated by reference to Exhibit 10.2 included in our current report on Form 8-K filed on January 3, 2020).**            </font>           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="padding-left: 31.5pt; text-align: justify; text-indent: -31.5pt">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="padding-left: 31.5pt; text-align: justify; text-indent: -31.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10.26           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/812796/000121390020024260/ea126067ex10-2_soligenix.htm">             Amendment No. 1 to At Market Issuance Sales Agreement dated August 28, 2020 between Soligenix, Inc. and B. Riley FBR, Inc. (incorporated by reference to Exhibit 10.2 included in our current report on Form 8-K filed on August 28, 2020).            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="padding-left: 31.5pt; text-align: justify; text-indent: -31.5pt">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="padding-left: 31.5pt; text-align: justify; text-indent: -31.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10.27           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/812796/000121390020036345/f10q0920ex10-1_soligenix.htm">             Third    Extension and    Amendment to Lease dated July 7, 2020 between CPP II LLC and Soligenix,    Inc. (incorporated by reference to Exhibit 10.1 included in our Quarterly Report on Form 10-Q for the fiscal quarter ended September    30, 2020).            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="padding-left: 31.5pt; text-align: justify; text-indent: -31.5pt">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="padding-left: 31.5pt; text-align: justify; text-indent: -31.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10.28           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="http://www.sec.gov/Archives/edgar/data/812796/000121390020043028/ea131740ex10-1_soligenix.htm">             Loan and Security Agreement, dated December 15, 2020. (incorporated by reference to Exhibit 10.1 included in our current report on Form 8-K filed on December 16, 2020).            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="padding-left: 31.5pt; text-align: justify; text-indent: -31.5pt">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="padding-left: 31.5pt; text-align: justify; text-indent: -31.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            10.29           </font>          </td>          <td style="text-align: justify">           <a href="http://www.sec.gov/Archives/edgar/data/812796/000121390020043028/ea131740ex10-2_soligenix.htm">            Third Amendment to Employment Agreement dated as of December 10, 2020, between Soligenix, Inc. and Christopher J. Schaber, PhD. (incorporated by reference to Exhibit 10.2 included in our current report on Form 8-K filed on December 16, 2020). **           </a>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="padding-left: 31.5pt; text-align: justify; text-indent: -31.5pt">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="padding-left: 31.5pt; text-align: justify; text-indent: -31.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            21.1           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="f10k2020ex21-1_soligenix.htm">             Subsidiaries of the Company. *            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="padding-left: 31.5pt; text-align: justify; text-indent: -31.5pt">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="padding-left: 31.5pt; text-align: justify; text-indent: -31.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            23.1           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="f10k2020ex23-1_soligenix.htm">             Consent of EisnerAmper LLP. *            </a>           </font>           <font style="font-size: 10pt">           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="padding-left: 31.5pt; text-align: justify; text-indent: -31.5pt">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="padding-left: 31.5pt; text-align: justify; text-indent: -31.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            31.1           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="f10k2020ex31-1_soligenix.htm">             Certification of the Chief Executive Officer pursuant to Exchange Act rule 13(a)-14(a) (under Section 302 of the Sarbanes-Oxley Act of 2002). *            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="padding-left: 31.5pt; text-align: justify; text-indent: -31.5pt">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="padding-left: 31.5pt; text-align: justify; text-indent: -31.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            31.2           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="f10k2020ex31-2_soligenix.htm">             Certification of the Chief Financial Officer pursuant to Exchange Act rule 13(a)-14(a) (under Section 302 of the Sarbanes-Oxley Act of 2002). *            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="padding-left: 31.5pt; text-align: justify; text-indent: -31.5pt">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="padding-left: 31.5pt; text-align: justify; text-indent: -31.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            32.1           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="f10k2020ex32-1_soligenix.htm">             Certification of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. *            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="padding-left: 31.5pt; text-align: justify; text-indent: -31.5pt">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top; background-color: rgb(204,238,255)">          <td style="padding-left: 31.5pt; text-align: justify; text-indent: -31.5pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            32.2           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <a href="f10k2020ex32-2_soligenix.htm">             Certification of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. *            </a>           </font>          </td>         </tr>         <tr style="vertical-align: top; background-color: White">          <td style="padding-left: 31.5pt; text-align: justify; text-indent: -31.5pt">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="width: 10%; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            101.INS           </font>          </td>          <td style="width: 90%; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            XBRL Instance Document           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            101.SCH           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            XBRL Taxonomy Extension Schema Document           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            101.CAL           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            XBRL Taxonomy Extension Calculation Linkbase Document           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            101.DEF           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            XBRL Taxonomy Extension Definition Linkbase Document           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            101.LAB           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            XBRL Taxonomy Extension Label Linkbase Document           </font>          </td>         </tr>         <tr style="background-color: White">          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="background-color: rgb(204,238,255)">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            101.PRE           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            XBRL Taxonomy Extension Presentation Linkbase Document           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            *           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Filed herewith.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            **           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Indicates management    contract or compensatory plan.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            †           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Portions of this    exhibit have been omitted pursuant to a request for confidential treatment.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <!-- Field: Page; Sequence: 77; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         74         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <a name="a_019">          </a>          SIGNATURES         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Inaccordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned,thereunto duly authorized.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td colspan="2">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             SOLIGENIX, INC.            </b>           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td colspan="2">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="width: 60%">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 4%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             By:            </b>           </font>          </td>          <td style="border-bottom: black 1.5pt solid; width: 36%">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             /s/    Christopher J. Schaber            </b>           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Christopher J. Schaber, PhD           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Chief Executive Officer and President           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Date:March 30, 2021        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Inaccordance with the Exchange Act, this report has been signed below by the following persons on behalf of the registrant and inthe capacities indicated and on the dates indicated.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom">          <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Name            </b>           </font>          </td>          <td style="width: 2%">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Capacity            </b>           </font>          </td>          <td style="width: 2%">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Date            </b>           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="border-bottom: black 1.5pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             /s/    Christopher J. Schaber            </b>           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Chairman of the Board,    Chief Executive Officer and           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            March 30, 2021           </font>          </td>         </tr>         <tr>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Christopher J. Schaber,    PhD           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            President    (principal executive officer)           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="border-bottom: black 1.5pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             /s/    Gregg A. Lapointe            </b>           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Director           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            March 30, 2021           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Gregg A. Lapointe, CPA           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="border-bottom: black 1.5pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             /s/    Diane L. Parks            </b>           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Director           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            March 30, 2021           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Diane L. Parks, MBA           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="border-bottom: black 1.5pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             /s/    Robert J. Rubin            </b>           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Director           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            March 30, 2021           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Robert J. Rubin, MD           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="border-bottom: black 1.5pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             /s/    Jerome B. Zeldis            </b>           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Director           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            March 30, 2021           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Jerome B. Zeldis, MD, PhD           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="border-bottom: black 1.5pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             /s/    Jonathan Guarino            </b>           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Chief Financial Officer,    Senior Vice President, and           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            March 30, 2021           </font>          </td>         </tr>         <tr>          <td style="vertical-align: top">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Jonathan Guarino,    CPA, CGMA           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Corporate    Secretary (principal accounting officer)           </font>          </td>          <td style="vertical-align: bottom">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="vertical-align: bottom; text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 78; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         75         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         <b>          SOLIGENIX,INC. AND SUBSIDIARIES         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <a name="a_020">          </a>          CONSOLIDATEDFINANCIAL STATEMENTS         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         <b>          Tableof Contents         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">        <tbody>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-bottom: 1.5pt; background-color: White">          </td>          <td style="border-bottom: Black 1.5pt solid; background-color: White; text-align: center">           <b>            Page           </b>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 91%">           <a href="#a_0001">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Consolidated Balance Sheets    as of December 31, 2020 and 2019            </font>           </a>          </td>          <td style="width: 9%; text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            F-2           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>           <a href="#a_0002">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Consolidated Statements of Operations for the    Years Ended December 31, 2020 and 2019            </font>           </a>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            F-3           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td>           <a href="#a_0003">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Consolidated Statements of Comprehensive Loss    for the Years Ended December 31, 2020 and 2019            </font>           </a>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            F-4           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>           <a href="#a_0004">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Consolidated Statements of    Changes in Shareholders’ Equity for the Years Ended December 31, 2020 and 2019            </font>           </a>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            F-5           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td>           <a href="#a_0005">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Consolidated Statements of Cash Flows for the    Years Ended December 31, 2020 and 2019            </font>           </a>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            F-6           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>           <a href="#a_0006">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Notes to Consolidated Financial Statements            </font>           </a>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            F-7 - F-23           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td>           <a href="#a_0007">            <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">             Report of Independent Registered Public Accounting    Firm            </font>           </a>          </td>          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            F-24           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 79; Options: NewSection; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         1         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <a name="a_0001">          </a>          Soligenix,Inc. and Subsidiaries          <br/>          Consolidated Balance Sheets          <br/>          As of December 31, 2020 and 2019         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: center">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2020          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-weight: bold">           Assets          </td>          <td>          </td>          <td colspan="2">          </td>          <td>          </td>          <td>          </td>          <td colspan="2">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom">          <td>           Current assets:          </td>          <td>          </td>          <td colspan="2">          </td>          <td>          </td>          <td>          </td>          <td colspan="2">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 76%; text-align: left; padding-left: 0.25in">           Cash and cash equivalents          </td>          <td style="width: 1%; font-weight: bold">          </td>          <td style="width: 1%; font-weight: bold; text-align: left">           $          </td>          <td style="width: 9%; font-weight: bold; text-align: right">           18,676,663          </td>          <td style="width: 1%; font-weight: bold; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           5,420,708          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-left: 0.25in">           Contracts and grants receivable          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           203,774          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           1,018,835          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-left: 0.25in">           Research and development incentives receivable          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           361,096          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           444,043          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">           Prepaid expenses and other current assets          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">           225,473          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           609,739          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left">           Total current assets          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           19,467,006          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           7,493,325          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left">           Security deposit          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           22,777          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           22,757          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in">           Office furniture and equipment, net of accumulated depreciation of $158,769 and $135,038, respectively          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           23,510          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           36,093          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left">           Deferred issuance cost          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           53,523          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           39,324          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left">           Intangible assets, net          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           -          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           19,699          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left">           Right-of-use lease assets          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           228,027          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           125,412          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left">           Research and development incentives receivable          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           73,142          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 1.5pt">           Other assets          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">           23,250          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           38,750          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-bottom: 4pt">           Total assets          </td>          <td style="font-weight: bold; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">           19,891,235          </td>          <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           7,775,360          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-weight: bold; text-align: left">           Liabilities and shareholders’ equity          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left">           Current liabilities:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-left: 0.25in">           Accounts payable          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">           $          </td>          <td style="font-weight: bold; text-align: right">           2,129,844          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           2,735,442          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-left: 0.25in">           Accrued expenses          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           2,638,308          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           3,157,386          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-left: 0.25in">           Accrued compensation          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           875,096          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           298,173          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-left: 0.25in">           Paycheck protection program loan          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           324,979          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-bottom: 1.5pt">           Lease liabilities - current          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">           112,294          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           121,075          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left">           Total current liabilities          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           6,080,521          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           6,312,076          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left">           Non-current liabilities:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left">           Convertible debt, net          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           9,859,739          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left">           Paycheck protection program loan          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           92,851          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">           Lease liabilities, net of current          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">           116,296          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           6,149          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-bottom: 1.5pt">           Total liabilities          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">           16,149,407          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           6,318,225          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left">           Commitments and contingencies          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left">           Shareholders’ equity:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">           Preferred stock: 350,000 shares authorized; none issued or outstanding          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; text-indent: -9pt; padding-left: 27pt">           Common stock, $.001 par value; 75,000,000 and 50,000,000 shares authorized; 30,643,656 and 21,753,124 shares issued and outstanding at December 31, 2020 and 2019, respectively          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           30,644          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           21,753          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-left: 0.25in">           Additional paid-in capital          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           196,949,655          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           177,006,004          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-left: 0.25in">           Accumulated other comprehensive loss          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           (24,337          </td>          <td style="font-weight: bold; text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (45,010          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">           Accumulated deficit          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">           (193,214,134          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">           )          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           (175,525,612          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-bottom: 1.5pt">           Total shareholders’ equity          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">           3,741,828          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           1,457,135          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 4pt">           Total liabilities and shareholders’ equity          </td>          <td style="font-weight: bold; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">           19,891,235          </td>          <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           7,775,360          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         Theaccompanying notes are an integral part of these consolidated financial statements.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 80; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         2         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <a name="a_0002">          </a>          Soligenix,Inc. and Subsidiaries          <br/>          Consolidated Statements of Operations          <br/>          For the Years Ended December 31, 2020 and 2019         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2020          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td>           Revenues:          </td>          <td>          </td>          <td colspan="2">          </td>          <td>          </td>          <td>          </td>          <td colspan="2">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 76%; text-align: left; padding-left: 0.25in">           Contract revenue          </td>          <td style="width: 1%; font-weight: bold">          </td>          <td style="width: 1%; font-weight: bold; text-align: left">           $          </td>          <td style="width: 9%; font-weight: bold; text-align: right">           1,930,533          </td>          <td style="width: 1%; font-weight: bold; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           3,215,639          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">           Grant revenue          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">           428,914          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           1,414,277          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left">           Total revenues          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           2,359,447          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           4,629,916          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-bottom: 1.5pt">           Cost of revenues          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">           (1,820,949          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">           )          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           (3,567,415          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">           Gross profit          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">           538,498          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           1,062,501          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left">           Operating expenses:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-left: 0.25in">           Research and development          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           10,145,778          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           8,122,610          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-left: 0.25in">           General and administrative          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           3,979,227          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           3,480,912          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">           Research and development expense - milestone          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">           5,000,000          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 1.5pt">           Total operating expenses          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">           19,125,005          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           11,603,522          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left">           Loss from operations          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           (18,586,507          </td>          <td style="font-weight: bold; text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (10,541,021          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left">           Other income (expense):          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-left: 0.25in">           Foreign currency transaction loss          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           (23,385          </td>          <td style="font-weight: bold; text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (7,809          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-left: 0.25in">           Interest income (expense)          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           (10,882          </td>          <td style="font-weight: bold; text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           148,968          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">           Research and development incentives          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">           95,359          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           433,594          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left">           Net loss before income taxes          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           (18,525,415          </td>          <td style="font-weight: bold; text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (9,966,268          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-bottom: 1.5pt">           Income tax benefit          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">           836,893          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           610,676          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 4pt">           Net loss          </td>          <td style="font-weight: bold; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">           (17,688,522          </td>          <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">           )          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           (9,355,592          </td>          <td style="padding-bottom: 4pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-bottom: 4pt">           Basic and diluted net loss per share          </td>          <td style="font-weight: bold; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">           (0.64          </td>          <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">           )          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           (0.48          </td>          <td style="padding-bottom: 4pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 4pt">           Basic and diluted weighted average common shares outstanding          </td>          <td style="font-weight: bold; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">           27,486,949          </td>          <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           19,376,508          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         Theaccompanying notes are an integral part of these consolidated financial statements.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 81; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         3         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         <b>          Soligenix,Inc. and Subsidiaries         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <a name="a_0003">          </a>          ConsolidatedStatements of Comprehensive Loss         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         <b>          Forthe Years Ended December 31, 2020 and 2019         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: center">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2020          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 76%; text-align: justify">           Net loss          </td>          <td style="width: 1%; font-weight: bold">          </td>          <td style="width: 1%; font-weight: bold; text-align: left">           $          </td>          <td style="width: 9%; font-weight: bold; text-align: right">           (17,688,522          </td>          <td style="width: 1%; font-weight: bold; text-align: left">           )          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           (9,355,592          </td>          <td style="width: 1%; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">           Other comprehensive loss:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">           Foreign currency translation adjustments          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">           20,673          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           (41,341          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-bottom: 4pt">           Comprehensive loss          </td>          <td style="font-weight: bold; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">           (17,667,849          </td>          <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">           )          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           (9,396,933          </td>          <td style="padding-bottom: 4pt; text-align: left">           )          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         Theaccompanying notes are an integral part of these consolidated financial statements.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 82; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         4         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <a name="a_0004">          </a>          Soligenix,Inc. and Subsidiaries          <br/>          Consolidated Statements of Changes in Shareholders’ Equity          <br/>          For the Years Ended December 31, 2020 and 2019         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">        <tbody>         <tr style="vertical-align: bottom">          <td style="padding-bottom: 1.5pt">          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           Common Stock          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td colspan="2" style="font-weight: bold; text-align: center">           Additional           <br/>           Paid–In          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td colspan="2" style="font-weight: bold; text-align: center">           Accumulated Other           <br/>           Comprehensive          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td colspan="2" style="font-weight: bold; text-align: center">           Accumulated          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">          </td>          <td style="padding-bottom: 1.5pt">          </td>         </tr>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Shares          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Par Value          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Capital          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Loss          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Deficit          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Total          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 28%; font-weight: bold; text-indent: -10pt; padding-left: 10pt">           Balance, December 31, 2018          </td>          <td style="width: 1%; font-weight: bold">          </td>          <td style="width: 1%; font-weight: bold; text-align: left">          </td>          <td style="width: 9%; font-weight: bold; text-align: right">           17,682,839          </td>          <td style="width: 1%; font-weight: bold; text-align: left">          </td>          <td style="width: 1%; font-weight: bold">          </td>          <td style="width: 1%; font-weight: bold; text-align: left">           $          </td>          <td style="width: 9%; font-weight: bold; text-align: right">           17,683          </td>          <td style="width: 1%; font-weight: bold; text-align: left">          </td>          <td style="width: 1%; font-weight: bold">          </td>          <td style="width: 1%; font-weight: bold; text-align: left">           $          </td>          <td style="width: 9%; font-weight: bold; text-align: right">           172,436,176          </td>          <td style="width: 1%; font-weight: bold; text-align: left">          </td>          <td style="width: 1%; font-weight: bold">          </td>          <td style="width: 1%; font-weight: bold; text-align: left">           $          </td>          <td style="width: 9%; font-weight: bold; text-align: right">           (3,669          </td>          <td style="width: 1%; font-weight: bold; text-align: left">           )          </td>          <td style="width: 1%; font-weight: bold">          </td>          <td style="width: 1%; font-weight: bold; text-align: left">           $          </td>          <td style="width: 9%; font-weight: bold; text-align: right">           (166,170,020          </td>          <td style="width: 1%; font-weight: bold; text-align: left">           )          </td>          <td style="width: 1%; font-weight: bold">          </td>          <td style="width: 1%; font-weight: bold; text-align: left">           $          </td>          <td style="width: 9%; font-weight: bold; text-align: right">           6,280,170          </td>          <td style="width: 1%; font-weight: bold; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">           Issuance of common stock pursuant to FBR At Market Issuance Sales Agreement          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           3,824,585          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           3,824          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           4,138,632          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           4,142,456          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">           Cost associated with issuance of common stock          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (152,517          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (152,517          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">           Issuance of common stock to vendors          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           245,700          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           246          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           205,492          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           205,738          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-indent: -10pt; padding-left: 10pt">           Exercise of common stock options          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           1,882          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           1,882          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">           Share-based compensation expense          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           376,339          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           376,339          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">           Foreign currency translation adjustment          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (41,341          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (41,341          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">           Net loss          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           (9,355,592          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           )          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           (9,355,592          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-weight: bold; text-indent: -10pt; padding-left: 10pt">           Balance, December 31, 2019          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           21,753,124          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">           $          </td>          <td style="font-weight: bold; text-align: right">           21,753          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">           $          </td>          <td style="font-weight: bold; text-align: right">           177,006,004          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">           $          </td>          <td style="font-weight: bold; text-align: right">           (45,010          </td>          <td style="font-weight: bold; text-align: left">           )          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">           $          </td>          <td style="font-weight: bold; text-align: right">           (175,525,612          </td>          <td style="font-weight: bold; text-align: left">           )          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">           $          </td>          <td style="font-weight: bold; text-align: right">           1,457,135          </td>          <td style="font-weight: bold; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">           Issuance of common stock pursuant to FBR At Market Issuance Sales Agreement          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           6,438,431          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           6,439          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           14,191,721          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           14,198,160          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">           Cost associated with issuance of common stock          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (580,456          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (580,456          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">           Issuance of common stock for milestone          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           1,956,182          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           1,956          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           4,998,044          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           5,000,000          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">           Issuance of common stock to vendors          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           30,000          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           30          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           58,970          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           59,000          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-indent: -10pt; padding-left: 10pt">           Exercise of warrants          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           460,161          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           460          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           860,458          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           860,918          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-indent: -10pt; padding-left: 10pt">           Exercise of common stock options          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           5,758          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           6          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           4,981          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           4,987          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">           Share-based compensation expense          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           409,933          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           409,933          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">           Foreign currency translation adjustment          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           20,673          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           20,673          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">           Net loss          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           (17,688,522          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           )          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           (17,688,522          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-weight: bold; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">           Balance, December 31, 2020          </td>          <td style="font-weight: bold; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">           30,643,656          </td>          <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">           30,644          </td>          <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">           196,949,655          </td>          <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">           (24,337          </td>          <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">           )          </td>          <td style="font-weight: bold; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">           (193,214,134          </td>          <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">           )          </td>          <td style="font-weight: bold; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">           3,741,828          </td>          <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         Theaccompanying notes are an integral part of these consolidated financial statements.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 83; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         5         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         <b>          Soligenix,Inc. and Subsidiaries         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <a name="a_0005">          </a>          ConsolidatedStatements of Cash Flows         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         <b>          Forthe Years Ended December 31, 2020 and 2019         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: center">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2020          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-weight: bold; text-align: justify">           Operating activities:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 76%; text-align: justify">           Net loss          </td>          <td style="width: 1%; font-weight: bold">          </td>          <td style="width: 1%; font-weight: bold; text-align: left">           $          </td>          <td style="width: 9%; font-weight: bold; text-align: right">           (17,688,522          </td>          <td style="width: 1%; font-weight: bold; text-align: left">           )          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           (9,355,592          </td>          <td style="width: 1%; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">           Adjustments to reconcile net loss to net cash used in operating activities:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify; padding-left: 9pt">           Amortization and depreciation          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           62,372          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           54,450          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-left: 9pt">           Noncash lease expense          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           130,670          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           123,110          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify; padding-left: 9pt">           Share-based compensation          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           409,933          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           376,339          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-left: 9pt">           Issuance of common stock for milestone          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           5,000,000          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify; padding-left: 9pt">           Issuance of common stock for services          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           59,000          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           159,238          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-left: 9pt">           Deferred issuance costs written off          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           61,609          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify; padding-left: 9pt">           Amortization of deferred issuance costs associated with convertible debt          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           1,205          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-left: 9pt">           Gain on disposition of office furniture          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           -          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (3,843          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify">           Change in operating assets and liabilities:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-left: 9pt">           Contracts and grants receivable          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           815,061          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           182,880          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify; padding-left: 9pt">           Prepaid expenses and other current assets          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           384,424          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (452,255          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-left: 9pt">           Security deposit          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           (20          </td>          <td style="font-weight: bold; text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (23          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify; padding-left: 9pt">           Research and development incentives receivable          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           21,924          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (444,043          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-left: 9pt">           Operating lease liability          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           (131,845          </td>          <td style="font-weight: bold; text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (121,938          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-left: 9pt">           Accounts payable and accrued expenses          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           (1,157,160          </td>          <td style="font-weight: bold; text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           1,968,565          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">           Accrued compensation          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">           576,923          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           3,545          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">           Net cash used in operating activities          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">           (11,454,426          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">           )          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           (7,509,567          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-weight: bold; text-align: justify">           Investing activities:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-left: 9pt">           Purchases of office furniture and equipment          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           (7,147          </td>          <td style="font-weight: bold; text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (30,209          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">           Proceeds from sale of office furniture          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           5,500          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0.25in">           Net cash used in investing activities          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">           (7,147          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">           )          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           (24,709          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-weight: bold; text-align: justify">           Financing activities:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify; text-indent: -0.25in; padding-left: 0.25in">           Proceeds from issuance of common stock pursuant to FBR At Market Issuance Sales Agreement          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           14,198,160          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           4,142,456          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">           Costs associated with issuance of common stock          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           (656,264          </td>          <td style="font-weight: bold; text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (132,080          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify">           Proceeds from exercise of warrants          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           860,918          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">           Proceeds from the exercises of stock options          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           4,987          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           1,882          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify">           Proceeds from paycheck protection program          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           417,830          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">           Proceeds from convertible debt          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           10,000,000          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify">           Costs associated with issuance of convertible debt          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           (141,466          </td>          <td style="font-weight: bold; text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-bottom: 1.5pt">           Principal repayment – financing lease          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">           (7,516          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">           )          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           (6,803          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0.25in">           Net cash provided by financing activities          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">           24,676,649          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           4,005,455          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-bottom: 1.5pt">           Effect of exchange rate on cash and cash equivalents          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">           40,879          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           (34,188          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left">           Net increase (decrease) in cash and cash equivalents          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           13,255,955          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (3,563,009          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0.25in">           Cash and cash equivalents at beginning of year          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">           5,420,708          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           8,983,717          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify; padding-bottom: 4pt; padding-left: 0.25in">           Cash and cash equivalents at end of year          </td>          <td style="font-weight: bold; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">           18,676,663          </td>          <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           5,420,708          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-weight: bold; text-align: justify">           Supplemental information:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify; padding-left: 0.25in">           Cash paid for state income taxes          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">           $          </td>          <td style="font-weight: bold; text-align: right">           4,021          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           11,132          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-left: 0.25in">           Cash paid for interest          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">           $          </td>          <td style="font-weight: bold; text-align: right">           34,406          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify; padding-left: 0.25in">           Cash paid for lease liabilities:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-left: 27pt">           Operating lease:          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">           $          </td>          <td style="font-weight: bold; text-align: right">           141,050          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           140,017          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify; padding-left: 27pt">           Financing lease:          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">           $          </td>          <td style="font-weight: bold; text-align: right">           8,544          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           8,544          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">           Non-cash investing and financing activities:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-indent: 0.25in; text-align: justify">           Right-of use assets and lease liabilities recorded          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">           $          </td>          <td style="font-weight: bold; text-align: right">           240,727          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           255,965          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-indent: 0.25in; text-align: justify">           Deferred issuance cost reclassified to additional-paid-in capital          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">           $          </td>          <td style="font-weight: bold; text-align: right">           67,733          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           33,535          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-indent: 0.25in; text-align: justify">           Issuance of restricted common stock to vendor for website development costs          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">           $          </td>          <td style="font-weight: bold; text-align: right">           -          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           46,500          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-indent: 0.25in; text-align: justify">           Issuance of common stock to vendor included in prepaid expenses          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">           $          </td>          <td style="font-weight: bold; text-align: right">           -          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           2,550          </td>          <td style="text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         Theaccompanying notes are an integral part of these consolidated financial statements.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">       </p>       <!-- Field: Page; Sequence: 84; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         6         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <a name="a_0006">          </a>          Soligenix,Inc. and Subsidiaries          <br/>          Notes to Consolidated Financial Statements         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          Note1. Nature of Business         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <u>          Basisof Presentation         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Soligenix,Inc. (the “Company”) is a late-stage biopharmaceutical company focused on developing and commercializing productsto treat rare diseases where there is an unmet medical need. The Company maintains two active business segments: Specialized BioTherapeutics(formerly “BioTherapeutics”) and Public Health Solutions (formerly “Vaccines/BioDefense”).        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         TheCompany’s Specialized BioTherapeutics business segment is developing and moving toward commercialization of SGX301 (synthetichypericin) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (“CTCL”).With a successful Phase 3 study completed, regulatory approval is being sought and commercialization activities for this productcandidate are being advanced initially in the United States (“U.S.”). Development programs in this business segmentalso include a first-in-class innate defense regulator (“IDR”) technology, dusquetide (SGX942) for the treatment ofinflammatory diseases, including oral mucositis in head and neck cancer, and proprietary formulations of oral beclomethasone 17,21-dipropionate(“BDP”) for the prevention/treatment of gastrointestinal (“GI”) disorders characterized by severe inflammationincluding pediatric Crohn's disease (SGX203) and acute radiation enteritis (SGX201).        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         TheCompany’s Public Health Solutions business segment includes active development programs for RiVax         <sup>          ®         </sup>         , its ricintoxin vaccine candidate and SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease and itsvaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax         <sup>          TM         </sup>         , a vaccine candidate for the preventionof COVID-19 (caused by SARS-CoV-2). The development of its vaccine programs incorporates the use of the proprietary heat stabilizationplatform technology, known as ThermoVax         <sup>          ®         </sup>         . With the government funding from the National Institute of Allergy andInfectious Diseases (“NIAID”) and the Defense Threat Reduction Agency (“DTRA”), the Company will attemptto advance its programs.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company generates revenues under governmentgrants primarily from the National Institutes of Health (“NIH”) and government contracts from NIAID. The Company iscurrently developing RiVax® under a NIAID contract of up to $21.2 million over six years, a one-year NIH grant of $150,000in support of its SGX942 pediatric program and a two year $1.5M NIH grant to support manufacture, formulation (including thermostabilization)and characterization of COVID-19 and Ebola Virus Disease vaccine candidates in conjunction with the CoVaccine HT™ adjuvant.In addition, the Company has a subcontract of approximately $700,000 from a NIAID grant over five years for its thermostabilizationtechnology, and a DTRA subcontract of approximately $600,000 over three years for SGX943. The Company will continue to apply foradditional government funding.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         TheCompany is subject to risks common to companies in the biotechnology industry including, but not limited to, development of newtechnological innovations, dependence on key personnel, protections of proprietary technology, compliance with the United States(“U.S.”) Food and Drug Administration (the “FDA”) regulations, and other regulatory authorities, litigation,and product liability.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <u>          Liquidity         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        In accordance with Accounting Standards Codification205-40, Going Concern, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raisesubstantial doubt about the Company’s ability to continue as a going concern within one year after the date the consolidatedfinancial statements are issued. As of December 31, 2020, the Company had an accumulated deficit of $193,214,134. During the yearended December 31, 2020, the Company incurred a net loss of $17,688,522 and used $11,454,426 of cash in operations. The Companyexpects to continue to generate losses in the foreseeable future. The Company’s liquidity needs will be largely determinedby the budgeted operational expenditures incurred in regards to the progression of its product candidates. The Company’splans to meet its liquidity needs primarily include its ability to control the timing and spending on its research and developmentprograms and raising additional funds through potential partnerships and/or financings. From January 1, 2021 through March 30,2021, the Company sold 9,376,792 shares of common stock pursuant to the At the Market Issuance Sales Agreement (“FBR SalesAgreement”) with B. Riley FBR, Inc. (“FBR”) at a weighted average price of $1.75 per share. Based on the Company’sapproved operating budget, current rate of cash outflows, cash on hand, proceeds from government contract and grant programs, andproceeds available from the FBR Sales Agreement with FBR, management believes that its current cash will be sufficient to meetthe anticipated cash needs for working capital and capital expenditures for at least the next 12 months from issuance of the financialstatements.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 85; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         7         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0">        As of December 31, 2020, the Company had cash and cash equivalentsof $18,676,663 as compared to $5,420,708 as of December 31, 2019, representing an increase of $13,255,955 or 245%. As of December31, 2020, the Company had working capital of $13,386,485 as compared to working capital of $1,181,249, for the prior year, representingan increase of $12,205,236. The increase in cash and cash equivalents was primarily the result of proceeds from financing activitiespartially offset by cash used in operations.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Management’sbusiness strategy can be outlined as follows:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Following positive primary endpoint results for the Phase 3 clinical trial of SGX301, as well as further statistically significant improvement in response rates with longer treatment (18 weeks compared to 12 and 6 weeks of treatment), pursue New Drug Application (“NDA”) filing and commercialization in the U.S. while continuing to explore ex-U.S. partnership.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; font-size: 10pt">          </td>          <td style="width: 24px; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Continue to analyze the full dataset from the Phase 3 clinical trial of SGX942 to better understand why the study did not achieve the statistically significant benefit expected, despite demonstrating clinically meaningful reductions in oral mucositis consistent with the previous Phase 2 study. Any clarity gained from further analysis, especially with respect to specific subsets of patients that may benefit from SGX942 therapy, will be communicated to and discussed with the FDA and the European Medicines Agency.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Continue development of RiVax            <sup>             ®            </sup>            in combination with the Company’s ThermoVax            <sup>             ®            </sup>            technology to develop a new heat stable vaccine in biodefense with NIAID funding support.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Continue to apply for and secure additional government funding for each of the Company’s Specialized BioTherapeutics and Public Health Solutions programs through grants, contracts and/or procurements.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Pursue business development opportunities for the Company’s pipeline programs, as well as explore merger/acquisition strategies.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Acquire or in-license new clinical-stage compounds for development.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">        <font style="font-family: Times New Roman, Times, Serif">         TheCompany’s plans with respect to its liquidity management include, but are not limited to, the following:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.5in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.5in">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The Company has up to $2.16 million in active government contract and grant funding still available as of December 31, 2020 to support its associated research programs through 2022 and beyond, provided the federal agencies do not elect to terminate the contracts or grants for convenience. The Company plans to submit additional contract and grant applications for further support of its programs with various funding agencies;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The Company has continued to use equity instruments to provide a portion of the compensation due to vendors and collaboration partners and expects to continue to do so for the foreseeable future;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The Company will continue to pursue Net Operating Loss (“NOL”) sales in the state of New Jersey pursuant to its Technology Business Tax Certificate Transfer Program if available;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The Company plans to pursue potential partnerships for pipelineprograms. However, there can be no assurances that the Company can consummate such transactions;           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">          </td>          <td style="text-align: justify; font-size: 10pt">          </td>         </tr>         <tr style="vertical-align: top">          <td style="font-size: 10pt">          </td>          <td style="font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The Company has up to $10.0 million remaining available from the loan and security agreement with Pontifax Medison Finance as of March 30, 2021, which includes an immediately available $5 million line of credit and a $5 million late withdrawal loan that is contingent upon the initial filing of the NDA for CTCL;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The Company has up to $2.1 million remaining from the FBR Sales Agreement as of March 30, 2021 under the prospectus supplement updated August 28, 2020; and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The Company may seek additional capital in the private and/or public equity markets, to continue its operations, respond to competitive pressures, develop new products and services, and to support new strategic partnerships. The Company is evaluating additional equity/debt financing opportunities on an ongoing basis and may execute them when appropriate. However, there can be no assurances that the Company can consummate such a transaction, or consummate a transaction at favorable pricing.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.5in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 86; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         8         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          Note2. Summary of Significant Accounting Policies         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <u>          Principlesof Consolidation         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Theconsolidated financial statements include Soligenix, Inc., and its wholly and majority owned subsidiaries. All significant intercompanyaccounts and transactions have been eliminated as a result of consolidation.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <u>          OperatingSegments         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Operatingsegments are defined as components of an enterprise about which separate financial information is available that is evaluatedon a regular basis by the chief operating decision maker, or decision making group, in deciding how to allocate resources to anindividual segment and in assessing the performance of the segment. The Company divides its operations into two operating segments:Specialized BioTherapeutics and Public Health Solutions.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <u>          Cashand Cash Equivalents         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         TheCompany considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <u>          Contractsand Grants Receivable         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Contractsand grants receivable consist of amounts due from various grants from the NIH and contracts from NIAID, an institute of NIH, forcosts incurred prior to the period end under reimbursement contracts. The amounts were billed to the respective governmental agenciesin the month subsequent to period end and collected shortly thereafter. Accordingly, no allowance for doubtful amounts has beenestablished. If amounts become uncollectible, they are charged to operations.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <u>          IntangibleAssets         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Oneof the most significant estimates or judgments that the Company makes is whether to capitalize or expense patent and license costs.The Company makes this judgment based on whether the technology has alternative future uses, as defined in Financial AccountingStandards Board (“FASB”) Accounting Standards Codification (“ASC”) 730,         <i>          Research and Development         </i>         .Based on this consideration, the Company capitalizes payments made to legal firms that are engaged in filing and protecting rightsto intellectual property and rights for its current products in both the domestic and international markets. The Company believesthat patent rights are one of its most valuable assets. Patents and patent applications are a key component of intellectual property,especially in the early stage of product development, as their purchase and maintenance gives the Company access to key productdevelopment rights from Soligenix’s academic and industry partners. These rights can also be sold or sub-licensed as partof its strategy to partner its products at each stage of development as the intangible assets have alternative future use. Thelegal costs incurred for these patents consist of work associated with filing new patents designed to protect, preserve and maintainthe Company’s rights, and perhaps extend the lives of the patents. The Company capitalizes such costs and amortizes intangibleson a straight-line basis over their expected useful life – generally a period of 11 to 16 years.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         TheCompany did not capitalize any patent related costs during the years ended December 31, 2020 or 2019.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 87; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         9         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <u>          WebsiteDevelopment Costs         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In February 2019, Altamont PharmaceuticalHoldings, LLC (“Altamont”), a company which owned 5% or more of the Company’s shares of common stock at thetime, signed a service agreement with a third-party vendor to re-develop the Company’s website. Upon completion of the projectat the end of June 2019, the Company capitalized the related website development costs of $46,500 in accordance with FASB CodificationASC 350-50 “Accounting for Web Site Development Costs.” During the quarter ended September 30, 2019, the Company beganamortizing the website development costs on a straight-line basis over three years, the estimated useful life of the website.The Company will also review its capitalized website development costs periodically for impairment. Website amortization expensefor 2020 and 2019 was $15,500 and $7,750, respectively, and accumulated amortization was $23,250 and $7,750, respectively, asof December 31, 2020 and 2019. Website development costs are included in the other assets in the accompanying consolidated balancesheets.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <u>          Impairmentof Long-Lived Assets         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Officefurniture and equipment, website development costs and intangible assets with finite lives are evaluated and reviewed for impairmentwhenever events or changes in circumstances indicate that the carrying amount may not be recoverable. The Company recognizes impairmentof long-lived assets in the event the net book value of such assets exceeds the estimated future undiscounted cash flows attributableto such assets. If the sum of the expected undiscounted cash flows is less than the carrying value of the related asset or groupof assets, a loss is recognized for the difference between the fair value and the carrying value of the related asset or groupof assets. Such analyses necessarily involve significant judgment.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         TheCompany did not record any impairment of long-lived assets for the years ended December 31, 2020 or 2019.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <u>          FairValue of Financial Instruments         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         FASBASC 820 —         <i>          Fair Value Measurements and Disclosures,         </i>         defines fair value as the price that would be received tosell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.FASB ASC 820 requires disclosures about the fair value of all financial instruments, whether or not recognized, for financialstatement purposes. Disclosures about the fair value of financial instruments are based on pertinent information available tothe Company on December 31, 2020. Accordingly, the estimates presented in these financial statements are not necessarilyindicative of the amounts that could be realized on disposition of the financial instruments.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         FASBASC 820 specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observableor unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect marketassumptions. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities(Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement).        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 88; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         10         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Thethree levels of the fair value hierarchy are as follows:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Level 1 —    Quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at    the measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such    as exchange-traded instruments and listed equities.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Level 2 —    Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or    indirectly. Level 2 includes financial instruments that are valued using models or other valuation methodologies. These models    consider various assumptions, including volatility factors, current market prices and contractual prices for the underlying    financial instruments. Substantially all of these assumptions are observable in the marketplace, can be derived from observable    data or are supported by observable levels at which transactions are executed in the marketplace.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            Level 3 —    Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined    using pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is    unobservable.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The carrying amounts reported in the consolidatedbalance sheets for cash and cash equivalents, contracts and grants receivable, research and development incentives receivable,accounts payable, accrued expenses, and accrued compensation approximate their fair value based on the short-term maturity of theseinstruments.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The carrying amounts reported in the consolidatedbalance sheets for convertible debt and the loan under the Paycheck Protection Program (“PPP”) approximate their fairvalue based on their maturity dates.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <u>          RevenueRecognition         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         TheCompany’s revenues are primarily generated from government contracts and grants. The revenue from government contracts andgrants is based upon subcontractor costs and internal costs incurred that are specifically covered by the contracts and grants,plus a facilities and administrative rate that provides funding for overhead expenses and management fees. These revenues arerecognized when expenses have been incurred by subcontractors or when the Company incurs reimbursable internal expenses that arerelated to the government contracts and grants.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <u>          Researchand Development Costs         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Research and development costs are chargedto expense when incurred in accordance with FASB ASC 730,        <i>         Research and Development        </i>        . Research and development includes costssuch as clinical trial expenses, contracted research and license agreement fees with no alternative future use, supplies and materials,salaries, share-based compensation, employee benefits, equipment depreciation and allocation of various corporate costs.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <u>          Share-BasedCompensation         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Stockoptions are issued with an exercise price equal to the market price on the date of grant. Stock options issued to directors uponre-election vest quarterly for a period of one year (new director issuances are fully vested upon issuance). Stock options issuedto employees generally vest 25% on the grant date, then 25% each subsequent year for a period of three years. These options havea ten year life for as long as the individuals remain employees or directors. In general, when an employee or director terminatestheir position, the options will expire within three months, unless otherwise extended by the Board.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        From time to time, the Company issues restricted shares of commonstock to vendors and consultants as compensation for services performed under the Company’s 2015 Equity Incentive Plan (the“2015 Plan”). The fair value of the restricted shares is based on the share price of the Company’s common stockon the date of grant. The 2015 Plan provides for the grant of stock options, restricted stock, deferred stock and unrestrictedstock to the Company’s employees and non-employees (including consultants). The shares issued under the 2015 Plan are registeredon Form S-8 (SEC File No. 333-208515). However, as shares of common stock are not covered by a reoffer prospectus, the certificatesreflecting such shares reflect a Securities Act of 1933, as amended restrictive legend.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 89; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         11         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Thefair value of options issued during the years ended December 31, 2020 and 2019 was estimated using the Black-Scholes option-pricingmodel and the following assumptions:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            a dividend yield of 0%;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            an expected life    of 4 years;           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            volatility of 77%    - 85% for 2020 and 83% - 93% for 2019; and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            risk-free interest    rates ranging from 0.22% to 1.66% in 2020 and 1.44% to 2.50% in 2019.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Thefair value of each option grant made during 2020 and 2019 was estimated on the date of each grant using the Black-Scholes optionpricing model and recognized as share-based compensation ratably over the option vesting periods, which approximates the serviceperiod.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <u>          ForeignCurrency Transactions and Translation         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company’s wholly-owned subsidiaryin the United Kingdom (“UK”) incurs expenditures in multiple currencies including the U.S. dollar, the British Poundand the Euro to fund its clinical trial operations in the UK and select countries in Europe. In accordance with FASB ASC 830        <i>         ForeignCurrency Matters        </i>        , the UK subsidiary expresses its U.S. dollar and Euro denominated transactions in its functional currency,the British Pound, with related transaction gains or losses included in net loss. On a quarterly basis, the financial statementsof the UK subsidiary are translated into U.S. dollars and consolidated into the Company’s financials, with related translationadjustments reported as a cumulative translation adjustment (“CTA”), which is a component of accumulated other comprehensiveloss. In 2020 and 2019, the Company recognized foreign currency transaction losses of $23,385 and $7,809, respectively, in itsconsolidated statements of operations and a foreign currency translation loss of $24,337 and $45,010 as CTA in its consolidatedbalance sheets, respectively.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <u>          IncomeTaxes         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Deferred tax assets and liabilities are recognized for the futuretax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilitiesand their respective tax basis. A valuation allowance is established when it is more likely than not that all or a portion of adeferred tax asset will not be realized. A review of all available positive and negative evidence is considered, including theCompany’s current and past performance, the market environment in which the Company operates, the utilization of past taxcredits, and the length of carryback and carryforward periods. Deferred tax assets and liabilities are measured utilizingtax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered orsettled. No income tax provision or benefit has have been recorded through December 31, 2020 as a full valuation allowance hasbeen applied due to the net operating losses incurred by the Company since its inception. The Company recognizes accrued interestand penalties associated with uncertain tax positions, if any, as part of income tax expense. There were no tax related interestand penalties recorded for 2020 and 2019. Additionally, the Company has not recorded an asset for unrecognized tax benefits ora liability for uncertain tax positions at December 31, 2020 and 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <u>          Researchand Development Incentive Income and Receivable         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         TheCompany recognizes other income from United Kingdom research and development incentives when there is reasonable assurance thatthe income will be received, the relevant expenditure has been incurred, and the consideration can be reliably measured. The smallor medium sized enterprise (“SME”) research and development tax relief program supports companies that seek to researchand develop an advance in their field and is governed through legislative law by HM Revenue &amp; Customs as long as specificeligibility criteria are met.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 90; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         12         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Managementhas assessed the Company’s research and development activities and expenditures to determine which activities and expendituresare likely to be eligible under the SME research and development tax relief program described above. At each period end, managementestimates the refundable tax offset available to the Company based on available information at the time. As the tax incentivesmay be received without regard to an entity’s actual tax liability, they are not subject to accounting for income taxes.As a result, amounts realized under the SME R&amp;D tax relief scheme are recorded as a component of other income.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The research and development incentivereceivable represents an amount due in connection with the above program. The Company has recorded a research and development incentivereceivable of approximately $434,000 and $444,000 as of December 31, 2020 and 2019, respectively in the consolidated balance sheets.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Long-term          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Current          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 76%; padding-left: 0.25pt">           Balance at December 31, 2019          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           -          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           444,043          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-left: 0.25pt">           UK research and development incentives          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           95,359          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-left: 0.25pt">           UK research and development incentives cash receipt          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (126,703          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25pt">           Foreign currency translation          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           (22,217          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           )          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           43,756          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-bottom: 4pt; padding-left: 0.25pt">           Balance at December 31, 2020          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           73,142          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           361,096          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>        <b>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <u>          EarningsPer Share         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Basicearnings per share (“EPS”) excludes dilution and is computed by dividing income (loss) available to common stockholdersby the weighted-average number of common shares outstanding for the period. Diluted EPS reflects the potential dilution that couldoccur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in theissuance of common stock that shared in the earnings of the entity. Since there is a significant number of options and warrantsoutstanding, fluctuations in the actual market price can have a variety of results for each period presented.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Thefollowing table summarizes potentially dilutive adjustments to the number of common shares, which were excluded from the dilutedcalculation because their effect would be anti-dilutive due to the losses in each period.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td colspan="2" style="font-weight: bold; text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            For    the            <br/>            Year Ended           </font>          </td>          <td style="font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td colspan="2" style="font-weight: bold; text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            For    the            <br/>            Year Ended           </font>          </td>          <td style="font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            December 31,            <br/>            2020           </font>          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            December 31,            <br/>            2019           </font>          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 76%; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">            Common stock purchase    warrants           </font>          </td>          <td style="width: 1%; font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 1%; font-weight: bold; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 9%; font-weight: bold; text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            5,731,477           </font>          </td>          <td style="width: 1%; font-weight: bold; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 1%; font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 1%; font-weight: bold; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 9%; font-weight: bold; text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            6,192,711           </font>          </td>          <td style="width: 1%; font-weight: bold; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">            Stock options           </font>          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            1,933,804           </font>          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            1,506,972           </font>          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify; padding-bottom: 4pt">           <font style="font-family: Times New Roman, Times, Serif">            Total           </font>          </td>          <td style="font-weight: bold; padding-bottom: 4pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            7,665,281           </font>          </td>          <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="font-weight: bold; padding-bottom: 4pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            7,699,683           </font>          </td>          <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Theweighted average exercise price of the Company’s stock options and warrants outstanding at December 31, 2020 were $2.96and $2.96 per share, respectively.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <u>          Useof Estimates and Assumptions         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The preparation of financial statementsin conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions suchas the fair value of warrants and stock options that affect the reported amounts in the financial statements and accompanying notes.Actual results could differ from those estimates.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <b>         Note 3. Intangible Assets        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The following is a summary of intangibleassets which consists of licenses and patents:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: center">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           Cost          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           Accumulated           <br/>           Amortization          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           Net Book Value          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-weight: bold; text-align: justify">           December 31, 2020          </td>          <td>          </td>          <td colspan="2" style="text-align: justify">          </td>          <td>          </td>          <td>          </td>          <td colspan="2" style="text-align: justify">          </td>          <td>          </td>          <td>          </td>          <td colspan="2" style="text-align: justify">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 64%; text-align: justify; padding-left: 0.125in">           Licenses          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           462,234          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           462,234          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           -          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0.125in">           Patents          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           1,893,185          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           1,893,185          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify; padding-bottom: 4pt; padding-left: 0.25in">           Total          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           2,355,419          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           2,355,419          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           -          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-weight: bold; text-align: justify">           December 31, 2019          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify; padding-left: 0.125in">           Licenses          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           462,234          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           442,535          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           19,699          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0.125in">           Patents          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           1,893,185          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           1,893,185          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify; padding-bottom: 4pt; padding-left: 0.25in">           Total          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           2,355,419          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           2,335,720          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           19,699          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Amortization expense was $19,699 and $27,164in 2020 and 2019, respectively.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Based on the balance of licenses and patentsat December 31, 2020, there will be no more future annual amortization expense.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 91; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         13         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Note 4. Leases        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         OnJanuary 1, 2019, the Company adopted FASB ASU No. 2016-02, “Leases” (Topic 842) (the “Lease Standard”),a new standard which requires all leases with terms longer than 12 months be recognized by the lessee on its balance sheet asa right-of-use lease asset and a corresponding lease liability, including leases currently accounted for as operating leases,and key information about leasing arrangements to be disclosed.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         TheCompany adopted the Lease Standard under the alternative transition method permitted by ASU 2018-11. This transition method allowedthe Company to initially apply the requirements of the Lease Standard at the adoption date, versus at the beginning of the earliestperiod presented. The Company elected the transition package of practical expedients, which permits not separating lease and non-leasecomponents for all of its leases and the short-term lease recognition exemption for all of its leases that qualify; however, itdid not elect the use of hindsight practical expedient.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company classifies a lease for its office space at 29 EmmonsDrive, Suite B-10 in Princeton, New Jersey and a lease for a copy machine in the office as an operating lease and a financing lease,respectively, and recorded related right-of-use lease assets and lease liabilities accordingly. As of December 31, 2020 and 2019,the Company’s consolidated balance sheets included a right-of-use lease asset of $222,445 and $112,387 for the office spaceand $5,582 and $13,025 for the copy machine, respectively. Lease liabilities in the Company’s consolidated balance sheetsas of December 31, 2020 and 2019 included corresponding lease liabilities of $222,441 and $113,559 for the office space and $6,149and $13,665 for the copy machine, respectively.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Thefollowing represent a reconciliation of contractual lease cash flows to the right-of-use lease assets and liabilities recognizedin the financial statements:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: center">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Operating           <br/>           Lease          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Financing           <br/>           Lease          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-weight: bold; text-align: justify">           Contractual cash payments for the remaining lease term as of December 31, 2020:          </td>          <td>          </td>          <td colspan="2" style="text-align: justify">          </td>          <td>          </td>          <td>          </td>          <td colspan="2">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 76%; text-align: justify">           2021          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           133,300          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           6,408          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-bottom: 1.5pt">           2022          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           111,083          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">           Total          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">           244,383          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">           6,408          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">           Discount rate applied          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           10          </td>          <td style="text-align: left">           %          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           10          </td>          <td style="text-align: left">           %          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify">           Remaining lease term (months) as of December 31, 2020          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           22          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           9          </td>          <td style="font-weight: bold; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-weight: bold; text-decoration: underline; text-align: justify">           Right-of-use lease asset:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">           Right-of-use lease asset, January 1, 2019          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           235,497          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           20,468          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify; padding-bottom: 1.5pt">           Less: reduction/amortization          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           123,110          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           7,443          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">           Right-of-use lease asset, December 31, 2019          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           112,387          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           13,025          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify">           Add: new lease extension          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           240,727          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-bottom: 1.5pt">           Less: reduction/amortization          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           130,670          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           7,443          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify; padding-bottom: 1.5pt">           Right-of-use lease asset, December 31, 2020          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">           $          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           222,445          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">           5,582          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-weight: bold; text-decoration: underline; text-align: justify">           Lease liability:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">           Lease liability, January 1, 2019          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           235,497          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           20,468          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify; padding-bottom: 1.5pt">           Less: repayments          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           121,938          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           6,803          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">           Lease liability, December 31, 2019          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           113,559          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           13,665          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify">           Add: new lease extension          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           240,727          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-bottom: 1.5pt">           Less: repayments          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           131,845          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           7,516          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify; padding-bottom: 1.5pt">           Lease liability, December 31, 2020          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">           $          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           222,441          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">           $          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           6,149          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-weight: bold; text-decoration: underline; text-align: justify">           Lease expenses for the year ending December 31, 2019:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">           Lease expense          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           141,191          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify">           Amortization expense          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           7,443          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-bottom: 1.5pt">           Interest expense          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           1,741          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">           Total          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">           141,191          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">           9,184          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-weight: bold; text-decoration: underline; text-align: justify">           Lease expenses for the year ending December 31, 2020:          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">           Lease expense          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           139,876          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify">           Amortization expense          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           7,443          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-bottom: 1.5pt">           Interest expense          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           1,028          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-weight: bold; text-align: justify; padding-bottom: 1.5pt">           Total          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">           $          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           139,876          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">           $          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           8,471          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 92; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         14         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Note 5.         <font style="font-family: Times New Roman, Times, Serif">          AccruedExpenses         </font>        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Thefollowing is a summary of the Company’s accrued expenses:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: center">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           As of           <br/>           December 31,          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: center">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2020          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 76%; text-align: justify">           Clinical trial expenses          </td>          <td style="width: 1%; font-weight: bold">          </td>          <td style="width: 1%; font-weight: bold; text-align: left">           $          </td>          <td style="width: 9%; font-weight: bold; text-align: right">           2,510,111          </td>          <td style="width: 1%; font-weight: bold; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           3,020,030          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-bottom: 1.5pt">           Other          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">           128,197          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           137,356          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify; padding-bottom: 4pt; padding-left: 9pt">           Total          </td>          <td style="font-weight: bold; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">           2,638,308          </td>          <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           3,157,386          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Note 6. Convertible Debt        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On December 16, 2020, the Company enteredinto a $20 million convertible debt financing agreement with Pontifax Medison Debt Financing (“Pontifax”), the healthcare-dedicatedventure and debt fund of the Pontifax life science funds. Under the terms of the agreement with Pontifax, the Company will haveaccess to up to $20 million in convertible debt financing in three tranches, which will mature on June 15, 2025 and have an interestonly period for the first two years with an interest rate of 8.47% on borrowed amounts and an interest rate of 1% on amounts availablebut not borrowed as an unused line of credit fee. The agreement is secured by a lien covering substantially all of the Company’sassets, other than intellectual property. The agreement contains customary representations, warranties and covenants, includingcovenants by the Company limiting additional indebtedness, liens, including on intellectual property, guaranties, mergers and consolidations,substantial asset sales, investments and loans, certain corporate changes, transactions with affiliates and fundamental changes.Upon the closing of this transaction, the Company accessed the first tranche of $10 million, and has the option to draw the secondtranche of $5 million at any time over the next 12 months and the third tranche of $5 million upon filing of the SGX201 new drugapplication, subject to certain conditions. Interest expense incurred and paid in 2020 totaled $34,306. Deferred issuance costincurred were $141,466. The Company amortized $1,205 of issuance costs during the year ended December 31, 2020. The net cost of$140,261 has been recorded as a reduction of the carrying value of the $10,000,000 convertible debt borrowed as of December 31,2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Pontifax may elect to convert the outstanding loan drawn intoshares of the Company’s common stock at any time prior to repayment at a conversion price of $4.10 per share. The Companyalso has the ability to force the conversion of the loan into shares of the Company’s common stock at the same conversionprice, subject to certain conditions.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        Principal and interest payments due, assumingno conversion over the next five years is as follows:       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: left; border-bottom: Black 1.5pt solid">           <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">           </p>           <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">            <font style="font-family: Times New Roman, Times, Serif">             <b>              Year             </b>            </font>           </p>          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Principal          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            <b>             Interest            </b>           </font>          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <font style="font-family: Times New Roman, Times, Serif">             <b>              Total             </b>            </font>           </p>          </td>          <td style="padding-bottom: 1.5pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 64%; text-align: left">           2021          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           -          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           897,000          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           897,000          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left">           2022          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           897,000          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           897,000          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left">           2023          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           4,000,000          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           769,138          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           4,769,138          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left">           2024          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           4,000,000          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           430,338          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           4,430,338          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-bottom: 1.5pt">           2025          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           2,000,000          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           110,566          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           2,110,566          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 4pt">           Total          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           10,000,000          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           3,104,042          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           13,104,042          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 93; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         15         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <u>          CARESAct Loan         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On April 13, 2020, the Company was advisedthat one of its principal banks, JPMorgan Chase Bank, N.A., had approved a $417,830 loan (the “Loan”) under the PPPpursuant to the Coronavirus Aid, Relief and Economic Security Act that was signed into law on March 27, 2020.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Asa U.S. small business, the Company qualified for the PPP, which allows businesses and nonprofits with fewer than 500 employeesto obtain loans of up to $10 million to incentivize companies to maintain their workers as they manage the business disruptionscaused by the COVID-19 pandemic. The PPP provides for loans for amounts up to 2.5 times of the average monthly payroll expensesof the qualifying business. The PPP loan proceeds may be used for eligible purposes, including payroll, benefits, rent and utilities.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Loan, has a term of two years, is unsecured, and is guaranteedby the Small Business Administration. The short –term portion of the Loan is $324,979 and the long-term portion of the Loanis $92,851 with accrued interest expense of $2,730 as of December 31, 2020. The Loan bears interest at a fixed rate of 0.98%per annum, with the first ten months of interest and principal deferred. Some or all of the Loan may be forgiven if at least 60%of the Loan proceeds are used by the Company to cover payroll costs, including benefits and if the Company maintains its employmentand compensation within certain parameters during the eight-week or twenty-four-week period following the Loan originationdate and complies with other relevant conditions. The Company believes that it used the proceeds for purposes consistent with thePPP and expects to meet the conditions when the Company applies for forgiveness of the Loan, although forgiveness is not guaranteed.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Note 7. Income Taxes        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Theincome tax benefit consisted of the following for the years ended December 31, 2020 and 2019:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            2020           </font>          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            2019           </font>          </td>          <td style="padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">            Federal           </font>          </td>          <td style="font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="font-weight: bold; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="font-weight: bold; text-align: right">           -          </td>          <td style="font-weight: bold; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">            Foreign           </font>          </td>          <td style="font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="font-weight: bold; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="font-weight: bold; text-align: right">           -          </td>          <td style="font-weight: bold; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 76%; text-align: justify; padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">            State           </font>          </td>          <td style="width: 1%; font-weight: bold; padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: Black 1.5pt solid; width: 1%; font-weight: bold; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold; text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            (836,893           </font>          </td>          <td style="width: 1%; padding-bottom: 1.5pt; font-weight: bold; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            )           </font>          </td>          <td style="width: 1%; padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            (610,676           </font>          </td>          <td style="width: 1%; padding-bottom: 1.5pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-bottom: 4pt">           <font style="font-family: Times New Roman, Times, Serif">            Income tax benefit           </font>          </td>          <td style="font-weight: bold; padding-bottom: 4pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            (836,893           </font>          </td>          <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            )           </font>          </td>          <td style="padding-bottom: 4pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            (610,676           </font>          </td>          <td style="padding-bottom: 4pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            )           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Thesignificant components of the Company’s deferred tax assets and liabilities at December 31, 2020 and 2019 are as follows:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: center">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2020          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 76%; text-align: justify">           Net operating loss carry forwards          </td>          <td style="width: 1%; font-weight: bold">          </td>          <td style="width: 1%; font-weight: bold; text-align: left">           $          </td>          <td style="width: 9%; font-weight: bold; text-align: right">           27,022,000          </td>          <td style="width: 1%; font-weight: bold; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           23,936,000          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">           Orphan drug and research and development credit carry forwards          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           8,149,000          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           8,315,000          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify">           Equity based compensation          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           264,000          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           1,331,000          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-bottom: 1.5pt">           Intangibles          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">           817,000          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           1,051,000          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-weight: bold; text-align: justify">           Total          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           36,252,000          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           34,633,000          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-bottom: 1.5pt">           Valuation allowance          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">           (36,252,000          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">           )          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           (34,633,000          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify; padding-bottom: 4pt">           Net deferred tax assets          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           <b>            $           </b>          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           -          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           -          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company had gross NOLs at December31, 2020 of approximately $119,000,000 for federal tax purposes, approximately $25,000,000 for state tax purposes and approximately$1,200,000 for foreign tax purposes. Federal losses generated in 2018 or later will carry forward indefinitely. In addition, theCompany has approximately $8,149,000 of various tax credits which expire from 2021 to 2037. The Company may be able to utilizeits NOLs to reduce future federal and state income tax liabilities. However, these NOLs are subject to various limitations underInternal Revenue Code (“IRC”) Section 382. IRC Section 382 limits the use of NOLs to the extent there has been an ownershipchange of more than 50 percentage points. In addition, the NOL carry forwards are subject to examination by the taxing authorityand could be adjusted or disallowed due to such exams. Although the Company has not undergone an IRC Section 382 analysis, it islikely that the utilization of the NOLs may be substantially limited.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 94; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         16         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company and one or more of its subsidiariesfiles income tax returns in the U.S. Federal jurisdiction, and various state and local jurisdictions. During the year ended December31, 2020 in accordance with the State of New Jersey’s Technology Business Tax Certificate Program, which allowed certainhigh technology and biotechnology companies to sell unused NOL carry forwards to other New Jersey-based corporate taxpayers, theCompany sold New Jersey NOL carry forwards, resulting in the recognition of $836,893 of income tax benefit, net of transactioncosts. The Company has not yet sold its 2020 New Jersey NOLs but may do so in the future. There can be no assurance as to the continuationor magnitude of this program in the future.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Reconciliationsof the difference between income tax benefit computed at the federal and state statutory tax rates and the provision for incometax benefit for the years ended December 31, 2020 and 2019 were as follows:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: center">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2020          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 76%; text-align: justify">           Federal tax at statutory rate          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           (21.0          </td>          <td style="width: 1%; text-align: left">           )%          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           (21.0          </td>          <td style="width: 1%; text-align: left">           )%          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">           State tax benefits, plus sale of NJ NOL, net of federal benefit          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (5.8          </td>          <td style="text-align: left">           )          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           (8.8          </td>          <td style="text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify">           Foreign tax rate difference          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           0.1          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           0.3          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">           Orphan drug and research and development credits          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           4.8          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           1.8          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify">           Permanent differences          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           1.4          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           2.1          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify">           Foreign NOL adjustments          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           0.4          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           2.5          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify">           Expiration of tax attributes          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           6.9          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           8.8          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-bottom: 1.5pt">           Change in valuation allowance          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           8.7          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           8.3          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify; padding-bottom: 4pt; padding-left: 9pt">           Income tax benefit          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           (4.5          </td>          <td style="padding-bottom: 4pt; text-align: left">           )%          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           (6.0          </td>          <td style="padding-bottom: 4pt; text-align: left">           %)          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">        Entities are alsorequired to evaluate, measure, recognize and disclose any uncertain income tax provisions taken on their income tax returns. TheCompany has analyzed its tax positions and has concluded that as of December 31, 2020, there were no uncertain positions. The Company’sU.S. federal and state net operating losses have occurred since its inception and as such, tax years subject to potential tax examinationcould apply from 2011, the earliest year with a net operating loss carryover, because the utilization of net operating losses fromprior years opens the relevant year to audit by the IRS and/or state taxing authorities. Interest and penalties, if any, as theyrelate to income taxes assessed, are included in the income tax provision. The Company did not have any unrecognized tax benefitsand has not accrued any interest or penalties for the years ended December 31, 2020 and 2019.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On March 27, 2020, the Coronavirus Aid, Relief, and EconomicSecurity Act, or the CARES Act, was enacted and signed into law, and generally accepted accounting principles requires recognitionof the tax effects of new legislation during the reporting period that includes the enactment date. The CARES Act, among otherthings, includes changes to the tax provisions that benefits business entities and makes certain technical corrections to the 2017Tax Cuts and Jobs Act, including, permitting net operating losses, or NOLs, carryovers and carrybacks to offset 100% of taxableincome for taxable years beginning before 2021. In addition, the CARES Act allows NOLs incurred in 2018, 2019, and 2020 to be carriedback to each of the five preceding taxable years to generate a refund of previously paid income taxes. The CARES Act provides otherreliefs and stimulus measures. The Company has evaluated the impact of the CARES Act, and does not expect that any provision ofthe CARES Act would result in a material cash benefit to the Company or have a material impact on the Company’s financialstatements or internal controls over financial reporting.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Note 8. Shareholders’ Equity        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <u>          PreferredStock         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         TheCompany has 350,000 shares of preferred stock authorized, none of which are issued or outstanding.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <u>          CommonStock         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Thefollowing items represent transactions in the Company’s common stock for the year ended December 31, 2020:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify; font-size: 10pt">          </td>          <td style="width: 24px; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The Company issued 10,000 shares of restricted common stock on January 8, 2020, February 10, 2020 and March 12, 2020 for a total of 30,000 shares to a vendor as consideration for its service performed. The fair values for the shares issued were $1.68, $2.25 and $1.97 per share, respectively. The shares were fully vested on the date of grant and resulted in the recognition of $59,000 of expense during the year ended December 31, 2020.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            On March 23, 2020,the Company issued 1,956,182 fully vested shares of common stock to Hy Biopharma, Inc. (“Hy Biopharma”) as paymentfor a milestone. The fair value of the shares was $2.56 per share.           </font>          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="text-align: justify">          </td>          <td style="text-align: justify">          </td>         </tr>         <tr style="vertical-align: top">          <td>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            On November 25, 2020, the Company increased its authorized shares of common stock from 50,000,000 to 75,000,000.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">          </td>          <td style="width: 24px; text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify; font-size: 10pt">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            During the year ended December 31, 2020, the Company issued 460,161 shares of common stock as a result of warrant exercises and 5,758 shares of common stock as a result of option exercises. The weighted average exercise price per warrant and option was $1.87 and $1.19, respectively. The cash exercise price of $1,882 for 2,189 shares issued upon the exercise of such options was received in December 2019.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            During the year    ended December 31, 2020, the Company issued 6,438,431 shares of common stock pursuant to the FBR Sales Agreement at a weighted    average price of $2.21 per share.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 95; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         17         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Thefollowing items represent transactions in the Company’s common stock for the year ended December 31, 2019        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            On January 2, 2019,    the Company issued 60,000 shares of common stock to a vendor as partial consideration for its service performed. The fair    value of the shares was $0.96 per share.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            The Company issued    8,681 shares of restricted common stock on both April 29, 2019 and July 1, 2019 to a vendor as consideration for its service    performed. The fair values for the shares issued were $0.73 and $0.72 per share, respectively.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            On May 15, 2019,    the Company issued 50,000 shares of common stock to a vendor as partial consideration for its service performed. The fair    value of the shares was $0.83 per share. In addition, the Company issued to the vendor 25,000 shares of common stock with    a fair value of $0.98 per share on July 15, 2019, 5,000 shares of common stock with a fair value of $1.05 per share on August    15, 2019, and 10,000 shares with a fair value of $0.88 per share on September 15, 2019.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            On June 28, 2019,    the Company issued 78,338 shares of restricted common stock to Altamont, a company which owns 5% or more of the Company’s    shares of common stock, as reimbursement for its cost incurred related to the re-development of the Company’s website    and partial consideration for its service performed. The fair value of the shares was $0.71 per share.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            ●           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            During the year    ended December 31, 2019, the Company issued 3,824,585 shares of common stock pursuant to the FBR Sales Agreement at a weighted    average price of $1.08 per share.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Allissuances of the Company’s common stock for the years ended December 31, 2020 and 2019 described above, other than sharesissued under the FBR Sales Agreement and those issued to Hy Biopharma, were issued under the 2015 Plan and are registered on aRegistration Statement on Form S-8 (SEC File No. 333-208515). However, as shares of common stock are not covered by a reofferprospectus, the certificates evidencing such shares reflect a Securities Act of 1933, as amended, restrictive legend. The sharesissued to Hy Biopharma and those issued under the FBR Sales Agreement were registered on a Registration Statement on Form S-3(SEC File No. 333-239928).        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <u>          FBRAt Market Issuance Sales Agreement         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         OnAugust 11, 2017, the Company entered into the FBR Sales Agreement to sell shares of the Company’s common stock from timeto time, through an “at-the-market” equity offering program under which FBR acts as sales agent. Under the FBR SalesAgreement, the Company sets the parameters for the sale of shares, including the number of shares to be issued, the time periodduring which sales may be requested to be made, limitation on the number of shares that may be sold in any one trading day andany minimum price below which sales may not be made. The FBR Sales Agreement provides that FBR is entitled to compensation forits services in an amount equal to 3% of the gross proceeds from the sale of shares sold under the FBR Sale Agreement. The Companyhas no obligation to sell any shares under the FBR Sales Agreement, and may suspend solicitation and offers under the FBR SalesAgreement at any time.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         TheCompany’s shelf registration statement on Form S-3 (File No. 333- 217738) filed on May 5, 2017 (the “May 2017 RegistrationStatement”) with the U.S. Securities and Exchange Commission (the “SEC”) expired on August 10, 2020, but was available to be utilizedfor a period up to six months or until a new shelf registration statement was declared effective, whichever occurred first.All sales under the FBR Sales Agreement from August 11, 2017 through August 10, 2020 were made pursuant to the May 2017 RegistrationStatement.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Allsales of common stock made pursuant to the FBR Sales Agreement since the expiration of the May 2017 Registration Statementhave been, and future sales will be, made pursuant to the Company’s shelf registration statement on Form S-3 (File No. 333-239928) filed on July 17, 2020 (the "July 2020 Registration Statement") with the SEC, and any amendments thereto, thebase prospectus filed as part of such registration statement, and any prospectus supplements. The July 2020 Registration Statementwas declared effective on August 28, 2020.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 96; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         18         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On August 28, 2020, the Company filed a prospectus supplementto the FBR Sales Agreement to offer and sell shares of Company common stock having an aggregate offering price of up to $20.0 millionunder the July 2020 Registration Statement. As of March 30, 2021, there was $2.1 million available for the saleof common stock under the FBR Sales Agreement.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Note 9. Related Party Transaction        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        In February 2019, Altamont, a company whichowned 5% or more of the Company’s shares of common stock at the time, signed a service agreement with a third-party vendorto re-develop the Company’s website. Upon completion of the project at the end of June 2019, the Company issued 78,338 sharesof common stock of the Company, including 65,493 shares with a fair value of $46,500 to Altamont as reimbursement for the websitedevelopment costs incurred by Altamont on behalf of the Company. In accordance with FASB ASC 350-50 “Accounting for Web SiteDevelopment Cost”, the Company has capitalized the value of these shares as website development costs of $46,500. The balanceof 12,845 shares with a fair value of $9,120 was issued to Altamont as consideration for its contractual investor relation andweb hosting services and $2,550 and $6,570 was expensed during the years ended December 31, 2020 and 2019, respectively.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <b>         Note 10. Stock Option Plans and Warrantsto Purchase Common Stock        </b>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <u>          StockOption Plans         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         TheAmended and Restated 2005 Equity Incentive Plan (“2005 Plan”) was replaced by the 2015 Plan, which was approved inJune 2015. No securities are available for future issuance under the 2005 Plan. As of December 31, 2020, approximately 214,689shares are available for grants under the 2015 Plan, and are divided into four separate equity programs:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            1)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the Discretionary    Option Grant Program, under which eligible persons may, at the discretion of the Plan Administrator, be granted options to    purchase shares of common stock,           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            2)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the Salary Investment    Option Grant Program, under which eligible employees may elect to have a portion of their base salary invested each year in    options to purchase shares of common stock,           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            3)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the Automatic Option    Grant Program, under which eligible nonemployee Board members will automatically receive options at periodic intervals to    purchase shares of common stock, and           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: -0.25in">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">        <tbody>         <tr style="vertical-align: top">          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 24px">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            4)           </font>          </td>          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">            the Director Fee    Option Grant Program, under which non-employee Board members may elect to have all, or any portion, of their annual retainer    fee otherwise payable in cash applied to a special option grant.           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Sharesavailable for grant under the 2015 Plan were as follows:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.2in">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">        <tbody>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 88%; font-weight: bold; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">            Shares    available for grant at January 1, 2020           </font>          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 9%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            663,709           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-left: 9pt">           <font style="font-family: Times New Roman, Times, Serif">            Options granted           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            (520,812           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            )           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">           <font style="font-family: Times New Roman, Times, Serif">            Options    forfeited           </font>          </td>          <td style="padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            71,792           </font>          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">           <font style="font-family: Times New Roman, Times, Serif">            Shares    available for grant at December 31, 2020           </font>          </td>          <td style="padding-bottom: 4pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            214,689           </font>          </td>          <td style="padding-bottom: 4pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Activityunder the 2005 Plan and the 2015 Plan for the years ended December 31, 2020 and 2019 was as follows:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td colspan="2" style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td colspan="2" style="font-weight: bold; text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            Weighted            <br/>            Average           </font>          </td>          <td style="font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            Options           </font>          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            Options            <br/>            Exercise            <br/>            Price           </font>          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 76%; font-weight: bold; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">            Balance    outstanding at December 31, 2018           </font>          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 9%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            1,022,095           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="width: 9%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            5.32           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">            Granted           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            596,740           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            1.09           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">            Forfeited           </font>          </td>          <td style="padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            (111,863           </font>          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            )           </font>          </td>          <td style="padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="padding-bottom: 1.5pt; text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            3.27           </font>          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-weight: bold; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">            Balance outstanding    at December 31, 2019           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            1,506,972           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            3.77           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">            Granted           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            520,812           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            2.17           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-left: 0.125in; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">            Forfeited           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            (88,222           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            )           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            13.06           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-left: 0.125in; text-align: justify; padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">            Exercised           </font>          </td>          <td style="padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            (5,758           </font>          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            )           </font>          </td>          <td style="padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="padding-bottom: 1.5pt; text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            1.19           </font>          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">           <font style="font-family: Times New Roman, Times, Serif">            Balance    outstanding at December 31, 2020           </font>          </td>          <td style="padding-bottom: 4pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            1,933,804           </font>          </td>          <td style="padding-bottom: 4pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="padding-bottom: 4pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="padding-bottom: 4pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="padding-bottom: 4pt; text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            2.96           </font>          </td>          <td style="padding-bottom: 4pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Asof December 31, 2020, there were 1,310,442 options exercisable with a weighted average exercise price of $3.53 and a weightedaverage remaining contractual term of 7.24 years. As of December 31, 2020, there were 1,933,804 options outstanding with a weightedaverage exercise price of $2.96 and remaining term of 7.91 years.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 97; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         19         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         TheCompany awarded 520,812 and 596,740 stock options during the years ended December 31, 2020 and 2019, respectively, whichhad a weighted average grant date fair value per share of $0.97 and $0.68, respectively. The weighted-average exercise price,by price range, for outstanding options to purchase common stock at December 31, 2020 was:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">        <tbody>         <tr style="vertical-align: bottom">          <td style="border-bottom: Black 1.5pt solid">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">            <font style="font-family: Times New Roman, Times, Serif">             <b>             </b>            </font>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">            <font style="font-family: Times New Roman, Times, Serif">             <b>              Price                                         Range             </b>            </font>           </p>          </td>          <td style="padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <font style="font-family: Times New Roman, Times, Serif">             <b>              Weighted              <br/>              Average              <br/>              Remaining             </b>            </font>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <font style="font-family: Times New Roman, Times, Serif">             <b>              Contractual              <br/>              Life in Years             </b>            </font>           </p>          </td>          <td style="padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <font style="font-family: Times New Roman, Times, Serif">             <b>              Outstanding             </b>            </font>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <font style="font-family: Times New Roman, Times, Serif">             <b>              Options             </b>            </font>           </p>          </td>          <td style="padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <font style="font-family: Times New Roman, Times, Serif">             <b>              Exercisable             </b>            </font>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <font style="font-family: Times New Roman, Times, Serif">             <b>              Options             </b>            </font>           </p>          </td>          <td style="padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 64%">           <font style="font-family: Times New Roman, Times, Serif">            $0.71-$2.79           </font>          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 9%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            8.49           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 9%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            1,723,180           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 9%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            1,099,818           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>           <font style="font-family: Times New Roman, Times, Serif">            $6.40-$15.60           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            3.42           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            156,394           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            156,394           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">            $20.00-$39.80           </font>          </td>          <td style="padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="padding-bottom: 1.5pt; text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            2.58           </font>          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            54,230           </font>          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            54,230           </font>          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-bottom: 4pt; padding-left: 9pt">           <font style="font-family: Times New Roman, Times, Serif">            Total           </font>          </td>          <td style="padding-bottom: 4pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="padding-bottom: 4pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="padding-bottom: 4pt; text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            7.91           </font>          </td>          <td style="padding-bottom: 4pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="padding-bottom: 4pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            1,933,804           </font>          </td>          <td style="padding-bottom: 4pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="padding-bottom: 4pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            1,310,442           </font>          </td>          <td style="padding-bottom: 4pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         TheCompany’s share-based compensation expense for the years ended December 31, 2020 and 2019 was recognized as follows:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">           Share-based compensation          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2020          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 76%; text-align: justify">           Research and development          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           195,560          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           143,217          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-bottom: 1.5pt">           General and administrative          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           214,373          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           233,122          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify; padding-bottom: 4pt">           Total          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           409,933          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           376,339          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         AtDecember 31, 2020, the total compensation cost for stock options not yet recognized was approximately $584,000 and will be expensedover the next three years.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <u>          Warrantsto Purchase Common Stock         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Warrantactivity for the years ended December 31, 2020 and 2019 was as follows:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: center">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">           <font style="font-family: Times New Roman, Times, Serif">            Warrants           </font>          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <font style="font-family: Times New Roman, Times, Serif">             <b>              Weighted              <br/>              Average             </b>            </font>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <font style="font-family: Times New Roman, Times, Serif">             <b>              Exercise              <br/>              Price             </b>            </font>           </p>          </td>          <td style="padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 76%; font-weight: bold; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">            Balance    at December 31, 2018           </font>          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 9%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            6,303,643           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 1%">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="width: 9%; text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            3.09           </font>          </td>          <td style="width: 1%; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-left: 9pt">           <font style="font-family: Times New Roman, Times, Serif">            Granted           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            -           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify; padding-left: 9pt">           <font style="font-family: Times New Roman, Times, Serif">            Exercised           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">           <font style="font-family: Times New Roman, Times, Serif">            Expired           </font>          </td>          <td style="padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            (110,932           </font>          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            )           </font>          </td>          <td style="padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="padding-bottom: 1.5pt; text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            14.80           </font>          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-weight: bold; text-align: justify">           <font style="font-family: Times New Roman, Times, Serif">            Balance at December    31, 2019           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            6,192,711           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            2.88           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-left: 9pt">           <font style="font-family: Times New Roman, Times, Serif">            Granted           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: justify; padding-left: 9pt">           <font style="font-family: Times New Roman, Times, Serif">            Exercised           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            (461,234           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            )           </font>          </td>          <td>           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            1.87           </font>          </td>          <td style="text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">           <font style="font-family: Times New Roman, Times, Serif">            Expired           </font>          </td>          <td style="padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="padding-bottom: 1.5pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="padding-bottom: 1.5pt; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-weight: bold; text-align: justify; padding-bottom: 4pt">           <font style="font-family: Times New Roman, Times, Serif">            Balance    at December 31, 2020           </font>          </td>          <td style="padding-bottom: 4pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            5,731,477           </font>          </td>          <td style="padding-bottom: 4pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="padding-bottom: 4pt">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>          <td style="padding-bottom: 4pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">            $           </font>          </td>          <td style="padding-bottom: 4pt; text-align: right">           <font style="font-family: Times New Roman, Times, Serif">            2.96           </font>          </td>          <td style="padding-bottom: 4pt; text-align: left">           <font style="font-family: Times New Roman, Times, Serif">           </font>          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 98; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         20         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Theremaining life, by grant date, for outstanding warrants at December 31, 2020 was:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="border-bottom: Black 1.5pt solid">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">            <font style="font-family: Times New Roman, Times, Serif">             <b>             </b>            </font>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">            <font style="font-family: Times New Roman, Times, Serif">             <b>              Grant Date             </b>            </font>           </p>          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Exercise           <br/>           Price          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Remaining           <br/>           Contractual           <br/>           Life in Years          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Outstanding           <br/>           Warrants          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Exercisable           <br/>           Warrants          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 52%">           12/16/2016          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           3.95          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           0.96          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           2,403,405          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 9%; text-align: right">           2,403,405          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>           11/3/2017          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           2.50          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           1.83          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           49,872          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           49,872          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td>           4/1/2018          </td>          <td>          </td>          <td style="text-align: left">           $          </td>          <td style="text-align: right">           1.95          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           2.24          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           10,000          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           10,000          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-bottom: 1.5pt">           7/2/2018          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="padding-bottom: 1.5pt; text-align: left">           $          </td>          <td style="padding-bottom: 1.5pt; text-align: right">           2.25          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt; text-align: right">           1.01          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           3,268,200          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           3,268,200          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-bottom: 4pt; padding-left: 9pt">           Total          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt; text-align: left">           $          </td>          <td style="padding-bottom: 4pt; text-align: right">           2.88          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt; text-align: right">           2.02          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           5,731,477          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           5,731,477          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          Note11. Concentrations         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         AtDecember 31, 2020 and 2019, the Company had deposits in major financial institutions that exceeded the amount under protectionby the Securities Investor Protection Corporation (“SIPC”). Currently, the Company is covered up to $1,000,000 bythe SIPC and at times maintains cash balances in excess of the SIPC coverage.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          Note12. Commitments and Contingencies         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         TheCompany has commitments of approximately $500,000 at December 31, 2020 for several licensing agreements with consultants and universities.Additionally, the Company has collaboration and license agreements, which upon clinical or commercialization success, may requirethe payment of milestones of up to $7.9 million and/or royalties up to 6% of net sales of covered products, if and when achieved.However, there can be no assurance that clinical or commercialization success will occur. In June 2018, the Company paid approximately$197,000 in milestone payments.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        The Company currently leases approximately 6,200 square feetof office space at 29 Emmons Drive, Suite B-10 in Princeton, New Jersey pursuant to a lease that expires in October 2022. Thisoffice space currently serves as the Company’s corporate headquarters, and both of the Company’s business segments(Specialized BioTherapeutics and Public Health Solutions), operate from this space. The rent for the first 10 months of 2019 wasapproximately $11,625. The rent for the last two months of 2019 and the first 10 months of 2020 was approximately $11,883 per month,or approximately $23.00 per square foot, and then decreased to approximately $11,108, or approximately $21.50 per square foot,starting November 2020, which rate will continue for the remainder of the lease period.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        On September 3, 2014, the Company entered into an asset purchaseagreement with Hy Biopharma pursuant to which the Company acquired certain intangible assets, properties and rights of Hy Biopharmarelated to the development of Hy BioPharma’s synthetic hypericin product. As consideration for the assets acquired, the Companypaid $275,000 in cash and issued 184,912 shares of common stock with a fair value based on the Company’s stock price on thedate of grant of $3,750,000. These amounts were charged to research and development expense during the third quarter of 2014 asthe assets will be used in the Company’s research and development activities and do not have alternative future use pursuantto generally accepted accounting principles in the U.S. The Company is required to issue Hy Biopharma shares of common stock uponthe achievement of certain milestones. In March 2020, the Company issued 1,956,182 fully vested shares of common stock to Hy Biopharmaas payment for achieving a milestone: the Company determining the Phase 3 clinical trial of SGX301 to be successful in the treatmentof CTCL. The number of shares of common stock issued to Hy Biopharma was calculated using an effective price of $2.56 per share,based upon a formula set forth in the purchase agreement. Provided all future success-oriented milestones are attained, the Companywill be required to make additional payments of up to $5.0 million, if and when achieved. Payments will be payable in restrictedsecurities of the Company provided they do not exceed 19.9% ownership of the Company’s outstanding stock. As of December31, 2020, no other milestone or royalty payments have been paid or accrued.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">       </p>       <!-- Field: Page; Sequence: 99; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         21         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         InJanuary 2020, the Company’s Board of Directors authorized the amendment of Dr. Schaber’s employment agreement to increasethe number of shares of the Company’s common stock from 5,000 to 500,000 issuable to Dr. Schaber immediately prior to thecompletion of a transaction, or series or a combination of related transactions, negotiated by its Board of Directors whereby,directly or indirectly, a majority of its capital stock or a majority of its assets are transferred from the Company and/or itsstockholders to a third party.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Asa result of the above agreements, the Company has future contractual obligations over the next five years as follows:        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td style="text-align: left; border-bottom: Black 1.5pt solid">           <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">            <font style="font-family: Times New Roman, Times, Serif">             <b>             </b>            </font>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">            <font style="font-family: Times New Roman, Times, Serif">             <b>              Year             </b>            </font>           </p>          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Licensing Fee          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           Property and Other Leases          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid">           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <font style="font-family: Times New Roman, Times, Serif">             <b>             </b>            </font>           </p>           <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">            <font style="font-family: Times New Roman, Times, Serif">             <b>              Total             </b>            </font>           </p>          </td>          <td style="padding-bottom: 1.5pt">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 64%; text-align: left">           2021          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           100,000          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           139,708          </td>          <td style="width: 1%; text-align: left">          </td>          <td style="width: 1%">          </td>          <td style="width: 1%; text-align: left">           $          </td>          <td style="width: 9%; text-align: right">           239,708          </td>          <td style="width: 1%; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left">           2022          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           100,000          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           111,083          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           211,083          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left">           2023          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           100,000          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           100,000          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left">           2024          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           100,000          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           -          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">           100,000          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-bottom: 1.5pt">           2025          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           100,000          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           -          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>          <td style="padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; text-align: right">           100,000          </td>          <td style="padding-bottom: 1.5pt; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 4pt">           Total          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           500,000          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           250,791          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>          <td style="padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; text-align: right">           750,791          </td>          <td style="padding-bottom: 4pt; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <u>          Contingencies         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         TheCompany follows subtopic 450-20 of the FASB Accounting Standards Codification to report accounting for contingencies. Certainconditions may exist as of the date the financial statements are issued, which may result in a loss to the Company but which willonly be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, andsuch assessment inherently involves an exercise of judgment. A liability is only recorded if management determines that it isboth probable and reasonably estimable.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         <u>          COVID-19         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Basedon the current outbreak of SARS-CoV-2, the pathogen responsible for COVID-19, which has already had an impact on financial markets,there could be additional repercussions to the Company’s operating business, including but not limited to, the sourcingof materials for product candidates, manufacture of supplies for preclinical and/or clinical studies, delays in clinical operations,which may include the availability or the continued availability of patients for trials due to such things as quarantines, conductof patient monitoring and clinical trial data retrieval at investigational study sites.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         Thefuture impact of the outbreak is highly uncertain and cannot be predicted, and the Company cannot provide any assurance that theoutbreak will not have a material adverse impact on the Company’s operations or future results or filings with regulatoryhealth authorities. The extent of the impact to the Company, if any, will depend on future developments, including actions takento contain the coronavirus.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         <u>          EmergentBioSolutions Legal Proceedings         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         OnJuly 1, 2020, the Company filed a demand for arbitration against Emergent BioSolutions, Inc. and certain of its subsidiaries withthe American Arbitration Association in Mercer County, New Jersey. The Company alleges in the arbitration various breaches ofcontracts and warranties as well as acts of fraud. Emergent has answered that demand for arbitration denying the allegations andasserting affirmative defenses.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         TheCompany is seeking to recover damages in excess of $19 million from Emergent. While the Company intends to vigorously pursue thisarbitration, the Company cannot offer any assurances that it will recover any damages from Emergent.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         TheCompany has received invoices from Emergent related to the above matter. No accrual has been made for these invoices as managementdeems them invalid and not probable of being required to pay them based on the numerous breaches sited in the pending arbitration.These invoices total approximately $331,000.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">       </p>       <!-- Field: Page; Sequence: 100; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         22         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          Note13. Operating Segments         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         TheCompany maintains two active operating segments: Specialized BioTherapeutics and Public Health Solutions. Each segmentincludes an element of overhead costs specifically associated with its operations, with its corporate shared services group responsiblefor support functions generic to both operating segments.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           For the Years Ended           <br/>           December 31,          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: center">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2020          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-weight: bold">           Revenues          </td>          <td>          </td>          <td colspan="2">          </td>          <td>          </td>          <td>          </td>          <td colspan="2">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 76%; text-align: left; padding-left: 9pt">           Public Health Solutions          </td>          <td style="width: 1%; font-weight: bold">          </td>          <td style="width: 1%; font-weight: bold; text-align: left">           $          </td>          <td style="width: 9%; font-weight: bold; text-align: right">           2,242,078          </td>          <td style="width: 1%; font-weight: bold; text-align: left">          </td>          <td style="width: 1%; font-weight: bold">          </td>          <td style="width: 1%; font-weight: bold; text-align: left">           $          </td>          <td style="width: 9%; font-weight: bold; text-align: right">           3,402,014          </td>          <td style="width: 1%; font-weight: bold; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">           Specialized BioTherapeutics          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">           117,369          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">           1,227,902          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-bottom: 4pt; padding-left: 0.25in">           Total          </td>          <td style="font-weight: bold; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">           2,359,447          </td>          <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">           4,629,916          </td>          <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-weight: bold; text-align: left">           Income (Loss) from Operations          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-left: 9pt">           Public Health Solutions          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">           $          </td>          <td style="font-weight: bold; text-align: right">           (435,028          </td>          <td style="font-weight: bold; text-align: left">           )          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">           $          </td>          <td style="font-weight: bold; text-align: right">           153,969          </td>          <td style="font-weight: bold; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-left: 9pt">           Specialized BioTherapeutics          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           (13,610,715          </td>          <td style="font-weight: bold; text-align: left">           )          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           (6,738,284          </td>          <td style="font-weight: bold; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-bottom: 1.5pt; padding-left: 9pt">           Corporate          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">           (4,540,764          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">           )          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">           (3,956,706          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-bottom: 4pt; padding-left: 0.25in">           Total          </td>          <td style="font-weight: bold; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">           (18,586,507          </td>          <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">           )          </td>          <td style="font-weight: bold; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">           (10,541,021          </td>          <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">           )          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-weight: bold; text-align: left">           Amortization and Depreciation Expense          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-left: 9pt">           Public Health Solutions          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">           $          </td>          <td style="font-weight: bold; text-align: right">           21,672          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">           $          </td>          <td style="font-weight: bold; text-align: right">           17,507          </td>          <td style="font-weight: bold; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-left: 9pt">           Specialized BioTherapeutics          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           11,839          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           18,122          </td>          <td style="font-weight: bold; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-bottom: 1.5pt; padding-left: 9pt">           Corporate          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">           28,861          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">           18,821          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-bottom: 4pt; padding-left: 0.25in">           Total          </td>          <td style="font-weight: bold; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">           62,372          </td>          <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">           54,450          </td>          <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="font-weight: bold; text-align: left">           Other Income (Expense), Net          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-left: 9pt">           Specialized BioTherapeutics          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">           $          </td>          <td style="font-weight: bold; text-align: right">           71,974          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           425,785          </td>          <td style="font-weight: bold; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-bottom: 1.5pt; padding-left: 9pt">           Corporate          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">           (10,882          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">           )          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">           148,968          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-bottom: 4pt; padding-left: 0.25in">           Total          </td>          <td style="font-weight: bold; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">           61,092          </td>          <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">           574,753          </td>          <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td>          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="font-weight: bold; text-align: left">           Share-Based Compensation          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>          <td>          </td>          <td style="text-align: left">          </td>          <td style="text-align: right">          </td>          <td style="text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="text-align: left; padding-left: 9pt">           Public Health Solutions          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">           $          </td>          <td style="font-weight: bold; text-align: right">           47,453          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">           $          </td>          <td style="font-weight: bold; text-align: right">           36,003          </td>          <td style="font-weight: bold; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-left: 9pt">           Specialized BioTherapeutics          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           148,107          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           107,214          </td>          <td style="font-weight: bold; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-bottom: 1.5pt; padding-left: 9pt">           Corporate          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">           214,373          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">           233,122          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-bottom: 4pt; padding-left: 0.25in">           Total          </td>          <td style="font-weight: bold; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">           409,933          </td>          <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">           376,339          </td>          <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">        <tbody>         <tr style="vertical-align: bottom">          <td>          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           As of December 31,          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="text-align: center">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2020          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">           2019          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold">          </td>         </tr>         <tr style="vertical-align: bottom">          <td style="font-weight: bold">           Identifiable Assets          </td>          <td>          </td>          <td colspan="2">          </td>          <td>          </td>          <td>          </td>          <td colspan="2">          </td>          <td>          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="width: 76%; text-align: left; padding-left: 9pt">           Public Health Solutions          </td>          <td style="width: 1%; font-weight: bold">          </td>          <td style="width: 1%; font-weight: bold; text-align: left">           $          </td>          <td style="width: 9%; font-weight: bold; text-align: right">           176,447          </td>          <td style="width: 1%; font-weight: bold; text-align: left">          </td>          <td style="width: 1%; font-weight: bold">          </td>          <td style="width: 1%; font-weight: bold; text-align: left">           $          </td>          <td style="width: 9%; font-weight: bold; text-align: right">           1,018,673          </td>          <td style="width: 1%; font-weight: bold; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="text-align: left; padding-left: 9pt">           Specialized BioTherapeutics          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           147,784          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold">          </td>          <td style="font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; text-align: right">           41,705          </td>          <td style="font-weight: bold; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">          <td style="padding-bottom: 1.5pt; padding-left: 9pt">           Corporate          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">           19,567,004          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; padding-bottom: 1.5pt">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">          </td>          <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: right">           6,714,983          </td>          <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: left">          </td>         </tr>         <tr style="vertical-align: bottom; background-color: White">          <td style="padding-bottom: 4pt; padding-left: 0.25in">           Total          </td>          <td style="font-weight: bold; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">           19,891,235          </td>          <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">          </td>          <td style="font-weight: bold; padding-bottom: 4pt">          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left">           $          </td>          <td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right">           7,775,360          </td>          <td style="padding-bottom: 4pt; font-weight: bold; text-align: left">          </td>         </tr>        </tbody>       </table>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <b>          Note14. Subsequent Events         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">         <u>          SalesPursuant to the Company’s FBR At Market Issuance Sales Agreement         </u>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        From January 1, 2021 through March 30,2021, the Company issued 9,376,792 shares of common stock pursuant to the FBR Sales Agreement at a weighted average price of $1.75per share.       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <!-- Field: Page; Sequence: 101; Value: 1 -->       <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid">        <p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">         F-         <!-- Field: Sequence; Type: Arabic; Name: PageNo -->         23         <!-- Field: /Sequence -->        </p>       </div>       <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt">        <p style="margin: 0pt">        </p>       </div>       <!-- Field: /Page -->       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <i>          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">        <font style="font-family: Times New Roman, Times, Serif">         <b>          <a name="a_0007">          </a>          REPORTOF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font: 7pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <font style="font-size: 9.5pt">         To the Board of Directorsand Stockholders of        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <font style="font-size: 9.5pt">         Soligenix, Inc.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif; font-size: 7pt">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <font style="font-size: 9.5pt">         <b>          <i>           Opinion on theFinancial Statements          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font: 7pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <font style="font-size: 9.5pt">         We have audited theaccompanying consolidated balance sheets of Soligenix, Inc. and Subsidiaries (the “Company”) as of December31, 2020 and 2019, and the related consolidated statements of operations, comprehensive loss, shareholders’ equity, and cash flowsfor each of the years then ended and the related notes (collectively referred to as the “financial statements”).In our opinion, the financial statements present fairly, in all material respects, the consolidated financial position of the Companyas of December 31, 2020 and 2019, and the consolidated results of their operations and their cash flows for each of the years then ended,in conformity with accounting principles generally accepted in the United States of America.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font: 7pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <font style="font-size: 9.5pt">         <b>          <i>           Basis for Opinion          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font: 7pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <font style="font-size: 9.5pt">         These financial statementsare the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financialstatements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (UnitedStates) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S.federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font: 7pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <font style="font-size: 9.5pt">         We conducted our auditsin accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assuranceabout whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not requiredto have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are requiredto obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectivenessof the Company’s internal control over financial reporting. Accordingly, we express no such opinion.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font: 7pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <font style="font-size: 9.5pt">         Our audits includedperforming procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performingprocedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosuresin the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management,as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis forour opinion.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font: 7pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <font style="font-size: 9.5pt">         <b>          <i>           Critical AuditMatter          </i>         </b>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font: 7pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <font style="font-size: 9.5pt">         The critical auditmatter communicated below is a matter arising from the current period audit of the financial statements that was communicated to theaudit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especiallychallenging, subjective, or complex judgments. The communication of the critical audit matter does not alter in any way our opinion onthe financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinionon the critical audit matter or on the accounts or disclosures to which it relates.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font: 7pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <font style="font-size: 9.5pt">         <i>          Accrual for ClinicalTrial Expenses         </i>        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font: 7pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <font style="font-size: 9.5pt">         As described in Note2 to the financial statements, the Company is required to estimate at each balance sheet date its expenses resulting from its obligationsunder contracts with vendors, clinical research organizations and consultants and under clinical site agreements in connection with conductingclinical trials. The Company recorded accrued expenses for the clinical trial accruals of $2.5 million, which are included in accruedexpenses on the December 31, 2020 consolidated balance sheet. The amounts recorded for clinical trial accruals represent the Company’sestimate of the unpaid clinical trial expenses based on the progress of the research and development services for clinical trials comparedto the amounts paid for clinical trials through December 31, 2020.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font: 7pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <font style="font-size: 9.5pt">         We identified management’sestimates of the accruals for clinical trial expenses as a critical audit matter due to the significant management judgement and subjectivityin estimating the accruals. Auditing the Company’s clinical trial accruals involved a high degree of subjectivity due to the significantestimation required in determining the progress to completion of specific tasks conducted under the Company’s clinical trials andthe costs of those tasks that will be invoiced by the vendors, clinical research organizations and consultants and under clinical siteagreements subsequent to the date that the financial statements are issued.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font: 7pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <font style="font-size: 9.5pt">         Addressing the matterinvolved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the financial statements.We obtained an understanding and evaluated the design of controls over management’s estimation process, including the process ofestimating the expenses incurred to date based on the status of the clinical trials, the significant assumptions about the status ofresearch and development services incurred and the completeness and accuracy of the data used to calculate the estimates. We performedprocedures over the clinical trial accruals that included, among others, reading selected agreements and change orders with the vendors,clinical research organizations and consultants, and evaluating the significant assumptions described above and the methods used in developingthe clinical trial estimates and calculating the amounts that were unpaid at the balance sheet date. We made direct inquiries of financialand clinical personnel on the status of the clinical trials, progress to completion of clinical trials, method of allocating contractualcharges to specific tasks performed during the clinical trials, and the status of change orders. We compared the current estimate ofexpenses incurred to estimates previously made by management and assessed the historical accuracy of management’s previous estimates.We also examined invoices issued and payments made to service providers after the balance sheet date.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font: 7pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font: 7pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <font style="font-size: 9.5pt">         /s/ EisnerAmper LLP        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font: 7pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <font style="font-size: 9.5pt">         We have served asthe Company’s auditor since 2010.        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font: 7pt Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <font style="font-size: 9.5pt">         EISNERAMPER LLP        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <font style="font-size: 9.5pt">         Iselin, New Jersey        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">        <font style="font-size: 9.5pt">         March 30, 2021        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">        <font style="font-family: Times New Roman, Times, Serif">        </font>       </p>       <p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">        <font style="font-family: Times New Roman, Times, Serif">         F-24        </font>       </p>       <!-- Field: Rule-Page -->       <div style="margin: 0pt auto; width: 100%">        <div style="border-top: Black 1.5pt solid; font-size: 1pt">         <font style="font-family: Times New Roman, Times, Serif">         </font>        </div>       </div>       <!-- Field: /Rule-Page -->      </text>     </description>    </filename>   </sequence>  </type> </document></body>